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ABSTRACT 
The incidence of sudden cardiac death (SCD) in all age groups is one per thousand 
life-years. In recent decades, with the development of genetic research, molecular 
genetics has been able to clarify the diagnosis of serious life-threatening heart di-
sease and to optimize treatments, and to assess the risk of disease and necessity of 
heart monitoring for the affected relatives. Additionally, the development of stem 
cell-based technologies has further helped to study genetic disease at cellular level. 
In the outpatient clinic for genetic cardiac diseases, we found interesting families 
whose diseases we further studied in more detail clinically and under laboratory con-
ditions. Monogenic, dominantly inherited cardiac diseases were the focus. All these 
diseases are associated with an increased risk of sudden death at a young age. Early 
diagnosis and well-targeted treatments can significantly improve patients' prognosis. 
A large family carrying a sodium channel SCN5A gene mutation D1275N was 
found in the Pirkanmaa area in Finland. A clinical phenotype of family members 
included severe conduction defect and atrial arrhythmias. In this thesis, we analyzed 
12-lead electrocardiogram (ECG) in that family and discovered ECG changes that 
predict conduction defect progression and cardiogenic thromboembolic complica-
tion. With these results, we will be able to predict the need for anticoagulation and 
pacemaker treatments of gene mutation carriers before complications appear. 
Hypertrophic cardiomyopathy (HCM) is a common monogenic heart disease that 
is estimated to appear in one in 500 individuals. So far, hypertrophic cardiomyo-
pathy-causing gene defects have been most commonly found in sarcomere proteins 
corresponding to cardiac contraction. In the second part of the work, we were able 
to demonstrate for the first time the calcium handling protein junctophilin-2 (JPH2) 
gene to cause hypertrophic cardiomyopathy. This protein is a non-sarcomeric cal-
cium regulator. This JPH2 p.(Thr161Lys) variant is a new Finnish mutation causing 
atypical HCM in many unrelated families.  
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inheritable 
rare cardiac disorder associated with exercise- and emotional stress-induced  
ventricular extrasystole and tachycardia in the absence of structural heart disease. 
The efficacy of medications in these patients is poor. CPVT is caused by mutations 
in ryanodine receptor 2 (RyR2) gene. Combining a clinical trial with stem cell study, 
viii 
we investigate the effect of a certain medication (dantrolene) on patients and their 
stem cell-derived cardiomyocytes. First of all, we observed a clear mutation-specific 
response – N-terminal mutations responded well to the treatment while the drug had 
no effect in patients having mutations in the C-terminal part of the gene. Secondly, 
we did a major discovery the patients and their stem cell-derived cardiomyocytes 
responded similarly on the medication – if the patient responded, also his stem cell-
derived cardiomyocytes responded, and if the patient did not, neither the cells did. 
The results demonstrated that the location of the mutation has a significant role in 
drug-responsiveness, and that stem cell-derived cell can be used for treatment opti-
mization in patients with genetic cardiac diseases without testing the drugs in pa-
tients. 
Human embryonic stem cells (hESCs) and human induced pluripotent stem cells 
(hiPSCs) are generally called pluripotent stem cells (hPSCs). These cells can be dif-
ferentiated into any cell of human body. In this thesis, we analyze stem cell derived 
cardiomyocytes. Some electrophysiological aspects of human pluripotent stem cell-
derived cardiomyocytes (hPSC-CMs) can be studied using microelectrode arrays 
(MEAs), where the cells are cultured on electrodes and ECG-type of field potential 
(FP) recordings can be obtained. The QT interval in 12-lead ECG is beating-rate-
dependent and correction formulas have been created to abolish the effect of the 
rate. We investigated whether the same formulas could be used when studying stem 
cell-derived cardiomyocytes. We compared the FP duration (FPD) to the QT time 
of electrocardiogram (ECG) from healthy individuals with low basic heart rate and 
performed stress exercise test to increase heart rate. We found that the repolarization 
parameter FPD in hPSC-cardiomyocytes (hPSC-CMs) behaved similarly as QT time 
in ECG recordings, and thus the same rate correction formula can be applied to 
electrical recordings in cell culture situations. 
In conclusion, the identification of the underlying genetic detect aims at identi-
fying individuals at increased risk, and clinical parameters can be found to predict 
the need of further treatments. Additionally, stem cell technologies will be powerful 
in the future to optimize treatments in patient- and mutation-specific manner. 
 
 
 
 
ix 
TIIVISTELMÄ 
Sydänperäisen äkkikuoleman ilmaantuvuus kaikissa ikäryhmissä on yksi tuhatta hen-
kilövuotta kohden. Viime vuosikymmeninä geenitutkimusten kehittymisen myötä on 
molekyyligenetiikan avulla kyetty selventämään vakavien nuorellakin iällä henkeä uh-
kaavien sydänsairauksien diagnostiikkaa, optimoimaan hoitoja sekä arvioimaan sai-
rastuneen lähisukulaisten sairastumisriskiä ja sydänseurantatarvetta. Lisäksi kantaso-
lutekniikoiden kehittyminen helpottaa geneettisten sairauksien tutkimista solutasolla. 
Perinnöllisiä sydänsairauksia hoitaessa löysimme mielenkiintoisia sukuja, joiden 
sairauksia tutkimme kliinisesti ja laboratorio-oloissa. Tämä väitöskirja käsittelee mo-
nogeenisia vallitsevasti periytyviä sydänsairauksia, joihin erityisesti diagnosoimatto-
mana liittyy äkkikuoleman riski nuorena. Varhaisella diagnostiikalla ja oikein kohden-
netuilla hoidoilla potilaiden sairauden ennustetta voidaan merkittävästi parantaa.  
Totesimme laajassa pirkanmaalaisessa suvussa esiintyvän natriumkanava SCN5A 
D1275N geenimutaation, joka aiheuttaa sydämessä vakavia johtumishäiriöitä ja eteis-
peräisiä rytmihäiriöitä johtaen fataaleihin sydänperäisiin tromboembolisiin kompli-
kaatioihin. Selvitimme 12-kytkentäisen sydänsähkökäyrän (EKG) löydöksien 
liittymistä SCN5A D1275N geenivirheeseen ja geenivirheen  tromboembolisille 
komplikaatioille altistavien EKG löydösten ja tahdistin hoitoa vaativien 
johtumishäiriöiden ennakoitavuutta. Löysimme geenivirheeseen liittyviä 
sydänsairauden etenemistä ennakoivia EKG-muutoksia, joiden perusteella voimme 
jatkossa suunnitella geenivirheen kantajien hoitoja mahdollisimman oikea-aikaisesti 
ennen komplikaatioiden ilmaantumista.   
    Hypertrofinen eli paksuseinäinen sydänlihassairaus on yleinen vallitsevasti periy-
tyvä sydänsairaus esiintyen yhdellä henkilöllä 500:sta. Toistaiseksi hypertrofista kar-
diomyopatiaa aiheuttavia geenivirheitä on eniten löytynyt sydämen supistumisesta 
vastaavista sarkomeeriproteiineista. Toisessa osatyössä pystyimme osoittamaan en-
simmäistä kertaa ei-sarkomeerisen kalsiumin säätelyyn vaikuttavan junktofiliinipro-
teiinia koodaavan JPH2 – geenivirheen vaikuttavan perinnöllisen hypertrofisen kar-
diomyopatian syntyyn. Analysoimalla yhdeksän perheen JPH2 (Thr161Lys) geenivir-
heen kantajien sydänmanifestaatioita totesimme JPH2 geenivirheen yksinään aiheut-
tavan hypertrofista kardiomyopatiaa.  
x 
Katekoliamiiniherkkä polymorfinen kammiotakykardia (CPVT) on harvinainen 
perinnöllinen rytmihäiriösairaus, joka ilmaantuu fyysisen tai henkisen rasituksen yh-
teydessä katekolamiinien provosoidessa kammiolisälyöntisyyttä ja monimuotoista 
kammiotakykardiaa terverakenteisessa sydämessä. Rytmihäiriöiden hoidossa käytet-
tävien lääkitysten teho on huono ja vaihteleva tautia aiheuttavan ryanodiinireseptori 
2 (RyR2) mutaation kantajilla.  Yhdistimme kliinisen ja kantasolututkimuksen tutki-
malla dantroleeni-lääkkeen vaikutusta RyR2 mutaatiopotilailla ja heidän kantasoluis-
taan johdetuilla sydänsoluilla. Erityisesti, tutkimme mutaatiospesifistä lääkevastetta – 
N-terminaalimutaatioiden vaste hoitoon oli hyvä, kun taas C-terminaaliosan geeni-
virheen kantajilla ei ollut vastetta tutkitulle lääkkeelle. Merkittävin havaintomme oli 
huomata potilailla ja heidän kantasoluistaan johdetuilla sydänsoluilla (hiPSC-CM) 
olevan samanlainen lääkevaste. Jos potilas respondoi, myös hänen hiPSC-CM res-
pondoivat lääkeaineelle, ja jos lääke ei tehonnut potilaaseen, se ei toiminut myöskään 
soluviljelmillä. Tutkimustulos kuvastaa mutaation sijainnilla olevan merkittävän vai-
kutuksen lääkevasteeseen. Siten voimme hiPSC-sydänsolumalleja käyttäen opti-
moida geneettisesti sydänsairaan potilaan hoitoja testaamatta lääkettä potilaalla.  
Ihmisen alkion kantasoluja (hESC) ja indusoituja kantasoluja (hiPSC) kutsutaan 
yleisesti pluripotenteiksi kantasoluiksi (hPSC). Näitä soluja voidaan muuntaa erilai-
siksi ihmisen soluiksi. Soluviljelytekniikoilla tuotettujen ihmisen sydänsolujen (hPSC-
CM) sähköisiä ominaisuuksia voidaan mitata käyttäen mikroelektrodeja (MEA). Näi-
den avulla rekisteröidään solun sähköistä potentiaalia (FP), jonka ajatellaan vastaavan 
ihmiseltä otettavaa EKG-rekisteröintiä. QT-aika 12-kytkentäisessä EKG:ssa on      
sykeriippuvainen ja korjauskaavoilla pyritään poistamaan sykkeen muutoksen vaiku-
tusta QT-aikaan. Tutkimme Bazettin kaavan soveltuvuutta hPSC-CM-solumalleissa. 
Vertasimme FP-aikaa (FPD) EKG:n QT-aikaan eri syketaajuuksilla terveillä henki-
löillä syketaajuutta polkupyörärasituksella nopeuttaen. Totesimme hPSC-CM solujen 
repolarisaatioparametrien käyttäytyvän samoin kuin QT-aika EKG:ssa, siten sama 
korjauskaava sopii soluviljelmien sähköiseen rekisteröintiin. 
Molekyyligeneettinen diagnoosi helpottaa potilaiden ja heidän terveiden lähisuku-
laisten sydänsairauden sairastumisriskin arviota, sairauden diagnostiikkaa ja hoitoa. 
Lisäksi kantasolutekniikoilla voimme tulevaisuudessa optimoida potilas- ja mutaatio-
spesifisiä hoitotapoja. 
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1 INTRODUCTION 
Two groups of familial diseases are responsible for sudden cardiac death especially 
in young: cardiomyopathies and channelopathies. Congenital cardiac channelo-
pathies are primary electrical disorders related to mutations in genes encoding car-
diac ion channels and/or their regulatory proteins leading to channelopathies and 
life-threatening arrhythmias. On the other hand, cardiomyopathies are related to mu-
tations in genes encoding several categories of structural proteins. (Magi et al., 2017; 
Garcia-Elias & Benito, 2018.) Therefore, genotype studies have become an essential 
part of clinical diagnosis (Magi et al., 2017). Molecular genetic diagnosis improves 
the ability to predict risk for diseases and enable understanding of the pathophysio-
logy, which improve prevention and therapy (Zipes et al., 2019).  
Mutations in the SCN5A gene cause cardiac sodium (Na+) channel dysfunction 
associating with variable conduction diseases, arrhythmias, atrial standstill, even fatal 
ventricular arrhythmias and dilative cardiomyopathy (Remme et al., 2008). The car-
riers of a SCN5A mutation need a clinical and electrocardiogram (ECG) follow-up 
because of the risk associated with severe conduction defects (Probst et al., 2006). 
Mutations in the cardiac Na+ channel encoded by the gene SCN5A can result in 
many different phenotypes (Remme et al., 2008). Some of the Finnish SCN5A 
D1275N mutation carriers had progressive conduction disease and atrial arrhythmias 
before they died of a cardioembolic stroke at a young age (Laitinen-Forsblom et al., 
2006). 
Hundreds of different disease-causing mutations have been identified in genes 
that encode proteins of the sarcomere, which is the basic contractile unit of cardiac 
myocyte (Roma-Rodrigues & Fernandes, 2014; Zipes et al., 2019). The critical role 
of calcium (Ca2+) in excitation-contraction coupling and linking alterations in Ca2+ 
handling with hypertrophic remodeling is known. Consequently, investigators have 
suggested that mutations in genes encoding Ca2+-handling proteins, such as juncto-
philin 2 (JPH2), might be associated with hypertrophic cardiomyopathy (HCM). 
(Landstrom & Ackerman, 2012.) HCM affects 0.2% of the global population (Frey 
et al., 2012). In HCM, typically the left ventricular wall is asymmetric thickened 
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(Elliot et al., 2008). Phenotype is varied, and HCM can be asymptomatic or cause 
fatal arrhythmias and heart failure (Roma-Rodrigues & Fernandes, 2014). 
Ryanodine receptor 2 (RyR2) is responsible for calcium regulation in the cardio-
myocyte (Priori & Chen, 2011). Catecholaminergic polymorphic ventricular tachy-
cardia (CPVT) caused by RyR2 gene mutation is a malignant stress-induced                
arrhythmogenic disease that may lead to sudden death in children and young adults 
(Priori et al., 2002; Zipes et al., 2019). CPVT belongs to a group of inheritable dis-
orders referred to as channelopathies without structural heart disease, caused by mu-
tations in genes coding for channel-proteins that regulate cardiac electrical function 
(Imberti et al., 2016).  
The first stable human embryonic stem cell (hESC) lines were derived in the 
1990s (Thomson et al., 1998). Human induced pluripotent stem cells (hiPSCs) by 
derived programming of differentiated human somatic cells into a pluripotent state 
allow creation of patient- and disease-specific stem cells (Takahashi et al., 2007). It 
is possible to record the electrical activity of cardiomyocytes with field potentials 
(FPs) using microelectrode arrays (MEAs) (Stett et al., 2003; Reppel, 2004). In MEA, 
peak-to-peak interval (PPI) is determined as time between two depolarizing sodium 
[Na+] peaks, PPI is analogues with RR in the ECG. The field potential duration 
(FPD) has been claimed to be analogous with the QT interval in the ECG. (Stett et 
al., 2003.)  
In the first publication, the aim was to investigate the significance of the gene 
mutation in ECG changes. In the second publication, the aim was to find out the 
pathogenicity of the likely HCM causing gene by exploring the heart expressions of 
the gene mutation carriers. In next two publications, the aim was to find out the 
suitability of the human pluripotent stem cell-derived cardiomyocyte (hPSC-CM) cell 
model to study changes in the human heart rate. The optimal management of heart 
disease requires the understanding of the association between the causative muta-
tions and the clinical phenotype. 
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2 LITERATURE REVIEW 
2.1 Heart and cardiomyocytes 
 
The heart consists of four chambers: the right and left atria and ventricle. Cardio-
myocytes within the heart are required to pump in order to provide effective cont-
raction–relaxation cycle of myocytes action that can ensure adequate blood perfusion 
of the various organs and tissues in the body through a network of blood vessels. 
(Woodcock & Matkovich, 2005.) Cardiomyocytes (atrial, ventricular and nodal cells) 
form approximately 75% of the total ventricular volume and weight, but only one 
third of the total number of cells (Zipes et al., 2019). The heart consists different of 
cell types, each with their own contribution to structural, biochemical, mechanical 
and electrical properties of the functional heart (Xin et al., 2013) (Figure 1). The 
sarcomere is the basic contractile unit of cardiac myocyte, composed of thick myosin 
and thin actin filaments (Knollmann & Roden, 2008; Zipes et al., 2019) (Figure 2).  
Specialized cardiomyocytes form is the cardiac conduction system, which is res-
ponsible for the control of rhythmic beating of the heart (Woodcock & Matkovich, 
2005).  
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Figure 1. Heart cell types and conduction pathways.  
                SAN, sinoatrial node; AVN, atrioventricular node; BB, Bachmann bundle; 
                Ainp, Minp, Pinp, anterior, middle, and posterior internodal pathways; HIS, 
                his bundle; RBB, right bundle branch; LBB, left bundle branch. 
                Modified from Xin et al., 2013. 
 
2.2 Electrophysiology of the heart  
2.2.1 Cardiac excitation 
The mechanical activity of the heart is controlled by electrochemical impulses. These 
impulses are intrinsic to the heart but are also modulated by neuronal activity 
through the autonomic nervous system. (Keating & Sanguinetti, 2001.) Atrial activa-
tion begins in the sinoatrial node (SAN) or the neighboring atrial pacemakers. SAN 
is primary pacemaker. It spreads in radial fashion to depolarize the right   atrium, the 
interatrial septum, and then the left atrium. (Nerbonne & Kass, 2005; Surawicz & 
Knilans, 2008.) This impulse is transmitted to all atrial myocytes, leading to coordi-
nated depolarization and the contraction of the atria (Keating & Sanguinetti, 2001).  
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Three specialized pathways (the anterior, middle, and posterior internodal path-
ways) link the SAN to the atrioventricular node (AVN). An interatrial pathway, the 
Bachmann bundle, connects the right and left atria. (Sedmera & Gourdie, 2014.) The 
main function of the AVN is the generation of a delay between the activation of the 
atria and the ventricles. A bundle of His is the continuation of the penetrating bundle 
on the ventricular side of the AVN before the left and right bundles (Zipes et al., 
2019). Purkinje fibers connect with the ends of the bundle branches. The Purkinje 
system is a complex network of cardiac cells located at the endocardium that is spe-
cialized in the rapid conduction of electrical signals in the ventricles. It is necessary 
to coordinating the myocardial activation and coordination of AV valves. (Guirau-
don & Jones, 2014; Sedmera & Gourdie, 2014.) (Figure 1). The parasympathetic 
nerves, which slow heart rate, are distributed mainly to the SAN and AVN, to a 
lesser extent to the muscle of atria, and very little directly to the ventricular muscle. 
The sympathetic nerves, which increase heart rate, are distributed to all parts of heart. 
(Hall, 2016.) 
 
Figure 2.    A ventricular cardiomyocyte. Illustrated are the protein complexes (especially SCN5A,     
RyR2 and JPH2), cardiomyocyte architecture and intracellular organelles involved in 
cardiac excitation–contractile coupling, which is explained in the text. Red stars indicate 
proteins encoded by genes that are mutated in primary arrhythmia syndromes, two of 
them are RyR2 and SCN5A. Green stars indicate protein complexes in which mutations in 
multiple genes cause cardiomyopathies often associated with arrhythmias; these 
complexes include the sarcomere. Modified from Knollmann & Roden, 2008. 
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2.2.2 Cardiac action potential  
Electrical signaling in the heart involves the passage of ions through ionic channels: 
sodium (Na+), potassium (K+) and calcium (Ca2+). The movements of these ions 
across the cell membrane through channel pores generate excitation and signals in 
cardiac myocytes that are required for normal electrophysiological activity. 
(Nerbonne & Kass, 2005; Zipes et al., 2019.) The regulation of the contractility of 
the individual cardiomyocytes is tightly mediated by multiple ion channels and         
regulatory proteins and exchangers that accurately control Ca2+ entry into and out 
of the cell and the sarcoplasmic reticulum (SR) (Woodcock & Matkovich, 2005)  
(Figure 2). 
Potassium currents determine the resting membrane potential and govern           
repolarization in cardiac myocytes. The transfer rate of potassium ions is dependent 
of the beating rate. (Aziz et al., 2018.) The starting event in the cardiac cycle is memb-
rane depolarization, which occurs with ion entry through connexin channels from a 
neighbouring cardiomyocyte followed by opening of voltage-gated Na+ channels and 
Na+ entry (Knollmann & Roden, 2008). Sodium channels play an essential role in 
the initiation, propagation, and maintenance of cardiac excitation throughout the 
heart (Terrenoire et al., 2007). The cardiac action potential (AP) is initiated by the 
depolarization of the sarcolemma (Woodcock & Matkovich, 2005). The resultant 
rapid depolarization of the membrane inactivates Na+ channels and opens both K+ 
channels and Ca2+ channels. The entry of Ca2+ into the cell triggers the release of 
Ca2+ from the sarcoplasmic reticulum through the ryanodine channel 2 (RyR2). Ca2+ 
binds to the troponin complex and activates the contractile apparatus. Cellular rela-
xation occurs on the removal of Ca2+ from the cytosol by the Ca2+-uptake pumps of 
the SR and by Na+/Ca2+- exchange (NCX) with the extracellular fluid. Intracellular 
Na+ homeostasis is achieved by the Na+/K+ pump. (Knollmann & Roden, 2008.) 
(Figure 3). 
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Figure 3.   (A) Cardiac action potential and transmembrane ionic currents that participate in each 
phase. Phase 0: rapid depolarization due to entrance of Na+ currents into the cell. SCN5A 
encodes the rapid sodium channel. Phase 1: early repolarization initiated by outward       
K+ currents. Phase 2: a plateau phase marked by the Ca2+ entry into the cell against K+ 
outward repolarizing currents. Phase 3: end of repolarization produced by K+ currents 
upon Ca2+ channel-inactivation. Phase 4: resting membrane potential (about -90 mV) 
determined by inward-rectifier K+ currents. OW, outward currents; IW, inward currents. IKs, 
delayed-recti¿er; IKr, rapid delayed-recti¿er; ICaL, inward Ca2+ currents through the L-type 
voltage-dependent calcium channels  
                (B) Excitation-contraction coupling: during action potential, Ca2+ entry in phase 2 induces a 
large release of Ca2+ from the sarcoplasmic reticulum through the RyR2 receptor that 
allows cell contraction. After repolarization, Ca2+ is extruded from the cell through the 
Na+/Ca2+ exchanger or taken back into the SR through SERCA2a to allow cell relaxation.  
JPH2 has an important role in the maintenance of effective Ca2+ handling. Figure modified 
from Garcia-Elias & Benito, 2018. 
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2.2.3 The cardiac sodium channel 
Voltage-gated sodium channels (Nav) are broadly expressed in the human body. The 
Nav 1.5 is the main Nav expressed in the heart (Moreau & Chahine, 2018). The 
Nav1.5 channels are transmembrane proteins of cardiomyocyte for the rapid up-
stroke of the cardiac action potential and for rapid impulse conduction through car-
diac tissue (Balser, 1999). Nav1.5 channels mediate the inward sodium current (INa) 
and induce fast depolarization, thereby initiating the excitation–contraction coupling 
cascades in the cells. The upstroke speed of the AP and conduction is determined 
by the numbers of Nav1.5 channels that are available for opening. The inactivation 
process is usually rapid and stable for most ion channels. (Han et al., 2018.) The 
number of sodium channels and their electrophysiological function differ between 
various parts of the heart (Remme et al., 2008; Remme et al., 2013). The voltage-
gated sodium channel is encoded by the SCN5A gene (Remme & Bezzina, 2010). 
 
2.2.4 The cardiac potassium channel 
Voltage-gated potassium channels (Kv) are the most various family of voltage-         
dependent channels in the heart (Zipes et al., 2019). K+ channels play a pivotal role 
in the AP repolarization process. Some of the K-channels are primarily responsible 
for early repolarization, whereas others drive late repolarization and others are open 
throughout the cardiac cycle. (Schmitt et al., 2014.) Reduced potassium channel pro-
tein levels or function causes prolonged repolarization and long QT, for example the 
genetic syndromes long-QT 1 and 2, even drug-induced long-QT. Reduced potas-
sium channel expression or function may lead to other disease states, as in heart 
failure and hypertrophy. (Huang et al., 2013.) 
 
2.2.5 The cardiac calcium channel 
The regulation of intracellular calcium (Ca2+) is very important in all cell types (Kush-
nir et al., 2018). The main function of cardiac muscle cells is to enforce cardiac exci-
tation-contraction-relaxation, which depends on the electrical Ca2+ transport and 
contractile properties (Zipes et al., 2019). Therefore, calcium is an important second 
messenger in cardiac function (Bers, 2002). Ca2+ release through RyR2 is triggered 
by Ca2+ entering via CaV1.2 during depolarization. In the heart, RyR2 are organized 
on the SR in Ca2+ release units associated with CaV1.2 on the transverse tubules      
 29 
(T-tubules) forming SR/T-tubule junctions. (Franzini-Armstrong et al., 2005.) The 
depolarization of the cell membrane causes Ca2+ to enter the cardiomyocyte through 
CaV1.2 during the prolonged plateau phase of the cardiac action potential. This Ca2+-
induced Ca2+-release is required for myocardial contraction. (Wong et al., 1992.) Ca2+ 
is also important for the activation of signal transduction pathways responsible for 
hypertrophic cardiac remodeling and heart failure by controlling gene transcription 
via Ca2+-dependent signaling as well as for cardiac development, cardiac energy ho-
meostasis, and eventually for cell death (Freichel et al., 2017). 
 
2.2.6 Cardiac ryanodine receptors 
Ryanodine receptors (RyR) are intracellular Ca2+-permeable channels that provide 
the sarcoplasmic reticulum Ca2+ release required contractions for skeletal underlying 
RyR1 and RyR2 for cardiac muscle (Betzenhauser & Marks, 2010). RyRs are massive 
structures comprising the largest known ion channel-bearing macromolecular     
complex in the human genome (Santulli et al., 2018). RyR2 encodes a calcium ion 
transporter, which is responsible for the calcium induced calcium release that results 
in ventricular contraction. RyR2 is responsible for calcium regulation in the cardio-
myocyte. (Priori & Chen, 2011.) 
 
2.2.7 Junctophilin 2 
Junctophilin 2 (JPH2) is an important membrane-binding structural protein in car-
diomyocytes for the coupling of transverse (T) tubule-associated L-type Ca2+ chan-
nels (LTCC) and type-2 ryanodine receptors on the sarcoplasmic reticulum within 
junctional membrane complexes (JMC) (Nishi et al., 2000; Takeshima et al., 2000). 
JPH2 provides a structural bridge between the plasmalemma and sarcoplasmic reti-
culum and is essential for precise Ca2+-induced Ca2+ release during excitation-cont-
raction coupling in cardiomyocytes (Guo et al., 2015). Signaling between these two 
Ca2+ channels is required for normal cardiac contractility (Matsushita et al., 2007) 
(Figure 2 and 3). 
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2.3 Electrocardiogram  
The primary clinical tool for evaluating cardiac electrical events is an electrocardio-
gram (ECG). The APs are responsible for the atrial and ventricular activations, and 
this electrical activation is recorded by ECG. (Surawicz & Knilans, 2008.) The ECG 
is characterized by different waves that represent specific phases of the cardiac acti-
vation sequence: the P wave reflects atrial depolarization, the QRS complex repre-
sents ventricular depolarization, and the T wave indicates ventricular repolarization 
(Terrenoire et al., 2007) (Figure 4). 
    
Figure 4.   Cardiac electrical activity: (A) ECG and action potential.  Green lines indicate PR, QRS 
and QT intervals. (B) Action potential and transmembrane ionic currents in each phase, 
especially sodium current. Modified from Amin et al., 2010 and Ravens & Cerbai, 2008. 
2.3.1 P wave and PR interval 
The P wave corresponding to atrial depolarization, the early part of the P wave may 
be considered to represent the electrical potential generated by the upper part of the 
right atrium, and the late part as that by the left atrium and the inferior right atrial 
wall (Surawicz & Knilans, 2008). 
The PR interval includes atrial depolarization and atrial repolarization (Ta) (Su-
rawicz & Knilans, 2008; Childers, 2011). 
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2.3.2 QRS complex and QT interval 
The QRS complex corresponding to ventricular depolarization from which the axis, 
duration and configuration are determined and from these results we can evaluate 
the normality of ventricular activation (Surawicz & Knilans, 2008).  
The QT interval stands for the duration of ventricular electrical systole (Surawicz 
& Knilans, 2008). The QT interval also includes ventricular depolarization. ST seg-
ment and T wave are ¾ of the QT interval which is used to represent ventricular 
repolarization. (Airaksinen et al., 2016.) The QT interval is determined by the cardiac 
action potential, which is balanced between inward and outward currents of myo-
cardial cells (Visken, 2009). 
 
2.3.3 QTc 
Normally the QT interval decreases with increasing heart rate (Karjalainen et al., 
1994) due to an increase in potassium flux across the cell membrane (Aziz et al., 
2018). There are many formulas describing this relation. QTc formula attempts to 
separate the dependence of the length of the QT interval from the length of the RR 
interval (Surawicz & Knilans, 2008).  
 The duration of the mechanical ventricular systole is determined by the original     
Bazett’s formula: Systole = K¥cycle. The normal value for K is 0.37 for men and 0.4 
for women. (Bazett, 1920.) The most widely used is the formula derived by Bazett: 
QTc = QT/¥RR (Funck-Brentano & Jaillon, 1993). Rate correction of the QT        
interval should not be efforted when RR interval variability is large (Rautaharju et 
al., 2009). QT interval and QTc are expressed in milliseconds and RR interval in 
seconds. Nevertheless, the upper limit of the normal QTc value is less than 0.441 
seconds. (Surawicz & Knilans, 2008.)   
QT/RR hysteresis value means how quickly; and QT/RR adaptation how much 
QT interval changes when heart rate changes (Malik et al., 2018). QT/RR hysteresis 
is independent of the static QT/RR relationship (Malik et al., 2008). 
 
2.3.4 Pathologies of conduction time 
Cardiac conduction, as assessed by the PR interval and QRS duration, is an im-
portant electrophysiological character and a determinant of arrhythmic risk (Smith 
J.G. et al., 2009). A wide, notched or low-amplitude Ta can predict an interatrial 
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conduction disturbance with or without atrial enlargement. The Ta wave represents 
atrial repolarization and the interval from the beginning of the P wave to the end of 
Ta is the atrial equivalent of the ventricular QT interval. (Childers, 2011.) PR pro-
longation is also associated with an increased risk of atrial fibrillation (Shulman et al., 
2015), a need for pacemaker implantation, and excess mortality (Cheng et al., 2009). 
Progressively increasing conduction defects predict atrial paralysis and atrial arrhyth-
mias (Probst et al., 2003; Sajeev et al., 2006). Many investigators considered frag-
mented QRS (fQRS) as an independent predictor of cardiac events (Morita et al., 
2008; Das & Zipes, 2009; Chatterjee & Changawala, 2010). The abnormal duration 
of the QT interval has been found in epidemiologic studies to identify individuals at 
high risk of sudden cardiac death (Zhang et al., 2011). 
The definition of normal QT time is difficult because abnormality QT interval 
can be either “too long” or “too short”. Large population studies suggest that, for 
the adult population, normal QTc values for males are 350 to 450 ms and for females 
360 to 460 ms. (Visken, 2009.) However, the upper limit for the normal QTc for 
both genders is 440 milliseconds (Surawicz & Knilans, 2008). Nevertheless, the Ba-
zett’s correction overestimates the number of patients with a prolonged QT (Patel 
et al., 2016). Nonetheless, marked abnormalities of the QT interval may be caused 
by many different reasons and situations: genetic disorders (e.g., long/short QT   
syndrome), pharmacologic agents (e.g., antiarrhythmics, antipsychotics, antibiotics), 
electrolyte abnormalities (e.g., hypokalemia and hypomagnesemia), and their inter-
actions (Zhang et al., 2011). Especially when pharmacologic agents cause QT 
changes, it is possible to choose individual treatments for patients by combining 
evidence from in vivo and in vitro studies using human pluripotent stem cell-derived 
cardiomyocyte (hPSC-CM) techniques (Yamazaki et al., 2018). 
 
 
2.3.5 Electrophysiological studies on human induced pluripotent 
        stem cell-derived cardiomyocytes (hiPSC-CMs) 
With the microelectrode arrays (MEAs) technology, it is possible to record field po-
tentials (FPs) generated by cells with electrical activity, including cardiomyocytes 
(Stett et al., 2003; Reppel et al., 2004). The MEA biosensor is in vitro system to moni-
tor both acute and chronic effects of drugs and toxins and to perform functional 
studies under physiological or induced pathophysiological conditions that mimic in 
vivo damages (Stett et al., 2003).  
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In the heart, FP represents spread of excitation and the conduction velocity in 
MEA, and FP corresponds intrinsic AP, and AP duration is the same than FP dura-
tion (FPD) (Halbach et al., 2003). Peak-to-peak interval (PPI) is determined as time 
between two depolarizing sodium [Na+] peaks, PPI is analogues with RR interval. 
The FPD has been claimed to be analogous with the QT interval on the ECG. (Stett 
et al., 2003.) (Figure 5) 
The Bazett’s formula for correcting FPD (cFPD) for rate-depended modulation 
is commonly used with MEA recordings:  cFPD = FPD/¥PPI  (Caspi et al., 2009; 
Itzhaki et al., 2011). 
 
 
 
                     
Figure 5.    Characteristics of field potential (FP) (upper panel) and ECG (lower panel) recordings.  A 
FP trace from one of the recording electrodes on the microelectrode array generated by 
the spontaneously beating human embryonic stem cell–derived cardiomyocytes. The field 
potential duration (FPD) and peak-to-peak interval (PPI) is also depicted in the first cardiac 
FP cycle along with the sodium (Na+), calcium (Ca2+), and potassium (K+) currents in the 
cardiac FP components.   
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2.4 Methods to study genetics of cardiac diseases 
2.4.1 Genetic testing in clinical practice 
Genes are the fundamental units of hereditary (Krebs et al., 2018). Over the past 
several decades, the causative genes have been identified for a range of cardiovascu-
lar diseases. This knowledge has provided explanations to patients, improved the 
ability to predict risk for diseases, and enabled understanding of the pathophysio-
logy; therefore, we can improve prevention and therapy. (Zipes et al., 2019.) 
Genes are encoded by deoxyribonucleic acid (DNA), which comprises four dif-
ferent bases: adenine (A), cytosine (C), guanine (G) and thymine (T). DNA has two 
opposing strands that form A-T and G-C base pairs, and coil into a double helix 
structure. (Watson & Crick, 1953.) The human genome contains about 6 billion base 
pairs across the 46 chromosomes. About 1% of the genomic DNA encodes the es-
timated 20 000 genes in humans. (Zipes et al., 2019.) The DNA sequence of a gene 
that codes protein is known as the exon. Mutations are heritable changes in the base 
sequence of DNA. (Krebs et al., 2018.) 
 
2.4.1.1 Modes of inheritance 
Disease can be a result from a defect in a single gene (monogenic) or from many 
genes (polygenic) (Zipes et al., 2019).  For monogenic diseases, modes of inheritance 
include autosomal dominant, autosomal recessive and X-linked heritability. Mito-
chondrial genetic disorders are maternally inherited. In autosomal dominant disor-
ders, a single defective allele of a gene from the mother or father suffices to the cause 
phenotype, whereas in autosomal recessive disorders both copies from mother and 
father need to be defective to lead to the phenotype. (Zipes et al., 2019.) Genetic 
variants are inherited (familial) or represent spontaneously derived (sporadic) de novo 
variants occurring for the first time in an individual (Tester & Ackerman, 2011).  
Most common cardiovascular diseases are polygenic disorders requiring variants 
in more than one gene to cause a disease (Zipes et al., 2019). Many cardiomyopathies 
and channelopathies are the consequences of a single gene defect and are thus in-
herited according to Mendelian law (Corrado et al., 2005), in which case the change 
is necessary and sufficient to cause disease (Zipes et al., 2019). Studies on genotype–
phenotype correlations led to the identification of affected asymptomatic individuals 
and healthy mutation carriers in every condition (Corrado et al., 2005).  
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Cardiac disease mutations are remarkable for substantial variation in clinical       
expression. Both genetic heterogeneity (e.g. several genes that cause the same         
disease) and allelic variation (different mutations in the same gene) contribute to 
variable morphological phenotypes and disease severity. Genetic variation, lifestyle, 
and other contributory factors that account for differences have an influence on 
clinical manifestations in family members with identical mutations. (Richards et al., 
2015; Burke et al., 2016.) 
 
2.4.1.2 Pathogenicity classification of genomic variants 
Genetic diagnostics has proven as an effective strategy to differentiate potential     
underlying causes and to rule out phenocopies. Accurate molecular genetic diagnosis 
helps to detect those phenocopies that might require different treatments. (Acker-
man et al., 2011; Vago et al., 2016.) 
When classifying such variants as pathogenic, we know that a mechanism of  
pathogenicity is consistent with the established inheritance pattern for the disease 
(Richards et al., 2015; Jarvik & Browning, 2016). Variants with very low population 
frequency and with strong evidence for cosegregation with disease phenotype, con-
servation across species, or functional evidence are classified as pathogenic. Variants 
are likely pathogenic, when they have lower strength for consegregation or limited 
functional evidence.  Otherwise likely pathogenic variants are like pathogenic ones. 
Designation “variant of uncertain significance (VUS)” is defined as a variant with 
restricted evidence for consegregation, limited or contradictory functional evidence, 
and variable conservation across species. (Richards et al., 2015.) 
The genotype–phenotype correlation is complicated when some phenotypes do 
not manifest in all individuals carrying the same gene mutation (incomplete penet-
rance), and when the type and severity of the phenotypes varies between genotype-
positive individuals (variable expressivity) (Giudicessi & Ackerman, 2013). 
 
2.4.1.3  Next-generation DNA sequencing technology 
In the last decade, sequencing technology (next-generation sequencing [NGS]) has 
facilitated the search for such genetic components spread over the genome. NGS is 
a sequencing technology that enables sequencing at a massive scale across the 
 36 
genome, and it can be used to identify additional genetic loci involved in a disease. 
NGS can be used in gene panels to sequence multiple genes simultaneously (e.g. 20–
109 comprehensive arrhythmia or cardiomyopathy-associated genes). (Myllykangas 
et al., 2011; Mizusawa, 2016.) 
Disease-causing genes for inherited arrhythmias have been successfully identified 
in the last three decades, resulting in a large impact on patient care (Mizusawa, 2016). 
Mutations in any gene encoding an ion channel protein can cause ion channel dys-
function, a so-called channelopathy. This channelopathy may lead to cardiac arrhyth-
mias and sudden cardiac death as the most severe clinical manifestation. (Brugada J. 
et al., 2007.) In the absence of structural heart disease, these arrhythmias, especially 
in the younger population, are often an outcome of genetic defects in specialized 
membrane proteins (Knollmann & Roden, 2008). 
During the last two decades, mutations especially in sarcomere genes have been 
found to comprise the most common cause for hypertrophic cardiomyopathy 
(HCM), but still a meaningful number of patients with dominant HCM are left with-
out molecular genetic diagnosis. NGS does not only enable evaluation of known 
HCM genes, but also candidate genes for cardiomyopathy are frequently tested, 
which may lead to a situation where conclusive interpretation of the variant requires 
extensive family studies. Diagnostic yield of molecular genetic testing in daily prac-
tice is 25–40% in HCM. (Walsh et al., 2017.)  
  
2.4.2 Stem cells 
Stem cells signify natural units of embryonic development and tissue regeneration.  
Pluripotent stem cells (PSC) have a nearly unlimited self-renewal capacity and deve-
lopmental potential to differentiate into virtually any cell type of an organism. (Wo-
bus & Boheler, 2005.) An embryonic stem cell line is derived from the inner cell 
mass of a blastocyst. The resulting human embryonic stem cell line can then be dif-
ferentiated into various cell types of the different embryonic lineages as well as into 
male or female germ cells. (Wobus & Boheler, 2005; Mountford, 2008.)  
The first stable human embryonic stem cell (hESC) lines were derived in 1998 
(Thomson et al., 1998) and first human induced pluripotent stem cell (hiPSC) lines 
in 2007. These cells are collectively called human pluripotent stem cells (hPSCs). 
(Takahashi et al., 2007.) Naturally found cells, pluripotency is associated with the 
cells of early embryos, which can generate all of the tissues in the organism. iPSCs 
are similar pluripotent stem cells, but they are produced from fully differentiated 
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cells by inducing the expression of genes necessary for pluripotency (Park et al., 
2008). 
 
2.4.2.1    Induced pluripotent stem cells 
The ability to generate induced pluripotent stem cells (iPSCs) by reprogramming 
somatic tissues is one of the greatest breakthroughs in biomedical science in the last 
decade. Notable advances have been made in reprogramming technologies beyond 
the stable integration of four core genes (octamer-binding transcription factor 4 
(Oct4), sex determining region Y-box 2 (Sox2), Kruppel-like factor 4 (Klf4) and 
myelosytomatosis viral oncogene homolog (c-Myc)) originally described by Yama-
naka and colleagues in 2006 for mouse cells (Takahashi et al., 2006; Yamanaka, 2008) 
and soon reproduced from human cells. (Takahashi et al., 2007; Park et al., 2008.) 
Although the integrated viral transgenes become transcriptionally silenced after re-
programming, insertional mutations and residual transgene or virally induced gene 
expression may interfere with differentiation or alter sub-sequent cell phenotypes, 
leading to questions of whether iPSCs and their derivatives really reflect a patient's 
own cells (Saha & Jaenisch, 2009). 
The iPSCs approach, pioneered by Takahashi and Yamanaka, allows the repro-
gramming of adult somatic cells into pluripotent stem cells by ectopic expression of 
a set of transcription factors. Human induced pluripotent stem cell-derived cardio-
myocytes (hiPSC-CMs) can be using for cardiac research. (Takahashi et al., 2007.) 
HiPSC-CMs have been used in many studies to assess molecular mechanism of dif-
ferent heart diseases. (Saha & Jaenisch, 2009; Smith A.S.T. et al., 2017.) (Figure 6) 
These cardiomyocytes have been extensively used for in vitro electrophysiological re-
cordings (Kehat et al., 2001; Reppel et al., 2005; Liang et al ., 2010). The role of 
patient- and disease-specific iPSC-CMs is a new platform with significant scientific 
and clinical potential in studying disorders related to sudden cardiac death (SCD) 
(Sallam et al., 2015). 
 
 38 
           
Figure 6.    Pluripotent hESCs and hiPSCs can be differentiated into various cell types using specific 
differentiation protocols. CM, cardiomyocyte. Modified from Laurila et al., 2016. 
2.5 Genetic cardiac diseases pathophysiology and gene mutations 
2.5.1 Sudden cardiac death 
Sudden cardiac death (SCD) depicts a natural and unexpected death from cardiac 
causes occurring within a short period of time (generally within 1 h of symptom 
onset) in the absence of any other potentially lethal condition (Magi et al., 2017). In 
adult populations, cardiomyopathies and cardiac channelopathies, along with coro-
nary heart disease (CHD), are the most common conditions that predispose patients 
to SCD. According to recent epidemiological studies of SCD in Western countries, 
CHD underlies about 75%, cardiomyopathies 10–15%, and ion channelopathies     
1–2% are diagnosed of the SCD cases. (Hayashi et al., 2015; Mizusawa, 2016.) The 
limits between inherited primary electrical heart diseases (channel-pathy) and struc-
tural heart muscle disease (cardiomyopathy) are still undefined (Corrado et al., 2005). 
A susceptible substrate can be present even in the absence of any structural heart 
disease detectable by conventional techniques, such as echocardiography or mag-
netic resonance imaging (Knollmann & Roden, 2008; Ackerman et al., 2011). 
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2.5.2 Cardiac channelopathies 
Cardiac channelopathies, primary electrical disorders result from mutations in genes 
encoding cardiac ion channels and/or their regulatory proteins, which result in modi-
fications in the cardiac action potential or in the intracellular calcium handling that 
lead to electrical instability (Garcia-Elias & Benito, 2018). The electrical substrate of 
cardiac channelopathies can develop depending on the affected gene and the effect 
of a particular mutation (loss- or gain-of-function) on the channels, receptors and 
regulators that participate in this process. A mutation may make a channel non-func-
tional, underactive, overactive or leaky. (Garcia-Elias & Benito, 2018; Skinner et al., 
2019.) It is said that each cardiac channelopathy has its own ECG signature and 
typical mode of presentation (Skinner et al., 2019). Typical channelopathies are long 
QT syndrome, short QT syndrome, Brugada syndrome and catecholaminergic poly-
morphic ventricular tachycardia (CPVT) (Fernández-Falgueras et al., 2017). 
 
2.5.2.1 Catecholaminergic polymorphic ventricular tachycardia 
Catecholaminergic polymorphic ventricular tachycardia is an inheritable cardiac dis-
order associated with adrenergic exercise- and emotional stress-induced ventricular 
tachycardia (VT) in the absence of structural heart disease and high incidence of 
sudden death with life-threatening polymorphic or bidirectional VT or ventricular 
fibrillation (VF) (Watanabe & Knollmann, 2011; Priori et al., 2015; Imberti et al., 
2016). CPVT is rare, estimated prevalence at 1:10 000 (Priori et al., 2002). Approxi-
mately 30% of patients with CPVT develop symptoms before 10 years of age, and 
60% before 40 years (Ackerman et al., 2011). A natural history of CPVT is showing 
up to 30% SCD before age 40 in the absence of antiadrenergic therapy (Napolitano 
et al., 2012).           
 
 Pathophysiology of CPVT 
During stress and exercise, catecholamines are released by the sympathetic nervous 
system and bind to beta-adrenergic receptors resulting in generation of cyclic ade-
nosine monophosphate (cAMP) and activation of protein kinase A (PKA) which has 
both direct functional as well as developmental effects (Kushnir et al., 2018). During 
sympathetic nervous system mediated stress, activation of RyR2 plays a key role in 
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increases in Ca2+ transient resulting in sustained enhancement of cardiac contractility 
(Bers, 2002; Kushnir et al., 2018). The slightest modification in the functioning of 
one of these players may modify the AP and/or the intracellular Ca2+ dynamics, 
potentially favouring an arrhythmogenic substrate (Garcia-Elias & Benito, 2018).  
CPVT is caused by mutations in genes involved in the intracellular calcium ho-
meostasis of cardiac cells (Obeyesekere et al., 2015). Arrhythmias in CPVT occur 
from diastolic Ca2+ leak (Kushnir et al., 2018). Two causative genes of CPVT have 
been identified: RyR2, encoding the cardiac ryanodine receptor Ca2+- release chan-
nel, and calsequestrin 2 (CASQ2), encoding cardiac calsequestrin (Watanabe & 
Knollmann, 2011). CPVT is inherited as an autosomal dominant or autosomal re-
cessive trait, usually with high penetrance (Laitinen et al., 2004). Approximately 60% 
of patients with CPVT have a mutation in the RyR2 (CPVT1), and CPVT2 cases are 
autosomal recessive mutations caused by mutations in CASQ2 gene, which encodes 
the calcium binding protein (calsequestrin). These are much rarer and cause about 
3–5% of CPVT cases (Skinner et al., 2019).  
 
Diagnosis of CPVT 
Diagnosis is based on (family) history of adrenergically induced syncope, response 
to stress testing and genetic analysis (Siegers et al., 2014).  Bidirectional VT is con-
sidered the diagnostic marker of CPVT. During an exercise stress test, CPVT pa-
tients display isolated premature beats at the beginning of exercise with a progressive 
worsening of the complexity of ventricular arrhythmias in response to an   increased 
workload. Typically, when the heart rate reaches 90 to 110 bpm, runs of non-sus-
tained or sustained VT appear and they may degenerate into sustained VT and VF 
unless exercise is promptly terminated. However, not all patients with CPVT mani-
fest this form of arrhythmia. Therefore, molecular screening of the RYR2 and 
CASQ2 genes are important to diagnose in patients with less typical phenotypic 
manifestations. (Leenhardt et al., 1995; Priori & Chen, 2011.) Delayed diagnosis leads 
to suboptimal treatment and unnecessary risk of SCD (Siegers et al., 2014). 
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2.5.2.1.1 Cardiac ryanodine receptors RyR2 mutation  
Sympathetic activation during exercise or emotional stress induces ventricular          
arrhythmias above a threshold heart rate in RyR2 mutation carriers (Priori et al., 2002; 
Laitinen et al., 2004; Kontula et al., 2005). Gain-of-function mutations of the RyR2 
receptor cause increased calcium (Ca2+) sensitivity, which leads to a premature and 
increased release of calcium from the sarcoplasmic reticulum during diastole, and 
adrenaline stimulate further calcium release, resulting in delay after depolarizations 
and triggered activity (Priori & Chen, 2011; Leenhardt et al., 2012; van der Werf & 
Wilde, 2013). RyR2 receptors are divided into four regions (i.e. N-terminal: 1–600; 
central: 2000–2500; C-terminal: 3700–4200 and 4500–5000) (Ono et al., 2010) (Fi-
gure 7). 
                       
Figure 7.   RyR2 protein, mutations studied in the study III and mutation clusters 1–4. Mutations in the  
study III (arrows) are located in different parts of the RyR2 protein and mutation clusters. 
Clusters are represented as black lines numbered from 1 to 4. Cluster 1 consists of amino 
acids (AA) 44–466, cluster 2 AA 2246–2534 and cluster 3 AA 3778–4201, and these three 
clusters are located in the N-terminal and central regions of the protein and form the 
cytoplasmic domain. Cluster 4 comprises AA 4497–4959 and forms the transmembrane 
domain, which is located in the C-terminal region. Modified from Priori & Chen, 2011. 
 
 42 
2.5.2.2 Cardiac conduction defect and atrial arrhythmias and sodium channel SCN5A       
gene mutations  
Abnormalities in cardiac conduction can occur due to a variety of factors, including 
developmental and congenital defects, acquired injury or ischemia of portions of the 
conduction system, or less frequently due to inherited diseases that alter cardiac con-
duction system function (Wolf & Berul, 2006). 
The gene SCN5A is located on chromosome 3p21 and encodes the alpha-subunit 
of the voltage-gated cardiac sodium channel NaV 1.5 (Remme et al., 2008; Veerman 
et al., 2015).  It is expressed in heart tissue and plays a critical role in the excitability 
of cardiomyocytes (Amin et al., 2010). Mutant Nav1.5 causes alterations in the peak 
and late sodium current and is associated with a wide range of congenital arrhyth-
mias. More than 400 SCN5A mutations have been found in the SCN5A gene. (Han 
et al., 2018.) The importance of INa for normal cardiac electrical activity is the reason 
for the high incidence of arrhythmias in cardiac sodium channel-pathies (Amin et al., 
2010).  
SCN5A encodes the rapid sodium channel. Regulation of the expression and 
proper function of voltage-gated ion channels at the plasma membrane of excitable 
cells is essential in maintaining cellular excitability and electrical impulse propagation. 
In the heart, voltage-gated sodium (Na+) channels determine the amplitude and slope 
of the action potential upstroke, which are especially important in the control of 
impulse conduction velocity, and in the maintenance of appropriate waves of exci-
tation through the working myocardium. (Nerbonne & Kass, 2005; Wilde & Amin, 
2018.)  
The dysfunction of these channels can lead to life-threatening cardiac arrhythmias 
(Herfst et al., 2003). Mutations in the SCN5A gene are involved in numerous inhe-
rited cardiac arrhythmias: long QT syndrome (LQTS), Brugada syndrome (BrS) 
(Brugada, J. et al., 2007; Makita et al., 2008), and sick sinus syndrome (SSS) (Gui et 
al., 2010), progressive cardiac conduction disease (PCCD) (Herfst et al., 2003), fa-
miliar atrial fibrillation (FAF) (Darbar et al., 2008; Remme & Bezzina, 2010) and 
atrial standstill (AS) (Groenewegen et al., 2003), which all potentially can lead to 
fatal arrhythmias at a relatively young age (Miles & Behr, 2016) (Figure 8). Very rare 
AS is associated with an increased risk of sudden death due to the occurrence of very 
low escape rhythm and an increased risk of thromboembolic stroke due to the high 
incidence of atrial fibrillation/flutter (AF) (Castro et al., 2009).  
Familiar atrial standstill has been associated with the SCN5A D1275N mutation 
combined with rare polymorphisms in an atrial-specific connexin40 (Cx40) gene 
(Groenewegen et al., 2003; Makita et al. 2005; Makita, 2009). In a large Finnish 
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family, cardiac conduction defects and atrial arrhythmias were also associated with 
the same SCN5A D1275N mutation, although not linked to the polymorphism in 
the Cx40 gene (Laitinen-Forsblom et al., 2006). For all that, no sudden cardiac death 
was documented in the Finnish family, at least four affected members suffered from 
cardioembolic stroke by the age of 31 and two of them died of stroke (Laitinen-
Forsblom et al., 2006). 
Makita et al. described progressive atrial dysfunction leading to the AS associa-
ted with SCN5A mutation L212P (Makita et al., 2005). The missense mutation, 
D1275N has been associated with a variety of unusual phenotypes, including dila-
ted cardiomyopathy (McNair et al., 2004; Hayano et al., 2017). SCN5A mutations 
with loss-of-function properties have been identified in patients with cardiac con-
duction defects, SSS (Makita et al., 2005, Gui et al., 2010). Probst et al. described 
progressively increased QRS duration in patients with SCN5A linked hereditary 
Lev–Lenegre disease affecting the His bundle and its branches (Probst et al., 2003). 
 
 
 
Figure 8.   Schematic representation of the primary structure of the cardiac sodium channel with 
location of SCN5A mutations associated with sodium channel overlap syndromes. Arrow 
shows where D1275N mutation is located in SCN5A gene. BrS indicates Brugada 
syndrome; LQT3, long-QT syndrome type 3; SSS, sick sinus syndrome; CCD, cardiac 
conduction defect; AS, atrial standstill; AF, atrial fibrillation; DCM, dilated cardiomyopathy. 
Modified from Remme et al., 2008. 
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2.5.2.2.1   SCN5A D1275N and loss of INa function 
SCN5A mutations cause arrhythmias through both gain- and loss-of-function  
mechanisms of the sodium channel (Tan, 2006; Han et al., 2018; Moreau & Chahine, 
2018). Gain-of-function mutations in SCN5A lead to more sodium influx into car-
diomyocytes through aberrant channel gating and cause for example long QT synd-
rome, whereas loss-of-function mutations in SCN5A lead to lower expression le-
vels of the SCN5A or production of defective Nav1.5 proteins. Some of the SCN5A 
mutations are loss- or gain-of mutations, and in overlap syndromes mutations have 
both loss-of-function and gain-of-function effects. (Wilde & Amin, 2018.) (Figure 
9). SCN5A mutations causing early-onset AF has been demonstrated to be gain-of-
function mutations (Olesen et al., 2012).  
     
Figure 9.   SCN5A mutations. Arrow shows where D1275N mutation is located in SCN5A gene. The 
red represents gain of INa-P, blue represents gain of INa-L, green represents loss of INa-P, 
yellow represents loss of INa-L, the mixed colors (text and ellipsoid) represent coexistence 
of gain- and loss-of-function mutations. The sodium current mediated by Nav1.5 consists 
of peak and late components (INa-P and INa-L) Domains I-IV. Modified from Han et al., 2018. 
 
 45 
The mutation present in the Finnish family SCN5A D1275N causing conduction 
defects and atrial arrhythmias (Laitinen-Forsblom et al., 2006) manifests a loss-of-
function when analyzed in transfected cells (Gui et al., 2010). Reduced sodium chan-
nel availability leads to conduction defects (Remme & Bezzina, 2010) leading to pro-
longation of atrial action potential duration (APD) (Roberts & Gallop, 2010). P-wave 
broadening and a tendency to PR-prolongation are manifested in the ECG of indi-
viduals with the SCN5A/5280delG mutation, presumably due to a reduction in Na+ 
current (Herfst et al., 2003). Reduced inward Na+ current causes also QRS-widening, 
slow heart rate including abnormal pauses (>2 second) and slow-fast alternation of 
heart rhythm (Detta et al., 2015).  In vitro electrophysiological studies showed reduced 
peak cardiac Na+ current as a key defect and this is consistent with the observed 
reduced conduction velocity (Watanabe et al., 2011) (Figure 10). 
Wilde and Brugada have described how loss of INa function could induce atrial 
fibrosis, which may cause atrial fibrillation in individuals with associated structural 
abnormalities including increased diastolic ventricular pressure in the setting of di-
lated cardiomyopathy with subsequent enlargement of the atria (Wilde A.A. & Bru-
gada R., 2011). Fibrosis is a complex process of abnormal tissue healing which ine- 
vitably leads to loss of physiological organ structure and function (Schaefer, 2018). 
      
Figure 10.  Schematic representation of SCN5A D1275N and loss of INa function. Modified from 
Roberts & Gallop, 2010; Remme & Wilde, 2014. 
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2.5.3 Cardiomyopathies 
Cardiomyopathy is a myocardial disorder in which the heart muscle is structurally 
and functionally abnormal. Cardiomyopathies are grouped into specific morpholo-
gical and functional phenotypes: hypertrophic cardiomyopathy (HCM), dilated car-
diomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC),  
restrictive cardiomyopathy (RCM). (Elliot et al., 2008.)  
DCM is defined as left ventricular dilatation and systolic dysfunction without 
coronary artery or valve disease. It may be caused by genes encoding sarcomeric 
proteins, cytoskeletal and even ion channel and gap junction proteins. (McKenna et 
al., 2017.) Many different conditions, such as tachycardia, infections, autoimmune 
disease et cetera, can also cause DCM (Japp et al., 2016).  
RCM is a myocardial disease characterized by impaired ventricular filling and re-
duced diastolic volume in the presence of normal systolic function and normal or 
near normal myocardial thickness (Elliot et al., 2008; McKenna et al., 2017).  
ARVC is a genetically determined cardiomyopathy characterized by fibrofatty re-
placement of the myocardium (Zipes et al., 2019).  Mutations of genes encoding for 
various cardiac proteins are an alternative approach to reclassify cardiomyopathies 
according to the causative genetic defect (Elliot et al., 2008). 
The diagnosis of heart failure (HF) can be combined with clinically assisted exa-
minations, such as ECG or echocardiography. A brain natriuretic peptide (BNP) is 
a laboratory test, which is also widely used as signiÀcant indicators for cardiac dys-
function. (Elliot et al., 2014.) 
 
2.5.3.1    Hypertrophic cardiomyopathy 
Hypertrophic cardiomyopathy (HCM) is a primary disorder of the heart without    
pathology in another organ (Roma-Rodrigues & Fernandes, 2014). HCM is consi-
dered the most common form of inherited cardiomyopathies, estimated to affect 
one in 500 in general population (Maron B.J. et al., 1995; Semsarian et al., 2015) and 
the most common identifiable cause of sudden death in young athletes (Maron B.J., 
2002). 
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Diagnosis of HCM 
Diagnosis of HCM is made by two-dimensional echocardiography showing hyper-
trophied end-diastolic left ventricular wall > 15 mm in the absence of other cardiac 
or systemic causes of hypertrophy such as aortic valve stenosis or hypertension. In 
a subject with a definitive HCM-causing mutation or in first-degree relatives with 
definite HCM, left ventricular maximal wall thickness > 13 mm is sufficient for hy-
pertrophic cardiomyopathy diagnosis. (Elliott et al., 2008, Elliott et al., 2014.) Cardiac 
hypertrophy is usually asymmetric with greatest involvement most commonly of the 
basal interventricular septum subjacent to the aortic valve. Other myocardial regions 
can also be affected: the apex, the mid-portion as well as the posterior wall of the 
left ventricle. (Marian & Braunwald, 2017.) Intraventricular obstruction usually oc-
curs at the left ventricular outflow tract (LVOT) but can be midventricular caused 
by hypertrophied papillary muscles and midventricular hypertrophy (Veselka et al., 
2017).  
Primary abnormalities of the mitral apparatus are common such as leaflet elon-
gation, papillary muscle hypertrophy or bifidity, and abnormal origins or insertions 
of the papillary muscles (Veselka et al., 2017). Approximately one-third of patients 
have resting septal anterior motion (SAM) of the mitral valve leaflets that results in 
obstruction to the LVOT, while another third has latent obstruction only during 
maneuvers that change loading conditions and LV contractility (Elliott et al., 2014). 
Sometimes severe septal-leaflet contact is even a sole finding of HCM (Sen-Chowdh-
ry et al., 2016), but it is not yet enough for HCM diagnosis (Elliott et al., 2014) (Figure 
11). At the cellular level, cardiac myocytes are hypertrophied, disorganized, and     
separated by areas of interstitial fibrosis (Marian & Braunwald, 2017). 
The disease is often sub-clinical and goes unrecognized mainly because many 
HCM patients are asymptomatic, but up to 25% will develop significant symptoms: 
chest pain, shortness of breath, exercise intolerance, palpitations, presyncope and 
syncope. However, sudden cardiac death may be the first manifestation of the          
disease. (Marziliano et al., 2012; Roma-Rodrigues & Fernandes, 2014; Veselka et al., 
2017.) Atrial and ventricular arrhythmias occur in approximately 20% of HCM       
patients, leading to a poorer prognosis because these patients have a higher proba-
bility of suffering stroke and HF (Roma-Rodrigues & Fernandes, 2014). 
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Genes associated with the left ventricular hypertrophy 
More than 1400 mutations in 20 or more genes, mainly encoding proteins of cardiac 
sarcomere, have been identified to underlie hereditary HCM (Maron B.J. & Maron 
M.S., 2013; Pinto & Reckman, 2018). HCM is a genotypically and phenotypically 
heterogeneous disease (Maron B.J. et al., 1995; Landstrom et al., 2011).  The varia-
bility of the phenotype is caused, at least in part, by the causal mutation acting in 
concert with a number of other genetic and of non-genetic influences. Approxi-
mately 60% of patients with HCM have a familial disease typically inherited in an 
autosomal dominant pattern. (Walsh et al., 2017.) Autosomal recessive and X-linked 
modes of inheritance are rare (Marian & Braunwald, 2017).  
Rarer causes of HCM include metabolic and mitochondrial disorders, congenital 
malformations and endocrinopathies (Elliott et al., 2014); cardiomyopathies of this 
kind are called phenocopies of HCM. Phenocopies of HCM are for example Ander-
son-Fabry disease (mutations in galactosidase alpha, GLA), Danon disease (muta-
tions in lysosomal-associated membrane protein 2, LAMP2), PRKAG2 related gly-
cogen storage disease (mutations in protein kinase AMP-activated non-catalytic sub-
unit gamma 2, PRKAG2), cardiac amyloidosis, neuromuscular diseases and malfor-
mation syndromes (Noonan spectrum syndromes) (Vago et al., 2016). 
The most established genes associating with HCM are myosin binding protein C 
(MYBPC3), myosin heavy chain 7 (MYH7), troponin I3, cardiac type (TNNI3), tro-
ponin T2, cardiac type (TNNT2), alpha tropomyosin 1 (TPM1), myosin light chain 
2 (MYL2), myosin light chain 3 (MYL3) and actin, alpha, cardiac muscle 1 (ACTC1) 
(Walsh et al., 2017). The role of candidate genes such as troponin C1, slow skeletal 
and cardiac type (TNNC1) (Schmidtmann et al., 2005) and actinin alpha 2 (ACTN2) 
(Chiu et al., 2010) has remained obscure. 
 
2.5.3.1.1    The junctophilin-2 mutation 
Human genetic mutations in junctophilin subtypes are linked to HCM (Takeshima 
et al., 2015), but the molecular mechanisms underlying JPH2 downregulation remain 
not fully understood (Guo et al., 2015). The JPH2 gene encodes the main juncto-
philin isoform in the heart (Garbino & Wehrens, 2010). JPH2 has a critical role in 
the maintenance of effective Ca2+ handling suggesting involvement in excitation–
contraction process linking alterations in Ca2+ handling with hypertrophic remo-    
deling (Landstrom et al., 2007). 
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Figure 11. (A) Schematic representation of HCM and heart failure due to sarcomeric and JPH2 
mutations. Mutations in the proteins responsible for the maintenance of cardiomyocyte 
structure and function result in inefficient or excessive use of ATP and a consequent 
energy deficiency. The energy deficiencies then compromise calcium homeostasis in the 
cell, resulting in, among other events, an increase in calcium sensitivity of the ATPase 
SERCA and increased cytosolic free calcium. The contractibility of the myocyte is 
compromised, resulting in cell death and consequent myocardial fibrosis. This myocardial 
fibrosis may result in left ventricular hypertrophy, increasing the risk of heart failure. 
Abbreviations: NCX, Na+/Ca2+- exchanger; DHPR, dihydropyridine receptor; RyR2, 
ryanodine receptor; JPH2, junctophilin 2; SERCA, sarco-/endoplasmic reticulum Ca2+-
ATPase; AMP, adenosine monophosphate; ATP, adenosine triphosphate.  
                   (B) Types of HCM. Arrow shows anterior mitral valve leaflet. Modified from Roma-
Rodrigues & Fernandes, 2014 and Lauschke & Maisch, 2009. 
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The JPH2 decreases the time required for calcium activation to induce the type 
II ryanodine receptors to release calcium into the calcium-induced calcium release 
receptors (Roberts R., 2017). Additionally, maintaining the ultrastructure of the car-
diac dyad, JPH2 negatively regulates RyR2 activity and helps retain Na+/Ca2+-ex-
changer (NCX) within the dyadic cleft to regulate local Ca2+ signaling. Loss of JPH2 
promotes RyR2-mediated SR Ca2+ leak and concurrently impairs NCX function due 
to subcellular redistribution of NCX, which further drives Ca2+ leakage. (Wang at al., 
2014.) 
Disruption of the junctional membrane complexes (JMC) is a common finding 
in failing hearts. It is assumed that JPH2 mutations affect JMC, which might have a 
role in SR Ca2+ release (Landstrom et al., 2007). Wang et al. also demonstrated a 
novel cellular mechanism underlying an enhanced SR Ca2+ leakage, following a JPH2 
knockdown associated with HF (Wang et al., 2014). The downregulation of JPH2 
gene has been associated with HF, and it has been suggested that mutations in this 
gene are associated with HCM (Takeshima et al., 2015) (Figure 11).  
 
2.5.3.1.2    Cardiomyopathy manifestations of JPH2 mutations 
JPH2 was initially published as a candidate gene for HCM in 2007 when Matsushita 
et al. found p.(Gly505Ser) in four probands among 148 Japanese HCM patients 
(Matsushita et al., 2007), but this variant was later found to be a common polymor-
phism present in up to 4–6% in Asian/African populations (Manrai et al., 2016). 
Before our JPH2 study, no convincing evidence of segregation within large pedigrees 
except for the p.(Glu85Lys) (Sabater-Molina et al., 2016), and no de novo JPH2 mu-
tations have been reported in patients with HCM. In 2007, Landstrom et al. found 
two rare missense and one frameshift variant in JPH2 in three probands with HCM, 
but their families were not studied or genotyped (Landstrom et al., 2007). Role of 
the JPH2 in cardiomyopathies has been obscure, as only one rare variant segregating 
with any type of cardiomyopathy causing DCM has been published. In 2016, Sa-
bater-Molina showed segregation of the JPH2 p.(Glu85Lys) with dilated cardiomyo-
pathy with or without left ventricular non-compaction cardiomyopathy (LVNC) fea-
tures in a large family. (Sabater-Molina et al., 2016.) About 10% of the HCM cases 
evolve into DCM with unknown causes (Nanni et al., 2003).  
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2.6 Treatments 
Channelopathy and cardiomyopathy mutations can cause severe brady- or tachy-   
arrhytmias and/or diastolic or systolic heart failure, but so far there is no cure, and 
we can only treat symptoms. Patients with CPVT with structural healthy heart and 
patients with hypertrophic heart, ventricular arrhythmias of both different patient 
groups are treated by betablockers and implantable cardioverter-defibrillator (ICD). 
(Zipes et al., 2019.) The asymptomatic nature of channelopathies and cardiomyo-
pathies is cause for search in family members who may be carrying genetic risk fac-
tors, making the identification of these disease manifestations of significant clinical 
importance (Fernández-Falgueras et al., 2017).  
 
2.6.1 SCN5A  
The term atrial cardiomyopathy is used, when we can show atrial electrical and/or 
mechanical dysfunction, and/or fibrosis. These changes increase the risk of atrial 
fibrillation and stroke. (Guichard & Nattel, 2017.) Progressively increased conduc-
tion defects predict atrial paralysis and atrial arrhythmias, which are a risk for car-
dioembolic stroke without anticoagulation (Probst et al., 2003; Sajeev et al., 2006).  
The antiarrhythmic drug is determined on a patient-by-patient basis depending on 
the conduction disorders. 
 
2.6.2  Hypertrophic cardiomyopathy 
Left ventricular hypertrophy predispose to both ventricular and atrial tachyarrhyth-
mias and different conduction defects.  HCM is the leading cause of sudden death 
in young individuals and an important cause of heart failure at any age. (Cooper et 
al., 2017.) Fibrosis progression predicts an increased risk of coming clinical events 
in HCM. Impaired energetics and perfusion abnormalities may cause fibrotic pro-
cess. (Raman et al., 2019.) 
The prevalence of atrial fibrillation within HCM is estimated to be 18%–28% 
(Cooper et al., 2017). The risk of thromboembolism is exaggerated in HCM and 
aggressive anticoagulation is recommended in European as well as American guide-
lines (Gersh et al., 2011; Elliott et al., 2014). Catheter ablation for AF should be 
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considered in patients without severe left atrial enlargement, who have drug refrac-
tory symptoms or are unable to take antiarrhythmic drugs (Elliott et al., 2014). 
Asymptomatic patients without LVOT obstruction (LVOTO) do not currently 
warrant medical therapy (Elliott et al., 2014; Cooper et al., 2017). Diastolic dysfunc-
tion is common, when the left ventricular end diastolic pressure is elevated. Beta-
blockers, regardless of whether there is coexisting LVOTO, is a good choice for 
treatment. Nondihydropyridine calcium-channel blockers (verapamil or diltiazem) 
must be used with caution in the presence of significant LVOT gradient. (Elliott et 
al., 2014; Marian & Braunwald, 2017.) Ƣ-blockers with vasodilatory effect nebivolol 
and carvedilol are contraindicated (Makavos et al., 2019). LVOT obstruction in 
HCM is associated with greater morbidity and mortality (Cooper et al., 2017). ß-
blockers are often sufficient to reduce the incidence and severity of exercise-induced 
LV outflow tract gradients. Disopyramide, used in combination with ß-blockers, also 
has negative ino-tropic effects and reduces basal LVOT gradients without 
proarrhythmic effects. If medical therapy is not enough, LVOT can be treated by 
surgical myectomy or alcohol septal ablation (surgical or percutaneous septum re-
duction). (Elliott et al., 2014.)    
The treatment of diastolic dysfunction can be needed also by diuretics. Spirono-
lactone is being tested for relief and/or regression of the fibrotic process in HCM. 
(Makavos et al., 2019.) Patients with HCM with symptoms of HF and impaired 
LVEF < 50% without LVOT obstruction should be treated with conventional thera-
py for systolic heart failure including angiotensin-converting-enzyme inhibitors, an-
giotensin-receptor blockers, Ƣ-blockers, and diuretics if necessary (Elliott et al., 2014; 
Marian & Braunwald, 2017). If a HCM patient has severe heart systolic or diastolic 
failure with maximal drug therapy, heart transplantation must be considered (Elliott 
et al., 2014; Zipes et al., 2019). 
 
2.6.3 CVPT 
Current therapeutic options are beta-antiadrenergic drugs, flecainide, implantable 
cardioverter-defibrillators (ICD) (Leenhardt et al., 2012; van der Werf & Wilde, 
2013; Priori et al., 2013) and left cardiac sympathetic denervation (Wilde et al., 2008; 
Hayashi et al., 2009).   
Beta-antiadrenergic medication is the cornerstone of antiarrhythmic treatment 
for all CPVT patients (Leenhardt et al., 2012; van der Werf & Wilde, 2013, Priori et 
al., 2013). The dual Na2+ and cardiac Ca2+-release channel inhibitor flecainide has 
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also shown beneficial effects (Watanabe et al., 2009). Flecainide blocks RyR2 chan-
nels, which is reduced by Ca2+ overload in vitro or by high dose catecholamine chal-
lenge in vivo (Hwang et al., 2019).  
ICDs are used if severe arrhythmic events occur despite optimal Ƣ-blocking treat-
ment. However, the use of ICDs is not without risk since ICD-shocks may further 
aggravate catecholamine release and initiate an uncontrolled electric storm.  
Left cardiac sympatectomy may be highly effective in patients with refractory to 
medical therapy. The left cardiac sympathetic denervation is an antifibrillatory inter-
vention that largely prevents norepinephrine release in the heart, reducing these ad-
renergically mediated life-threatening arrhythmias. (Wilde et al., 2008; Cho, 2016.)  
 
2.6.3.1 Dantrolene 
The ryanodine receptor type-1 (RyR1) is the skeletal muscle counterpart. Mutations 
in RyR1 result in malignant hyperthermia, a rare but life-threatening complication of 
general anesthesia occurring upon administration of volatile anesthetics or depolari-
zing muscle relaxants. Dantrolene is a specific and an effective treatment for malig-
nant hyperthermia. (Krause et al., 2004.)  
In animal models of CPVT1, dantrolene has been shown to have antiarrhythmic 
effects restoring interdomain interactions critical for the closed state of the RyR2 
Ca2+ channel (Kobayashi et al., 2005; S. Kobayashi, 2009). Dantrolene has also been 
demonstrated to have beneficial effects in iPSC derived CMs from a CPVT1 patient 
with an N-terminal S406L mutation (Jung et al., 2012), but no studies in patients 
have so far been reported. 
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3 AIMS OF THE STUDY 
The main aims of the present thesis were as follows: 
 
I  To determine the progressive 12-lead ECG changes caused by the genetic 
defect SCN5A D1275N and to investigate the ECG findings which may lead to 
thromboembolic complications and conduction disorders requiring pacemaker 
treatment.  
II  To determine the pathogenicity of JPH2 c.482C>A, p. (Thr161Lys) variant.  
.  
III  To determine the response of dantrolene medication in patients with diffe-
rent RyR2 mutations and whether the in vivo responses of patients correspond to 
the in vitro data obtained from hiPSC-CMs derived from the same patients.  
IV  To compare the dynamic electrophysiological characteristics of ECG to    
corresponding MEA recordings of hPSC-CMs. 
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4 MATERIALS AND METHODS 
4.1 Ethical consideration 
The local Ethics Committee gave their approval for the study I (R01128) and the 
study IV (R07110M and R08070). 
 Study II has been approved by the Ethical Review Committee of the Department 
of Medicine, University of Helsinki (Dnro 307/13/03/01/11) and by the Ethical 
Review Committee of the Department of Medicine, University of Tampere (R08070) 
and conforms to the ethical principles outlined in the Declaration of Helsinki.  
The third study was approved by the Ethical Review Committee of the Helsinki 
University Hospital (HUS 396/13/03/01/12) and was performed in accordance 
with the institutional guidelines and the Declaration of Helsinki. Clinical trial was 
registered with EudraCT (2012-005292-14). 
Oral information and written informed consent were obtained from all patients 
(I-IV).  
 
4.2 Patients and molecular genetic studies 
All participants are of Finnish ethnicity. 
 
4.2.1 Study I 
A Finnish family with 45 members was evaluated at the Heart Center, Tampere Uni-
versity Hospital. This study includes eleven SCN5A D1275N mutation carriers and 
two deceased obligate carriers. Their ages were 12–73 years, when ECGs were re-
corded. The SCN5A D1275N genotype analysis of the family members has been 
previously described in detail by Laitinen-Forsblom et al. Four (31%) affected family 
members had a stroke before the age of 31 years and two experienced a premature 
death. (Laitinen-Forsblom et al., 2006.) 
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4.2.2 Study II 
Nine index patients with the JPH2 variant c.482C>A, p.(Thr161Lys) and their rela-
tives from four Finnish hospitals were included. We described the heart manifesta-
tions of 26 patients with JPH2 c.482C>A, p.(Thr161Lys) mutation, one of them was 
deceased obligate carrier (17 males and nine females, range 8–80 years old). The adult 
participants were assessed clinically at Heart and Lung Center, Helsinki University 
Hospital, at the Heart Hospital, Tampere University Hospital or at the Seinäjoki 
Central Hospital by physical examination, resting 12-lead ECG, appropriate labora-
tory tests and transthoracic echocardiography (TTE). The children were evaluated 
clinically at Children’s Hospital, Helsinki University Hospital or at Department of 
Pediatrics, Tampere University Hospital. 
 
4.2.3 Study III  
The patients consisted of six individuals (mean age 50±10 years, range 37–59 years, 
five females), who were molecularly defined as heterozygous carriers of different 
gain-of-function RyR2 mutations causing CPVT1. They carried the following muta-
tions: c.168-301_c.273+ 722del1128 mutation (later called as exon 3 deletion) or 
point mutations p.P2328S (c.6982C>T), p.T2538R (c.7613C>G), p.L4115F 
(c.12343C>T), p.Q4201R (c.12602A>G) or p. V4653F (c.13957G>T) (Figure 7). 
They all used a beta-adrenergic blocking agent, two of the patients with ICD showed 
atrial pacing. Basic laboratory parameters and cardiac echo were normal in all pa-
tients. 
 
4.2.4 Study IV   
Five healthy volunteers (mean age 38.4+20 years, range 18–52 years, three males and 
two females), who have bradycardic heart rate (< 50 bpm). 
 
 57 
4.3 Methods 
4.3.1 ECG/ Studies I, II, IV 
Heart rate, P-wave duration and amplitude, PR interval and deviation from the base-
line, QRS duration, S-wave amplitude and upstroke, QT, and corrected QT (QTc; 
Bazett’s formula) intervals were measured manually according to established metho-
dology. Normal values were internationally accepted references values (Surawicz & 
Knilans, 2008). 
For QRS-complex fragmentation (fQRS), we used the definition by Das et al.: 
additional R wave (R’ prime), notching in nadir of the S wave, notching of R wave, 
or the presence of more than one R prime (fragmentation). Typical bundle branch 
block (BBB) pattern (QRS > 120 ms) – right or left – and incomplete RBBB were 
excluded from the definition of fQRS. (Das & Zipes, 2009; Basaran et al., 2011.) In 
the left anterior fascicular block (LAFB), QRS duration may be normal or slightly 
prolonged. The upper limits of the S-wave amplitude in leads V1–V3 were 1.8, 2.6, 
and 2.1mV. (Surawicz & Knilans, 2008.) The QT interval was measured according 
to established methodology (Postema & Wilde, 2014). In Figure 5, it is shown how 
heart rate is determined by RR cycle lengths (ms) before measured QT interval. QT 
interval is measured from the beginning of the QRS complex to the tangent to the 
end of the T wave. 
The diagnosis of junctional escape rhythm needed at least three successive      
complexes. Both the typical finding with a narrow QRS and possible cases with 
broad QRS due to pre-existing intraventricular conduction defect were included. 
(Surawicz & Knilans, 2008.) 
Atrial standstill is characterized by bradycardia (HR<50 bpm), the absence of P 
waves, and a junctional narrow or slightly wide QRS complex and regular escape 
rhythm (Groenewegen et al., 2003; Surawicz & Knilans, 2008).  
 
4.3.1.1 Study I 
Systematic 12-lead ECG analysis was performed in 13 family members carrying an 
SCN5A D1275N mutation. Conduction defects and supraventricular arrhythmias, 
including atrial fibrillation/flutter, atrioventricular nodal re-entry tachycardia 
(AVNRT) and junctional rhythm were searched for. 
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4.3.1.2 Study IV 
We compared sinus rhythm 12-lead ECG from healthy individuals to cardiac FP 
recordings of hESC-CMs recoded with MEAs to investigate how well the intricate 
components of the ECG and cardiac FP recordings correspond to each other.  
RR and QT interval were measured on a single selected lead V2 or V3 because 
of the clearest T wave during exercise. Heart rate was determined by RR cycle lengths 
(ms) before measured QT interval. Measurements were rounded to the nearest 5 ms. 
The QT interval and heart rate measured by the analysis program was used in the 
heart rate adjustment formulae from the Framingham Study, adjusting the measured 
QT intervals for heart rate using Bazett’s formula (Bazett, 1920; Sagie et al., 1992) 
and QT/RR values (Malik et al., 2008).  
 
4.3.2 Classification of genetic findings 
4.3.2.1 Study II 
Genetic testing was carried out from genomic DNA using the OS-Seq™ (oligo-nuc-
leotide-selective sequencing) NGS method (Myllykangas et al., 2011; Akinrinade et 
al., 2015). The genetic evaluation of the index patients with hypertrophic cardiomyo-
pathy was performed using the Blueprint Genetics Core Cardiomyopathy or Pan 
Cardiomyopathy Panels covering 69 and 103 genes, respectively, associated with car-
diomyopathies and their genetic phenocopies including JPH2 c.482C>A, 
p.(Thr161Lys) (NM_020433.4) variant.  
The ACMG-AMP (American College of Medical Genetics and Genomics-Asso-
ciation for Molecular Pathology) pathogenicity classification guidelines offer a set of 
categories that for classification of a variant as pathogenic and criterion for the evi-
dence for pathogenicity (Richards et al., 2015). N (= probability of observed cosegre-
gation if not pathogenic) is required to be smaller if all the segregation evidence 
comes from a single family, rather than two or more families, solely due to the con-
cern that evidence from a single family can be due to physical linkage between the 
observed variant and an unobserved causal variant. For example, under a dominant 
model, this probability is N= (½) m, where m is the number of meioses of the variant 
of interest that are informative for cosegregation. (Jarvik & Browning, 2016.) 
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4.3.3 Echocardiography and cardiac magnetic resonance imaging 
4.3.3.1 Study II 
HCM was clinically diagnosed according to ESC Guidelines (Elliott et al., 2008). In 
adults, the diagnosis of HCM requires LV wall thickness >15 mm as measured by 
any imaging technique. Correspondingly, the clinical diagnosis of HCM in first-      
degree relatives of patients with left ventricle hypertrophy (LVH) >15 mm is based 
on the presence of otherwise unexplained increased LV wall thickness >13 mm. In 
children, the diagnosis of HCM requires LV wall thickness more than two standard 
deviations greater than the predicted mean. (Elliott et al., 2008.) Cardiac magnetic 
resonance imaging (cardiac MRI = CMR) was performed in some cases especially in 
patients with borderline diagnostic findings at echocardiography. The presence of 
the JPH2 mutation c.482C>A, p.(Thr161Lys) mutation in the family history was ob-
tained and pedigrees were drawn. 
 
4.3.4 Exercise stress test 
4.3.4.1 Study III 
The antiarrhythmic potential of dantrolene in the treatment of CPVT was studied 
with both patients and their iPSC-CMs generated from them.  The clinical tests and 
the iPSC studies were performed separately and blinded. The follow up time of the 
patients was three days after the dantrolene infusion. 
All RyR2 patients underwent the exercise stress test three times: a baseline, the 
first day after intravenous infusion of dantrolene sodium (Dantrium, 1.5 mg per kg 
of body weight) and on the second day to assess the effects after dantrolene  sodium 
washout and to demonstrate the reproducibility of the basic exercise test. The exer-
cise test was performed with a bicycle ergometer. The initial load was 30 W, followed 
by increments of the load by 15 W each minute. 
Numbers of premature ventricular contractions (PVCs) during exercise and at 
recovery phase as well as the maximum number of consecutive PVCs were counted. 
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4.3.4.2 Study IV 
12-lead ECG was recorded at rest until heart rate decreased slower than 50 bpm. 
Starting at 20 W and the work rate was then increased 5 W manually by degrees. 
Exercise stress test was interrupted when the target heart rate (130 bpm) was 
reached.  
 
4.3.5  hPSC lines and studies 
4.3.5.1 Study III 
Studied iPSC lines were UTA.05605.CPVT generated from the patient with RyR2 
exon 3 deletion, UTA.05208.CPVT from the patient with mutation P2328S, 
UTA.07001.CPVT from the patient with mutation T2538R, UTA.03701.CPVT 
from the patient with mutation L4115F, UTA.05503.CPVT from the patient with 
mutation Q4201R, UTA.05404.CPVT from the patient with mutation V4653F and 
UTA.04602.WT from a healthy control individual. All the CPVT-iPSC lines were 
characterized for their karyotypes, mutations, pluripotency, immunocytochemistry, 
embryoid body and teratoma formation.  
iPSCs were co-cultured with murine visceral endoderm-like (END-2) cells (Hum-
brecht Institute, Utrecht, The Netherlands) to differentiate them into spontaneously 
beating CMs. 
The percentage of abnormal Ca2+ transients, such as multiple peaks comprising 
of two peaks, irregular phases, oscillations, and varying amplitude manifested as low 
peaks, were calculated from each studied cell line. Beating frequency and diastolic 
Ca2+ levels of CMs were analyzed during spontaneous baseline beating, and during 
adrenaline perfusion. These parameters were compared between mutated and cont-
rol cell lines and between each mutated cell line. 
For dantrolene studies, the changes in Ca2+ were recorded during spontaneous 
baseline beating, spontaneous beating during 1 ƬM adrenaline perfusion and spon-
taneous beating during 1 ƬM adrenaline together with 10 ƬM dantrolene (Sigma) 
perfusion. Diastolic Ca2+ levels and beating frequency were compared between 
adrenaline and dantrolene of CMs. 
In “responder” group dantrolene abolished virtually all the Ca2+ handling abnor-
malities, in “semi-responder” group dantrolene reduced them by more than 50%, in 
“non-responder” group dantrolene reduced them by less than 50%. 
 61 
4.3.5.2 Study IV 
We used commercial cell culture H7 hESCs (WiCell), and the hPSCs were differen-
tiated into cardiomyocyte clusters by co-culturing them with mouse endoderm cell 
line. FPs were measured by MEA. The same formula was used for FP recordings as 
well, only then QTc became cFPD, QT was FPD and RR was PPI (determined as 
time between two depolarizing sodium [Na+] peaks). FPD was determined as the 
time between the onset of initial deflection and return to baseline as described be-
fore. (Caspi et al., 2009.) 
We compared FPD to QT time and PPI to RR (Figure 5). 
 
4.3.6 Statistical Analysis 
4.3.6.1 Study III 
Statistical analysis of in vivo studies was made with SPSS 21.0 statistical software  
package (SPSS, Chicago, IL). Data are presented as average + 1 standard deviation 
(SD). Comparisons between phases were performed by the non-parametric Wil-
coxon test. The significance of in vitro differences between two groups was evaluated 
with the unpaired Student’s t-test. The significance of changes within a group was 
evaluated with the paired Student’s t-test. Data are expressed as average ± standard 
error of the mean (S.E.M.) and n refers to the number of cells. P < 0.05 was consi-
dered statistically significant in both in vivo and in vitro. 
 
4.3.6.2 Study IV  
Data are presented as mean ± SD. Statistical analyses were performed between the 
groups with two-tailed t-test using SPSS software (IBM). 
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5  RESULTS 
5.1 Study I: Pathognomonic ECG findings in patients with SCN5A 
D1275N mutation 
Notching of the R and S waves – including initial QRS fragmentation – and pro-
longed S-wave upstroke were present in all the affected family members (Table 1, 
Figures 12 and 13).  
Five (38%) mutation carriers had fascicular or bundle branch block, nine (69%) 
had atrial arrhythmias; no ventricular arrhythmias were found. Five mutation carriers 
had a VVI-type of pacemaker (PAMA) (Figure 14). Two of them were upgraded to 
a physiologic PAMA. One mutation carrier underwent an electrophysiology study 
proving to have fibrosis of the atrial lateral wall. 
 
 
Table 1. Distribution of 12-leads ECG parameters of the SCN5A D1275N patients.  
  ECG parameters   n = 13 (%)  Individual    
Junctional rhythm    3 (23%)                            (II:2, III:6, III:7) 
Atrial fibrillation or flutter                     9 (69%)                                  (I:1, II:1, II:3, II:4, III:1, III:3,III:4, III:5, III:7) 
Atrial tachycardia    1 (8%)                            (III:5)  
Flat P wave in lead II    4 (31%)                                  (II:1, II:2, III:2, III:7) 
P wave > 140 ms    2 (15%)                                  (I:1, III:2) 
PR interval > 200 ms    4 (31%)                                  (II:1, III:1, III:2, III:5) 
Fragmentation of initial QRS                                                      13 (100%)  
S-wave upstroke  55 ms in leads V2-3  13 (100%)                                               
Notching in nadir of the S wave in leads V1, V2, V3  13 (100%)  
QRS  120 ms     10 (77%)                                 (all except II:3, III:1, III:3)    
RBBB     4 (31%)                                   (I:1, III:6, III:7, IV:1) 
LAFB     4 (31%)                                   (I:1, II:3, III:6, III:7) 
Pacemaker     5 (38%)                                   (I:1, II:4, III:5, III:6,  III:7) 
RBBB, presence of right/left bundle branch block; LAFB, left anterior fascicular block  
Generations I-IV, from oldest to youngest. Age order in generation 1-7 from oldest to youngest 
 
 63 
 
Figure 12.  A typical 12-lead ECG in an asymptomatic patient with the SCN5A D1275N mutation.  
Wide arrow: low amplitude signal at the beginning QRS complex.                                                 
Narrow arrow: notch in S wave 
                               : flat P wave  
                            : PR depression 
                            : deep S wave in chest leads 
                            : prolonged S-wave upstroke  55 ms 
 
                       
Figure 13. The initial fragmentation of the QRS complex. Arrow shows a changing point with 
increasing amplitude in SCN5A D1275N patients, who progressed conduction defect 
                   from sinus rhythm to atrial standstill. 
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Figure 14.  SCN5A D1275N pedigree indicating the ECG findings. Four of nine children of the oldest 
obligate mutation carrier (patient I:1) had the SCN5A mutation, only these individuals were 
significant to genetic analysis and they together with their children are included. AF, atrial 
fibrillation or flutter; AT, atrial tachycardia; AV I, grade I atrioventricular block; AVNRT, 
atrioventricular nodal re-entry tachycardia; c, chronic; DCM, dilated cardiomyopathy; 
LAFB, left anterior fascicular block; p, paroxysmal; PAMA, implanted pacemaker; pr Pd, 
prolonged P duration; RBBB, right bundle branch block; SSS, sick sinus syndrome; TIA, 
transient ischemic attack; y, years. Generations I-IV, from oldest to youngest. Age order in 
generation 1-7 from oldest to youngest. 
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5.2 Study II: JPH2 c.482C>A, p.(Thr161Lys) clinical characteristics 
of the probands and their family members 
A heterozygous JPH2 c.482C>A, p.(Thr161Lys) (NM_020433.4) variant was ob-
served in nine unrelated Finnish probands with cardiomyopathy. Altogether the 
p.(Thr161Lys) was detected in 20 affected individuals. The variant cosegregated with 
HCM in six families (Families 2–4, 6–8) and in three families the mutation was found 
only in the probands (Family 9), in probands and young family member without 
HCM (Family 1) or in probands and in another family member without HCM (Fa-
mily 5). Proband (III.1) is a girl who developed HCM by the age of 7 years. She has 
also a well-established pathogenic nonsense mutation in MYBPC3 (c.3181C>T, 
p.(Gln1061*)). She has inherited both of the variants from her mildly affected grand-
father through her mother who is obligate carrier of both variants. Systolic heart 
failure or conduction abnormalities were observed in every family. (Table 2 and Fi-
gure 15). Average at diagnosis was 26.9±20.6 years in the nine probands and their 
maximum LV wall thickness was 20.4±5.2 mm. PAMA or ICD was implanted in 
6/20 (30%) and reduced LVEF (<47%) or elevated brain natriuretic peptide 
(proBNP) concentration (>300 ng/l) was observed in 9/20 (45%) of the patients. 
Penetrance of HCM was 48%, 71% and 100% by age of 40, 60 and 80, respectively. 
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Table 2. Clinical characteristics of the JPH2 probands and their family members.  
Family Age 
M/F 
Geno- 
type 
Conduction 
defect 
Arrhyth-
mias 
PM, 
ICD 
LV- 
WT 
LVEDD/ 
EF (%) 
pro-
BNP 
(ng/l) 
Age 
at dg 
Pheno- 
type 
Family 1 
I.1 
52M +/- no  AF ICD 20 46/56% 400 47 HCM 
Family 2 
I.1 44M +/- no no no 16 46/72% 76 44 HCM 
II.1 12M +/- no VT no 23 48/77% 315 12 HCM 
II.2 16M +/- pRBBB no no 6 51/63% NA - normal 
Family 3 
I.1 48M +/- RBBB no no 15 49/72% 44 41 HCM 
II.1 24M +/- LBBB VT ICD 29 44/75% 145 13 HOCM  
Family 4 
I.2 45M n.a. AVB3, 
LAFB, 
RBBB 
AF, VT PM 28 55/20% 8425  17 HOCM, 
SHF 
I.3 57F -/- no no no 14  43/60% 33 - LVH/ 
Hyper-
tens 
II.1 25M +/- no SVT no 22 45/67% 104 9 HCM 
II.2 17M +/- LAFB no no 20 49/55% NA 1 HCM 
III.3 8M +/- no  no no 11 35/>50% NA 1 HCM 
Family 5 
I.1 54M +/- no SVT no 10 50/70% NA - normal 
I.2 53F -/- no no no 11 44/83% 164 - normal 
II.1 25F +/- RBBB, 
LAFB 
VES, VT, SVT no 22 43/60% 5700 12 HCM, 
SHF 
Family 6 
I.1 62M +/-,* LAFB AF no 15 40/52% 998 61 HCM 
I.2 60F -/- NA NA NA NA NA NA - NA 
II.1 F (+/-,*) NA NA NA NA NA NA - HCM 
III.1 8F +/-,* NA no no 11 33/>60% 3928 7 HCM 
Family 7 
I.2 76F +/- LAFB AF no 27 49/56% NA ? HCM 
I.3 72F +/- no AF no 17 45/60% NA ? HCM 
I.4 80F (+/-) no AF no NA NA NA ? ? 
II.1 52M +/- AVB1 VES, SVT no 23 49/63% NA 43 HCM 
II.2 49M +/- AVB1 no no 21 60/50% NA ? HCM 
II.3 48M +/- no no no 11 NA NA - normal 
III.1 20F +/- no SVT no 12 44/66% NA 19 normal 
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Family 8 
I.1 43F (+/-) AVB3, 
LBBB 
AF, VT PM 18 70/30% 6637 25 HCM, 
SHF 
I.2 60F -/- no no no 13 40/71% 160 - LVH/Hy
pertens 
I.3 76F +/- AVB3, 
LAFB, 
RBBB 
no PM 12 46/40% 5267 67 HCM, 
SHF 
II.1 47M +/- AVB1, 
LBBB 
AF, VT ICD 15 51/37% 4426 36 HCM, 
SHF 
II.2 49F -/- no no no 10 49/66% 31 - normal 
III.1 15M +/- no no no 7 46/66% NA - normal 
Family 9           
I.1 63F +/- no AF PM 19 45/60% 4082 63 HCM 
Index patients are marked in bold. Symbols and abbreviations:  Age (M/F), age and gender (M, male; F, female); Genotype – +/- 
is heterozygous and (+/-) obligatory heterozygous for p.(Thr161Lys) in JPH2 and -/- is wild type, * heterozygous for MYBPC3 
Gln1061*; R/LBBB, right/left bundle branch block; LAFB, left anterior fascicular block; AVB1-3, atrioventricular block types 1-3; 
Arrhythmias – AF, atrial fibrillation/flutter; SVT, supraventricular tachycardia (>10 short episodes per day or SVT requiring cardio-
version); VT, ventricular tachycardia  3 beats with frequency >100/min; VES, ventricular extrasystoles >1000 per day; SVES, 
supraventricular extrasystoles >5000 per day; PM, ICD, CRT-P/D – pacemaker, implantable cardioverter-defibrillator, cardiac 
resynchronization therapy device; LV-WT, maximal left ventricular wall thickness; LVEDD & EF, left ventricular end-diastolic        
diameter (mm) and ejection fraction (%); Age at dg-age at diagnosis of cardiomyopathy; Phenotype – phenotype at diagnosis; 
HCM, hypertrophic cardiomyopathy; LVH, left ventricular hypertrophy; SHF, systolic heart failure 
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Figure 15.  Pedigrees of three families affected with the JPH2 c.482C>A, p.Thr161Lys, (rs587782951, 
NM_020433.4) variant. Circles represent women, squares men and triangles gender 
blinded. Black-filled symbols represent individuals who fulfill ESC 2008 diagnostic criteria 
for HCM (Elliot et al., 2008). One family member (Family 8:I.3) who had imminent 
cardiomyopathy with borderline LVH (12 mm), 3-degree AV block (AVB3), RBBB and 
severe systolic heart failure (SHF) was also considered as affected with HCM. Genotypes: 
+/- heterozygous for the JPH2 p.Thr161Lys, -/- wild type allele, * MYBPC3 p. Gln1061*. 
Age of the family members at last follow-up, maximum LV wall thickness and some other 
key signs of clinical disease are listed below the symbols. Symbols and abbreviations; 
arrows indicate index patients; RBBB, right bundle branch block; AF, atrial fibrillation; VT, 
ventricular tachycardia; SVT, supraventricular tachycardia; PM, pacemaker. Generations  
I-III, from oldest to youngest. Age order in generation 1-7 from oldest to youngest. 
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5.3 Study III: Antiarrhythmic effects of dantrolene in CPVT1 
patients and their iPSC derived CPVT1 CMs      
5.3.1 Antiarrhythmic effects of dantrolene in CPVT1 patients 
In the baseline study, patients exercised on an average 8±2 minutes reaching a maxi-
mum heart rate of 134±17 bpm. Exercise bicycle testing induced polymorphic pre-
mature ventricular contractions (PVCs) in all six patients and non-sustained ventri-
cular tachycardia (NSVT, episodes of 3 to 4 consecutive PVCs) in three of them. 
The average threshold sinus rate for the appearance of PVCs was 105±9 bpm. The 
total count of PVCs during the workload was 172±119 (range 43–391). 
Figure 16 illustrates an example of the PVCs and NSVT episodes during the base-
line study and after dantrolene. Dantrolene significantly increased the threshold at 
which the arrhythmias appeared from 105±9 to 120±17 bpm. The duration of the 
exercise phase and the maximal heart rate achieved during the exercise were similar 
to those in the baseline study. On day 2, after wash-out of dantrolene, the prevalence 
of PVCs was approaching that in the first baseline test. 
Dantrolene decreased the prevalence of PVCs in four patients, whereas in two 
patients the number of PVCs remained virtually the same (Figure 17). Dantrolene 
reduced arrhythmias in patients with the mutation in the N-terminal or central region 
of the RyR2 protein. Thus, dantrolene abolished 97% of PVCs in the patient with 
exon 3 deletion (cluster 1), 88% of PVCs in the patient with P2328S mutation (clus-
ter 2), 33% of PVCs in the patient with T2538R mutation (right after cluster 2) and 
77% of PVCs in the patient with L4115F mutation (cluster 3). In contrast, dantrolene 
abolished only 1 to 2% of PVCs in patients carrying mutation closer to (Q4201R, 
end of cluster 3) or within the transmembrane region (V4653F, cluster 4) (Figures 
17 and 18). 
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Figure 16. ECG examples of a 38-year-old patient carrying the RyR2 P2328S mutation. (A) Resting 
ECG showing sinus rhythm and normal QRS morphology. (B) Exercise ECG at the highest 
workload of 105Win the baseline study before dantrolene. PVCs include couplets and 
polymorphic NSVTs. (C) Disappearance of ventricular arrhythmias after administration of 
dantrolene (workload 105 W). (D) Exercise test on day two after 20-hours wash-out of 
dantrolene showing return of PVCs (workload 105 W). 
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Figure 17. Features of the PVCs. Number of PVCs in exercise stress test before (baseline) and after 
administration of intravenous dantrolene and 24 hours after dantrolene wash out. 
 
5.3.2 iPSC derived CPVT1 cardiomyocytes reproduced the clinical  
        antiarrhythmic responses to dantrolene 
The effects of dantrolene were divided into three groups based on their Ca2+ res-
ponses. In the “responder” group dantrolene abolished all the Ca2+ handling abnor-
malities, in the “semi-responder” group dantrolene reduced them by more than 50% 
and in the “non-responder” group dantrolene reduced them by less than 50%. iPSC-
CMs were found to clearly reproduce the varying individual clinical responses of 
dantrolene. In cell lines with the mutation in the N terminal or central region of the 
RyR2 protein, dantrolene abolished or reduced the majority of Ca2+ transient abnor-
malities. These mutations were within or in close proximity of clusters 1, 2 or 3. A 
detailed analysis indicated that in cardiomyocytes (CMs) with exon 3 deletion, 
P2328S, T2538R or L4115F, dantrolene abolished or reduced by more than 50% of 
Ca2+ abnormalities in 65–97% of cells. 
In contrast, the effect of dantrolene was only minimal in CMs carrying a mutation 
at the end of cluster 3 (Q4201R) or in the transmembrane region (cluster 4, mutation 
V4653F), in accordance with the in vivo dantrolene infusion data (Figure 18). Dant-
rolene had no effect on the Ca2+ transients in control CMs. Dantrolene did not 
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significantly affect the diastolic Ca2+ levels of CMs in which Ca2+ transient abnor-
malities were abolished. Dantrolene increased significantly the diastolic Ca2+ levels 
of control and Q4201R CMs where Ca2+ transients were unaltered by the drug. There 
was no correlation between the antiarrhythmic effect of dantrolene and its effect on 
beating frequency. 
 
 
Figure 18.  iPSC derived CMs reproduced the clinical responses of dantrolene.  In vivo and in vitro 
effects of dantrolene correspond within each RyR2 mutation. In vitro drug effects were 
categorized into three groups (responders, semi-responders and non-responders) 
depending on how dantrolene affected to the amount of Ca2+ abnormalities when 
compared to adrenaline response. In vivo responder group show the percentage of the 
abolished PVCs when compared to the baseline. Numbers of cells analyzed in exon 3 del 
n = 16, P2328S n = 32, T2538R n = 17, L4115F n = 36, Q4201R n = 22, V4653F n = 13. 
Modified from Priori & Chen, 2011. 
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5.4 Study IV: Findings of repolarization parameters in Vivo 12-lead 
ECG and in Vitro FP of hPSC-CM 
The heart rate in ECG ranged from 39 to 120 bpm and the beating hPSC-CMs clus-
ters were selected to match this range. The uncorrected mean FPD value was 375 
ms with a mean beating rate of 73 bpm, while the uncorrected mean QT was 397 ms 
with a mean heart rate 76 bpm (Figure 19 and Table 3). When FPD was corrected 
with Bazett’s formula, cFPD was 400 ms with SD 64 ms. Volunteers had a mean 
QTc 432 ms with SD 39 ms. 
QT/RR mean value of our volunteers was 0.433, ranging 0.40–0.46. The mean 
FPD/PPI value was 0.44.  
 
 
 
      
Figure 19. Correlation of beating rate and QT and FPD duration. RR-interval (ms) of 
electrocardiograms is plotted against QT-intervals (ms) and peak-to-peak interval (PPI, 
ms) of pluripotent stem cell–derived cardiomyocyte (hPSC-CM) recordings against field 
potential durations (FPD, ms). For hPSC-CMs, linear fitting shows a value of 
approximately 0.71 for the coefficient of determination and for ECGs about 0.68. 
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Table 3. The cardiac parameters measured from the electrocardiogram (ECG) and microelectrode 
array (MEA) recordings. Parameters were QT and RR interval (ms) in ECG measurements and field 
potential duration (FPD) and peak-to-peak interval (PPI) (ms) in MEA measurements. The first 
measurement is heart rate 40 beats per minute (bpm), second measurement 80 and third 
measurement 120 bpm in the ECG.  
                                                                                       ECG 
Parameter  
(Volunteer/hPSC-CM Cluster #) 
first                  second               third 
QT (Volunteer #1)   405                   365                    290 
RR (Volunteer #1) 1350                   750                    500 
QT (Volunteer #2) 
RR (Volunteer #2) 
  450                   410                    330 
1500                   750                    500 
QT (Volunteer #3) 
RR (Volunteer #3) 
  455                   410                    350 
1500                   750                    500   
QT (Volunteer #4) 
RR (Volunteer #4) 
  435                   385                    310 
1435                   750                    500 
QT (Volunteer #5) 
RR (Volunteer #5) 
  460                   390                    305 
1425                   750                    500  
                                                                                       MEA 
FPD (Cluster #1)                382                   393                    387 
PPI (Cluster #1)              1103                 1076                  1060      
FPD (Cluster #2)                240                   240                    242 
PPI (Cluster #2)              632                   632                    640        
FPD (Cluster #3)                308                   309                    329 
PPI (Cluster #3)                875                   879                    888 
FPD (Cluster #4)                442                   469                    456       
PPI (Cluster #4)                877                   862                    875 
FPD (Cluster #5)                365                   387                    397 
PPI (Cluster #5)                729                   756                    753 
FPD (Cluster #6)                313                   323                    338 
PPI (Cluster #6)                608                   593                    585 
FPD (Cluster #7)                277                   272                    266 
PPI (Cluster #7)                637                   621                    606 
FPD (Cluster #8)                470                   470                    539 
PPI (Cluster #8)              1271                 1228                  1203 
FPD (Cluster #9)                511                   532                    508    
PPI (Cluster #9)              1269                 1238                  1204 
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6 DISCUSSION  
In this thesis, we investigated mutations in three different genes causing inherited 
cardiac rhythm disorders or structural abnormalities. Mutation-specific ECG 
changes are caused by the D1275N mutation in SCN5A gene. Additionally through 
extensive genealogy research, we demonstrated the mutation p.Thr161Lys in the 
JPH2 gene causing HCM in several, unrelated families. We further investigated drug 
responsiveness of patients and hiPSC-CMs carrying different mutations in RyR2 
gene. Finally, the ECG parameters were compared to MEA parameters. It is im-
portant that we have methods to examine cardiomyocyte function that correlates 
with in vitro models of the native human myocardium, especially for basic research, 
but also for pharmaceutical industry. 
A family history is an important risk factor in many cardiovascular diseases. Stu-
dies of rare familial syndromes can identify molecules whose dysfunction leads to 
cardiomyopathies and arrhythmias with channelopathies, but more generally they 
also teach us about normal heart physiology and lead to an era of mechanism-based 
therapeutics. (Zipes et al., 2019.) 
Channelopathy and cardiomyopathy mutations have remarkable variation in their 
clinical manifestations, including variable morphological phenotypes and disease se-
verities (Burke et al., 2016). Other co-morbidities and other (non)-genetic factors can 
cause changes in myocardial as well as ion channel remodeling (Verkerk et al., 2018). 
 
6.1 ECG findings caused by the D1275N mutation in SCN5A gene 
The SCN5A D1275N mutation combined with rare polymorphisms in an atrial-spe-
cific connexin40 (Cx40) gene was first identified by Groenewegen’s group in 2003 
(Groenewegen et al., 2003). The SCN5A D1275N mutation is unique because it is 
associated with both arrhythmias and the DCM phenotype (Hayano et al., 2017). 
McNairs’s research team proposed that D1275N alteration in the ion channel gene 
SCN5A is associated with DCM and dysfunction in electrical excitability, caused by 
disruption of sodium channel function, also leads to dilation remodeling (McNair et 
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al., 2004; Gui et al., 2010). A study using a human SCN5A D1275N knock-in mouse 
(Watanabe et al., 2011) and later hiPSC-based model for SCN5A D1275N-related 
sodium channelopathy demonstrated reduced maximum sodium conductance re-
sulting from reduced NaV1.5 protein expression, which is dependent on proteasomal 
degradation (Hayano et al., 2017). 
Earlier, Aalto-Setälä’s group described a large family with a mutation in the 
SCN5A gene D1275N without Cx40 mutation with variable clinical phenotypes, in-
cluding supraventricular arrhythmias, atrial standstill, and sudden death due to 
thromboembolic stroke. Atrial fibrillation or flutter and AS were probable etiologic 
factors for thromboembolic stroke, and the deaths occurred at the age of 31 or 
younger. (Laitinen-Forsblom et al., 2006.)  
A 12-lead ECG is an easy and inexpensive tool for finding risk patients. In our 
SCN5A D1275N study, we justified ECG changes in cardiac molecular events due 
to a possible reduced sodium flow causing progressive conduction disorders. Typical 
changes of the 12-lead ECG predict conduction defects and atrial arrhythmias in the 
patients with the SCN5A D1275N. Additionally, the 12-lead ECG appeared to be 
abnormal in all affected family members. Many rare and common SCN5A variants 
are associated with cardiac conduction defects (Magnani et al., 2014) and atrial fibril-
lation with or without underlying heart disease (Darbar et al., 2008; Savio-Galimberti 
& Darbar, 2014). The mutation present in the Finnish family SCN5A D1275N cau-
sing conduction defects and atrial arrhythmias is a loss-of-function mutation when 
analyzed using the hiPSC-based model (Hayano et al., 2017). The final outcome 
SCN5A mutation on the phenotype depends on, which gating property is affected 
and how it is affected (Wilde & Amin, 2018). 
 
6.1.1 PR-segment changes 
Three of our SCN5A gene mutation D1275N carriers in sinus rhythm had a remark-
able PR depression in many leads just before junctional rhythm episodes. Therefore, 
we propose that abnormal PR depression in many inferolateral leads may predict 
atrial conduction defects associated with P-wave prolongation. We suggest that PR 
depression may be a precursor of atrial arrhythmias including conduction disorders, 
atrial fibrillation, and atrial standstill. Later also other investigators have documented 
PR depression in patients with SCN5A D1275N mutation (Moreau et al., 2018). 
Theoretically, the analysis of atrial repolarization may reveal important information 
regarding arrhythmic propensity, as does QT-interval analysis in case of ventricular 
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arrhythmias. PR depression may be considered as a marker of atrial repolarization 
abnormality with similar arrhythmogenic potential as the ST elevations for ventricu-
lar arrhythmias. We propose that changes of PR interval are similar risk to atrial 
arrhythmias than changes of QT interval to ventricular arrhythmias. Conditions that 
significantly reduce Na+ current (i.e. Brugada syndrome mutations) may selectively 
shorten the duration of the epicardial action potential. This condition creates a tem-
poral imbalance between endocardial and epicardial repolarization, and such electri-
cal heterogeneity may underlie the ST-segment elevation and proarrhythmic mani-
festations of the Brugada syndrome. (Balser, 2001.)  
SCN5A mutations with loss-of-function properties have been identified in pa-
tients with cardiac conduction defects, SSS (Makita et al., 2005), and AS (Groe-
newegen et al., 2003; Makita et al., 2005). PR prolongation was also associated with 
increased risk of atrial fibrillation (Shulman et al., 2015), need for pacemaker implan-
tation, and excess mortality (Cheng et al., 2009). We also found these changes in 31% 
of our SCN5A family members even though the mutation was different. One of our 
patients, who underwent an electrophysiology study, proved to have fibrosis of the 
right atrial lateral wall. Loss of INa function could induce atrial fibrosis, which may 
cause atrial fibrillation in individuals with associated structural abnormalities in-    
cluding increased diastolic ventricular pressure in the setting of dilated cardiomyo-
pathy with subsequent enlargement of the atria (Wilde A.A & Brugada R., 2011).  
Watanabe et al. studied the same SCN5A mutation as we did, and they observed 
slowed and disordered cardiac conduction and decreased contractile function in mice 
bearing the SCN5A mutation; mice with two D1275N alleles displayed worse phe-
notypes than those with one variant allele (Watanabe et al., 2011). Two of our pa-
tients needed upgrading from a VVI-type to a physiologic pacemaker. However, af-
ter atrial lead implantation, they were more symptomatic of atrial arrhythmias, sug-
gesting that atrial fibrosis could disturb pacemaker capture as was suggested by 
Chiang et al. Sometimes pacemaker capture difficulties were seen in both the atrium 
and the ventricle depending on SCN5A mutation if it also causes fibrosis on the 
ventricle (Chiang et al., 2015). 
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6.1.2 QRS fragmentation 
When looking for an electrical link between the genotype and the phenotype in our 
patients, we noted a distinct ECG pattern with fragmentation of the R wave espe-
cially in leads II, III, and aVF. This fragmentation is a low-amplitude signal at the 
beginning of the QRS complex with similarities to the epsilon wave in patients with 
ARVC (Nasir et al., 2004; Muhappan & Calkins, 2008), although in a different loca-
tion. In the normal heart, an activated cell of the conduction system moves to posi-
tive potential because of the rapid inward surge of Na+-ions. Na+ contributes the 
electrical energy for impulse conduction. (Ritchie et al., 2013.) Anomalous Na+ cur-
rent handling in SCN5A D1275N gene mutation may affect the initial part of the 
QRS complex, resulting in the observed R-wave fragmentation. We have no definite 
explanation for the fact that this fragmented signal appeared to be larger during junc-
tional rhythm. Functional change is possible as described in patients with progressive 
ARVC in which epsilon waves are caused by slow conduction in the right ventricle 
(Marcus & Zareba, 2009). Interestingly, all our SCN5A D1275N patients, who prog-
ressed from sinus rhythm to atrial standstill, showed an increase in the amplitude of 
the initial fragmentation of the QRS complex. It could be speculated that progressive 
increase of this "spike" in the initial part of the QRS may signal disorders in atrial 
conduction and there by predict cardiac thromboembolic diseases. In 2018, SCN5A 
D1275N mutation was reported as associative with left atrial dysfunction and stroke 
even in children (Moreau et al., 2018). Also 31% of our SCN5A D1275N mutation 
carriers have thromboembolic stroke at the age of 31 or younger (Laitinen-Forsblom 
et al., 2006). 
All our gene mutation carriers also had fragmentation of the S wave and a pro-
longed upstroke in the right precordial leads in the 12-lead ECG. FQRS has been 
defined as a marker of ARVC and the Brugada syndrome, both of which have been 
linked to Na+ channel dysfunction (Surawicz & Knilans, 2008; Rizzo et al., 2012). 
Prolonged S-wave upstroke in leads V1 through V3 is also a common ECG feature 
of ARVC (Nasir et al., 2004; Muhappan & Calkins, 2008). Morita et al. showed an 
over-representation of patients with the SCN5A mutation in patients with fQRS 
(33% versus 5% in non-affected individuals) (Morita et al., 2008). All of our patients 
have fQRS, and QRS fragmentation is said to be a prognostic tool in structural heart 
diseases (Haukilahti et al., 2016). 
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6.1.3 QRS-duration changes 
In the Cohorts for Heart and Aging Research in Genome Epidemiology (CHARGE) 
consortium QRS genome-wide association study meta-analysis, QRS duration was 
associated with future development of atrial fibrillation (Ritchie et al., 2013). Our 
SCN5A D1275N family members had prolonged QRS duration; many of them had 
different atrial arrhythmias and some of them had BBB. It is possible that SCN5A 
D1275N mutation also causes degenerative intraventricular conduction defects. 
Types of intraventricular conduction defects (such as LBBB, LAFB, and RBBB) 
were present in the family with SCN5A mutation in the classical description of        
idiopathic Lev–Lenegre disease (Probst et al., 2003). Te Riele et al. speculated that 
Nav1.5 is a multifunctional protein variant with their caused a variety of clinical phe-
notypes depending on genetic changes in Nav1.5. They showed using hiPSC-CMs 
from an ARVC patient with SCN5A variants that QRS duration was significantly 
prolonged. (te Riele et al., 2017.) Mutations in the cardiac Na+ channel encoded by 
the gene SCN5A can result in many different phenotypes. The wide array of clinical 
phenotypes explains the variable outcomes of the same mutation even within one 
family because many different factors affect the expression of the gene. (Moreau & 
Chahine, 2018.) 
 
6.1.4 Impact of the study on treatment 
Atrial standstill, a severe form of atrial cardiomyopathy, is associated with combined 
heterozygous mutations of SCN5A and Cx-40 genes (Groenewegen et al., 2003; 
Goette et al., 2016), and our SCN5A D1275N mutation patients have atrial cardio-
myopathy without Cx-40 mutation. SCN5A D1275N mutation carrier may need 
medication optimization including anticoagulation and antiarrhythmic medication 
and pacemaker reviews. Patients with SCN5A mutation are seen pacemaker capture 
difficulties in both the atrium and the ventricle (Chiang et al., 2015).  
We found progressive ECG changes in patients with SCN5A D1275N mutation. 
Consequently, we agree with Probst et al. that carriers of a SCN5A mutation need a 
clinical and ECG follow-up because of the risk associated with severe conduction 
defects (Probst et al., 2006). 
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6.2 The JPH2 gene p.(Thr161Lys) mutation causing hypertrophic 
cardiomyopathy 
We have identified the JPH2 p.(Thr161Lys) variant in nine Finnish index patients 
with HCM and have shown cosegregation of the variant with cardiomyopathy in six 
of these families. This is the first JPH2 variant shown to be causative for HCM. 
Altogether 26 heterozygotes individuals with the JPH2 c.482C>A, p.(Thr161Lys) 
(NM_020433.4) variant were found and the penetrance was 71% by age 60 and 100% 
by age 80. 
Several studies have highlighted the importance of JPH2 for normal cardiac phy-
siology. JPH2 is a cardiac specific member of the junctophilins and it has emerged 
as a potentially important regulator of excitation-contraction coupling in cardiomyo-
cytes. (Takeshima et al., 2000; Landstrom et al., 2007.) However, little is known about 
the significance of JPH2 as a causative gene for cardiomyopathy. 
 
6.2.1 JPH2 p.(Thr161Lys) versus two Finnish founder mutations 
Although it has been difficult to demonstrate phenotypic correlations between dif-
ferent genes and different mutations, there is a significantly worse outcome in pa-
tients tested positive versus negative for mutations in sarcomere genes (Lopes et al., 
2013). Cardiac phenotype related to these variants differs somewhat from typical 
HCM. In Finland, three mutations in sarcomere genes, myosin binding protein C 
(MYBPC3-Q1061X), alpha tropomyocin (TPM1-D175N), and myosin heavy chain 7 
(MYH7-R1053Q), account for about 23% of all cases with HCM (Kuusisto et al., 
2016). Two Finnish founder mutations for HCM have previously been published, 
one in myosin binding protein C (MYBPC3) gene and the other in alpha tropomyo-
cin (TPM1) gene (Hedman et al., 2004; Jääskeläinen et al., 2013). The JPH2 
p.(Thr161Lys) variant presented here differs from the other two founder mutations 
in clinical presentations. The JPH2 variant associates with earlier disease onset (27 
years vs. 52 and 49 years) than the MYBPC3 p.(Gln1061*) or TPM1 p.(Asp175Asn), 
respectively, although no patients under age of 16 were included in the previous 
study (Jääskeläinen et al., 2013). Systolic heart failure was observed in 5 (25%) and 
LV dysfunction was present in half of the affected patients with JPH2 variant when 
defined by EF<47% or elevated proBNP. Of the probands with MYBPC3 
p.(Gln1061*), none has had congestive heart failure. However, dyspnea was present 
in 31%. Also none of the index patients with the TPM1 p.(Asp175Asn) mutation 
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had significant systolic dysfunction (EF<46%) and only one (5%) had a history of 
systolic heart failure. Severe conduction defects defined by 3-degree AV-block or 
R/LBBB was observed in nine (45%) and AF in nine (45%) of the affected indivi-
duals or obligate carriers with JPH2 variant, but no SCDs were detected in our fa-
milies. AF is generally suggested because of increased atrial pressures and remodeling 
as an adaptation to diastolic dysfunction, possible LVOT obstruction, and atrial    
myopathy (Cooper et al., 2017).  
Of the individuals with MYBPC3 p.(Gln1061*) variant, 26% presented syn-
cope/presyncope, 23% had either chronic or paroxysmal AF, 9% have had sustained 
VT or VF and 26% had family history of SCD. Three out of 34 (9%) HCM patients 
carrying the TPM1 p.(Asp175Asn) presented with a documented SCD at young or 
middle age. Of the probands with TPM1 or MYBPC3 founder mutation, ICD was 
implanted in 2 (10%) and 7 (20%) patients respectively and no significant conduction 
problems necessitating pacemaker implantation were described in the index publica-
tions. (Hedman et al., 2004.) These observations highlight the significant differences 
in clinical presentation of the patients with the previously characterized founder mu-
tations compared to proposed JPH2 mutation described in this study. However, the 
degree of LV hypertrophy in patients with JPH2 mutation may be similar in patients 
with these founder mutations (22±5 mm, 18±6 mm and 20±5 mm with variant in 
MYPBC3, TPM1 or JPH2, respectively) (Hedman et al., 2004; Jääskeläinen et al., 
2013), although the JPH2 variants carriers were younger at a time of evaluation com-
pared to carriers of other founder mutations. It is known that significant variation in 
clinical presentation within and between the families with the same mutation exists 
in all types of HCM (Roma-Rodrigues & Fernandes, 2014). 
We identified one family (Family 6) where all three affected individuals carry the 
well-established pathogenic MYBPC3 variant, p.(Gln1061*), in addition to the JPH2 
p.(Thr161Lys) variant. Their phenotypic presentation did not differ significantly 
from the other families that are unexpected as patients with homozygosity/com-
pound heterozygosity or digenic pathogenic variants in sarcomere genes, which may 
present at very early age (Nanni et al., 2003; Saltzman et al., 2010). In literature, at 
least nine patients have been described to have homozygous or confirmed com-
pound heterozygous disease-causing variant in MYBPC3 and at least the other not-
truncating variant. In these patients, the mean age at onset was 4.1 years. Three of 
these cases presented at neonatal phase, of which all died before age of two months. 
(Dellefave et al., 2009; Marziliano et al., 2012.) All patients with homozygous or 
compound heterozygous truncating pathogenic mutations in MYBPC3 reported so 
far (n = 21) were diagnosed with severe cardiomyopathy and/or died within the first 
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few months of life (Marziliano et al., 2012). At the moment, it is unclear whether 
compound mutation present in sarcomere and non-sarcomere gene simultaneously 
has additive detrimental effect on disease onset and/or progression. 
 
6.2.2 Pathogenicity of JPH2 mutations 
Quick et al. have described a JPH2 p.(Ala405Ser) variant in a single patient with basal 
septal hypertrophy and diastolic dysfunction (Quick et al., 2017). Most of the pre-
viously published variants are absent or rare in the Exome Aggregation Consortium 
(ExAC) or the Genome Aggregation database (gnomAD) reference populations and 
therefore they have potential to be disease causing. Truncating JPH2 variants are 
relatively rare in ExAC reference population (carrier frequency 1 per 6,030 indivi-
duals) but due to the small size of the gene, the probability of being loss of function 
(LoF) intolerant (pLI) value is 0.01, which does not suggest that loss of function 
alterations would be poorly tolerated. The clinical data on HCM related to the pre-
viously published JPH2 missense variants is limited. Mostly, clinical HCM appears 
to be diagnosed after teenage but at least the patient with p.(Glu169Lys) manifested 
HCM at the age of 5 months (Beavers et al., 2013), similarly as two patients in our 
JPH2 study. 
We showed that the JPH2 p.(Thr161Lys) is classified as pathogenic based on the 
ACMG (the American College of Medical Genetics and Genomics) classification 
scheme (Richards et al., 2015), as the variant resides in a conserved position, is pre-
dicted to be deleterious by in silico prediction tools, is absent in control populations 
and cosegregates with dominant HCM in six families. 
 
6.3 Mutations in different localizations in the RyR2 gene affect the 
drug responsiveness in CPVT  
We studied the antiarrhythmic potential of dantrolene in the treatment of CPVT1 
assessing the efficacy of intravenously administered dantrolene in patients carrying 
various RyR2 mutations and compared these effects to in vitro studies using iPSC 
derived CMs generated from the same patients. Our findings demonstrate that int-
ravenous dantrolene abolished or markedly reduced arrhythmias in a subgroup of 
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CPVT1 patients with specific RyR2 mutations. By combining evidence from in vivo 
and in vitro studies, we suggest that the location of the RyR2 mutation affects the 
antiarrhythmic effect of dantrolene in CPVT1 (Figure 18). 
 
6.3.1 CPVT1 patient-specific iPSC derived cardiomyocytes 
Several studies using induced pluripotent stem cell (iPSC) technology (Takahashi et 
al., 2007) have shown the ability of CPVT1 patient-specific iPSC derived cardiomyo-
cytes (CMs) to replicate the disease phenotype in cell culture (Novak et al., 2011; 
Fatima et al., 2011; Jung et al., 2012; Kujala K. et al., 2012; Itzhaki et al., 2012; Di 
Pasquale et al., 2013). Dantrolene was reported to rescue the disease phenotype in 
iPSCs derived CMs from a single RyR2 S406L mutation carrier (Jung et al., 2012), 
but no in vivo data exists on its effects on CPVT1 patients. Usually dantrolene is a 
drug used to treat another ryanodine receptor disorder, for example malignant hy-
perthermia (Kobayashi et al., 2010). 
It is also a significant aspect that even if a drug is found to be beneficial in the 
patient-derived iPSC-CMs, it cannot be automatically concluded that this will trans-
late into a clinical benefit for patients with same disease. Here we show that dantro-
lene, if given intravenously, has an antiarrhythmic effect also in some but not in all 
patients with CPVT1. This antiarrhythmic effect was observed only in patients with 
RyR2 mutations in the N-terminal or central regions of RyR2 protein (clusters 1–3), 
whereas virtually no effect was seen in patients carrying mutations at the end of 
cluster 3 or in the transmembrane region (cluster 4). Although a dose-dependent 
effect cannot be excluded, similar observations on mutation-specific drug respon-
ses have been obtained in some other genetic disorders including long QT syndrome 
type 3 (Ruan et al., 2007), cystic fibrosis (O'Reilly et al., 2013), Wilson disease 
(Overeem et al., 2019), as well as in certain neoplastic diseases (Willyard, 2011). 
More than 150 mutations in RyR2 gene have been reported before our study and 
they are clustered in four hotspots (Priori & Chen, 2011). One third of the reported 
mutations are in clusters 1 and 2, and the rest are equally distributed between clusters 
3 and 4. Only 10% of RyR2 mutations have been found outside these clusters (Priori 
& Chen, 2011). The location of the RyR2 mutation appears to be critical for a fa-  
vorable effect of dantrolene. The binding site for dantrolene is localized in the N-
terminus of RyR2 between amino acid 601 and 620. (Paul-Pletzer et al., 2005; Koba-
yashi et al., 2009.) In previous studies (Kobayashi et al., 2005; Paul-Pletzer et al., 
2005; Kobayashi et al., 2009), it has been demonstrated that the dantrolene-binding 
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sequence is considered to constitute part of the domain switch region, suggesting 
that dantrolene is involved in the correction of defective unzipping and allosteric 
stabilization of interdomain interactions between the N- terminal and central regions 
of RyR2, resulting in inhibition of Ca2+ leak (Kobayashi et al., 2005; Suetomi et al.,  
2011; Wang et al., 2011). We also show that dantrolene abolished arrhythmias in 
CPVT1 patients with mutations of N terminal or central domain, suggesting that a 
defective interdomain interaction within the RyR2 could be the underlying ar-
rhythmogenic mechanism in the exon 3 deletion, P2328S, T2538R and L4115F. 
However, dantrolene did not suppress T2538R-related arrhythmias to the same ex-
tent as arrhythmias caused by other central region mutations. It has been speculated 
that differences in the mode of interdomain interaction in dantrolene-binding re-
gions may result in differences in its antiarrhythmic efficacy (Suetomi et al., 2011). 
Furthermore, other drug-binding regions in the carboxyl-terminal half of the RyR2 
or additional low affinity drug binding sites in the N-terminal area could exist (Ko-
bayashi et al., 2009). No previous studies on the effects of dantrolene on RyR2 mu-
tations in or close to the transmembrane are available; here we demonstrate that 
dantrolene has no or only minimal effect on arrhythmias if mutations are located in 
these areas. It is intriguing that the patient with Q4201R mutation did not respond 
to dantrolene even though this mutation is located in cytosolic portion of RyR2 and 
in cluster 3 although in its terminal part. This finding implies that the location of the 
mutation in a certain mutation cluster does not necessarily determine the antiarrhyth-
mic response and highlights the utility of the iPSC model for individual functional 
analysis. 
 
6.3.2 Dantrolene effects in the clinical setting and corresponding iPSC-CM 
models 
Our study showing similar patient-to-patient variation in dantrolene effects in the 
clinical setting and corresponding iPSC-CM models propose that, at least in theory, 
it may be possible to tailor an individual's medication in cell culture without predis-
posing the individual to the potentially serious side effects of a drug. Dantrolene did 
not affect normally beating CMs. This is consistent with previous reports showing 
that dantrolene inhibits only abnormal Ca2+ release and has no effect on the normal 
Ca2+ transients, suggesting that the native conformation of RyR2 may restrict binding 
of the drug and that dantrolene binding to RyR2 might be dependent on a specific 
conformational state present only in mutated cells. (Paul-Pletzer et al., 2005; 
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Kobayashi et al., 2009.) Defective calmodulin binding caused by RyR2 domain un-
zipping has also been shown to be restored by dantrolene (Xu et al., 2010; Ono et 
al., 2010), which may as well explain why dantrolene exerts effects on diseased but 
not healthy hearts. Although dantrolene as such would not be suitable for long-term 
treatment of CPVT1 due to its side effects, and although only a subset of patients 
would benefit from it, our data shows its antiarrhythmic potential for some patients. 
Although in our study of RyR2 mutations we showed that even patients with diffe-
rent mutations in the same gene benefit from dantrolene diffe-rently. 
Drug responses were similar in patients and their iPSC-CMs, in other words 
CPVT1 in vitro phenotypes depending on the nature of the mutation. Immature phe-
notype of the iPSC-CMs may too produce variation in arrhythmias. However, in a 
previous study of the same research group (Kujala K. et al., 2012) the electrophysio-
logy of CPVT1 iPSC-CMs appeared fairly mature, which also reflects that arrhyth-
mias are more consistent in CPVT1 CMs than in control CMs. In addition, the beat-
ing frequency of CPVT1 CMs was lower than that in control CMs. This is in line 
what has been reported also with CPVT1 patients (Lobo et al., 2011; van der Werf 
& Wilde, 2013). All the CPVT1 CMs showed similar disturbances in intracellular 
Ca2+ cycling. Ca2+ transient abnormalities were somewhat more common in the clus-
ter 4 mutation than in cluster 1, 2 and 3 mutations. Exon 3 deletion differed from 
all the other mutations by having lower diastolic Ca2+ levels and beating frequency 
both at baseline and during adrenaline perfusion. Exon 3 encodes secondary struc-
ture elements that are crucial for folding of the N-terminal domain. It has been pro-
posed that RyR2 with exon 3 deletion has evolved additional means to regulate Ca2+ 
release, by altering the conformation of the domain (Lobo et al., 2011), which may 
result in the observed differences in Ca2+ transients. 
 
6.4 Comparison of 12-lead ECG and in Vitro FP of hPSC-CM 
It is important that we have methods to search cardiomyocytes function, which cor-
relates to in vitro models of the native human myocardium. There are no direct re-
ports about the relationship of intricate electrophysiological characteristics between 
the human heart and hPSC-CMs. In our study IV, we investigated the relationship 
of electrical activation and beating rate clinically using ECG and MEA recordings in 
vitro of hPSC-CMs and found that the results correlated well with each other.  
 86 
The electrical properties of the heart are due to ion transfer across the cell memb-
rane. In vivo, the transfer rate of potassium ions is dependent of the beating rate (Aziz 
et al., 2018). The repolarization time presented as the QT interval in the ECG is, 
thus dependent on how fast the heart beats (Karjalainen et al., 1994). Because heart 
rate is normally the main determinant of repolarization length, there are several for-
mulas how to correct the measured QT interval so that QT intervals with different 
beating frequencies can be compared (Surawicz & Knilans, 2008). The simplest and 
most widespread approach to correct the QT interval is to divide its value by the 
square root of the preceding RR interval expressed in seconds (QTc= QT/¥RR), 
i.e., by using Bazett's formula (Bazett, 1920; Funck-Brentano & Jaillon, 1993).   
With hPSC-CMs, these same correction formulas have been used without any 
evidence whether the same formulas are effective during in vitro situations (Stett et 
al., 2003). In our QT/FPD study, we chose control individuals with a low baseline 
beating rate and performed a stress exercise test to obtain QT variation over the 
same beating frequency spectrum as obtained with spontaneously beating hPSC-
CMs. The cells were cultured on MEA platform, and the FPD corresponding to QT 
in ECG was measured. A strong correlation was observed between QT intervals and 
FPDs, and the correction of these parameters using Bazett’s formula gave similar 
results, thus confirming that the ion fluxes in cell culture present with corresponding 
performance as they do in vivo in the heart.  
Normally the QT interval of the heart increases with decreasing heart rate (Kar-
jalainen et al., 1994) due to decrease in potassium flux across the cell membrane 
(Aziz et al., 2018). The hPSC-CM beating rate in our cell cultures varied from 55 
(minimum) to 100 (maximum) bpm with the average of 73 bpm. We made compa-
rison with the cardiac parameters between ECG and MEA recordings and could 
show that QT and RR parameters correlate excellently with FPD and PPI results. In 
the volunteers who were used for the comparison, the heart rate varied between 39 
and 120 bpm with an average of 76 bpm.  
 
6.4.1 QT/RR versus FPD/PPI 
AHA/ACCF/HRS recommends that linear regression functions rather than the Ba-
zett’s formula be used for QT-rate correction although Bazett’s formula is the most 
widely used for QT-rate correction (Rautaharju et al., 2009). QT/RR value means 
how quickly and how much QT interval changes when heart rate changes (Malik et 
al., 2018) corresponding to FPD/PPI values in MEA. The over- or undercorrection 
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of QTc may lead to significant and systematic bias with both false positive and false 
negative findings, whereas QT/RR patterns in all different subjects will be charac-
terized by the same mathematical form. Population risk stratification studies inves-
tigating QT/RR patterns would also benefit from this mathematical description 
avoiding the heart rate influence. (Malik et al., 2013.) QT/RR mean value of our 
volunteers was 0.433, ranging from 0.40 to 0.46. The mean FPD/PPI value of 0.44 
indicates that the basal FPD in relation to the time between individual beats cor-
responds with QT/RR values.  
The coefficient of determination value of 0.71 is good for biological samples. Our 
results indicate that 71% of the FPD prolongation is explained by concurrent pro-
longation of the PPI. However, the FPD generally increased when PPI was pro-
longed corresponding to changes of QT time and RR cycle. Taken together with the 
observation that hPSC-CMs demonstrated fairly stable PPI dynamics within re- 
cordings, we conclude that they are rather reliable models in terms of their electro-
physiological aspects, especially when corrected for beating-rate-dependent FPD 
modulation. It is also known that in different individuals the predicted QT times 
may normally vary up to 90 ms even if the RR cycle lengths are the same (Surawicz 
& Knilans, 2008). QT time variation between our volunteers was less than 60 ms at 
various RR cycle lengths. The coefficient of determination of our volunteers was 
about 0.68 for ECG (Figure 19). 
 
6.4.2 QTc= QT/¥RR versus cFPD= FPD/¥PPI 
The cFPD value of 400 ms for hPSC-CMs is within the physiological normal range 
for QTc values. Because uncorrected FPD was 375 ms at 73 bpm, the Bazett’s for-
mula is adequately compensating for the rate-induced FPD shortening also in hESC-
CMs. Analogously, the volunteers had a mean QTc of 432 ms and their uncorrected 
mean QT was 397 ms with a mean heart rate of 76 bpm. However, a heart rate of 
60 bpm is the most optimal when using Bazett’s formula (Funck-Brentano & Jaillon, 
1993). Usually the relationship between QT/RR adaptation and mean QTc values 
means that those subjects who show longer QTc intervals have steeper QT/RR pat-
terns (Malik et al., 2013). In our study, we demonstrated that the relationship 
FPD/PPI adaptation and cFPD values functioned similarly to the relationship bet-
ween QT/RR adaptation and QTc values. It is also known that Bazett’s formula 
overcorrects the QT interval at high heart rates (Surawicz & Knilans, 2008). This 
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probably is the reason for this small, normal variations range difference between our 
cFPD and QTc values. 
However, there is no consensus regarding, which would be clinically the optimal 
formula (Fridericia's or Bazett's formula) (Izumi-Nakaseko et al., 2017). Still, Bazett’s 
formula is easy to use and widely applied and thus it was chosen in this study to 
compare in vitro and in vivo electrical parameters in different beating rates. 
 
6.5 Future perspectives 
As we learn to understand the cellular and molecular mechanisms in healthy heart 
and in disease states, we can find better methods for diagnostic and treatment pur-
poses. 
The hope is that molecular genetic approach can be applied to common types of 
arrhythmia, such as atrial fibrillation and SCD. Studies of large populations to iden-
tify common genetic variants that predispose individuals to arrhythmias hold similar 
promise for early detection and intervention in asymptomatic patients at high risk. 
Arrhythmias and cardiomyopathies are an important public health challenge. (Mi-
zusawa, 2016.) 
Some authors think that for example severe septal-leaflet contact is enough for 
HCM diagnosis (Sen-Chowdhry et al., 2016). In the future, molecular genetic diag-
nosis helps us to do diagnosis to patients with another anatomical abnormality of 
HCM without wall thickness. Further research is warranted to evaluate JPH2 variants 
and other genes related to Ca2+ handling in the cardiomyocyte to further shed light 
on the genetic background of HCM also using hPSC-CM techniques. Variant inter-
pretation and correlation to phenotype is still exacting as earlier studies form major 
pitfalls by false classifications related to small reference populations, coincidental 
segregations and evaluation of only a small subset of the potentially significant genes 
behind a patient's phenotype (Sedaghat-Hamedani et al., 2018). Large-scale genetic 
research will eventually bring more consistency to the evaluation of families with 
inherited cardiac diseases. Variant sharing with relevant information of the pheno-
type in mutation databases is important to develop the field further. (Garcia et al., 
2016.)  
Genetic diagnosis enables cost-effective screening of first-degree family members 
and eliminates healthcare expenditures for relatives without pathogenic mutations, 
resulting in substantial health care cost savings. Relatives who do not carry the 
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mutation can be excluded from regular cardiac follow-up and can be reassured that 
there is no increased risk in their offspring. (Zipes et al., 2019.)  
Maybe in the future we can use whole-exome sequencing (WES) and other next-
generation sequencing (NGS) approaches and to successfully identify genetic vari-
ants potentially contributing to the cardiomyopathies and life-threatening   arrhyth-
mias better than today (Miles & Behr, 2016). We also believe that someday we can 
use the novel classification of inherited cardiomyopathies, which is currently based 
upon the phenotypic expression. The new genomic classification should take into 
account the underlying gene mutations and the cellular level of expression of en-
coded proteins, thus distinguishing cytoskeleton (cytoskeletalopathies), sarcomeric 
(sarcomyopathies), desmosomal (desmosomalopathies), junctophilin (junctophi-
linopathies) cardiomyopathies, and ion channelopathies (Corrado et al., 2005).  
Then we can additionally choose optimal treatments individually for patients by 
combining evidence from in vivo and in vitro studies using iPS-cell techniques (Mer-
cola et al., 2013; Yamazaki et al., 2018; Pölönen et al., 2018). Even the recognition 
of potential mutation-specific responses will be important for future drug develop-
ment; one drug may not work for all patients even if the phenotype is the same. The 
genetic discoveries have enhanced understanding of the molecular pathogenesis of 
heart diseases and have stimulated efforts designed to identify new therapeutic 
agents. The multifunctional roles for cardiac proteins in cardiomyocytes may have 
implications for the development of novel therapeutic approaches for cardiomyo-
pathies, cardiac arrhythmias and heart failure.  
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6.6 Limitations of the studies 
In all the studies presented, the number of the patients is low due to the rarity of the 
diseases or mutations.  
 
6.6.1 Study I 
Our findings represent one large Finnish family with a specific gene mutation. These 
findings may not necessarily apply to other variants with mutations in the same gene. 
More studies are needed to explore the complete ECG pattern of SCN5A gene mu-
tations. 
 
6.6.2 Study II 
Most of the submissions of the JPH2 variants in ClinVar or other databases reviewed 
in this work did not include phenotype data and thus provide limited information 
for the clinical society.  
 
6.6.3 Study III   
According to the study design, we were permitted to study only acute effects of intra-
venously administered dantrolene. Although we titrated the dose of dantrolene ac-
cording to the weights of the patients, serum levels of the drug were not measured 
and could have varied from patient to patient, resulting in concentration-dependent 
variation in clinical responses. In addition, we used only a fixed concentration of 
dantrolene, selected on the basis of the work by Jung et al. (Jung et al., 2012) in our 
iPSC studies. 
  
6.6.4 Study IV 
Only one stem cell line was used in this study, but already with that we found a 
correlation with the corresponding parameters in 12-lead ECG thus increasing the 
number of cell lines would not have an effect of the results of the study. 
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7 SUMMARY AND CONCLUSIONS 
Study I clearly demonstrated that 12-lead ECG can be used to predict arrhythmias 
in individuals carrying the SCN5A D1275N mutation.  
In a Finnish family with the SCN5A D1275N mutation, ECG changes were very 
frequent. In addition to P-wave and PR changes, typical abnormalities were initial 
fragmented R waves in the inferior leads II, III, and aVF as well as the S wave in 
leads V1–V3 accompanied by slow S-wave upstroke and prolonged QRS duration. 
The progressively growing initial fragmentation of QRS complex in inferior leads 
before junctional escape rhythm was clearly visible. Atrial electrical changes (P-wave 
and PR duration) probably predispose to arrhythmias, such as junctional rhythm, 
atrial standstill, and atrial fibrillation with increased cardioembolic stroke risk.  
Our discoveries confirm that specific findings are present in the standard 12-lead 
ECG in individuals with the SCN5A mutations before clinical symptoms appear, 
and therefore ECG follow-up of asymptomatic individuals is recommended. 
 
Study II, we demonstrated that JPH2 p.(Thr161Lys) is a pathogenic mutation based 
on the ACMG classification scheme.  
We observed several Finnish families with JPH2 p.(Thr161Lys) and analyzed their 
cardiac findings. The main clinical features were left ventricular hypertrophy,            
arrhythmia vulnerability and conduction abnormalities including third degree AV-
block. Some patients had end-stage severe left ventricular heart failure with normal 
or mildly enlarged diastolic dimensions.  
Based on several clinical parameters, we propose that the heterozygous JPH2 
p.(Thr161Lys) variant is a new Finnish mutation causing atypical HCM, thus 
strengthening the role of non-sarcomeric JPH2 as a causative gene for HCM. 
 
Study III, we conclude that hiPSC-derived CMs could serve as a platform for drug 
development and to design personalized medication. 
We show here the proof of principle that intravenously administered dantrolene 
suppresses ventricular arrhythmias in patients with congenital RyR2 defect and that 
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the location of the RyR2 mutation affects the antiarrhythmic effect of this drug. We 
also demonstrated that hiPSC-derived CMs correctly predict the clinical response to 
dantrolene in CPVT1 patients in mutation-specific way. These findings illustrate the 
potential of hiPSC models to individualize the drug therapy of inherited diseases. 
 
Study IV, our results further validate the hESC-CM clusters as proper in vitro models 
of the native human myocardium. In this study, for the first time the relationship of 
ECG and cell culture MEA recordings were systematically compared. QT interval is 
beating-rate-dependent and QTc is the rate-corrected QT interval. The same correc-
tion formula (Bazett) was observed to be equally applicable to corresponding re-
polarization parameter (FPD and cFPD) in hPSC-CMs and thus the same rate cor-
rection formula can be used for electrical recordings in cell cultures. 
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Abstract 
 
Introduction: The cardiac sodium channel SCN5A regulates atrioventricular and ventricular  
depolarization as well as cardiac conduction. Patients with cardiac electrical abnormalities have an  
increased risk of sudden cardiac death (SCD) and cardio-embolic stroke. Optimal management of  
cardiac disease includes the understanding of association between the causative mutations and the  
clinical phenotype. A 12-lead electrocardiogram (ECG) is an easy and inexpensive tool for finding  
risk patients.  
                                                                                                                                    
Materials and methods: A blood sample for DNA extraction was obtained in a Finnish family 
with 43 members; systematic 12-lead ECG analysis was performed in 13 of the  
family members carrying an SCN5A D1275N mutation. Conduction defects and supraventricular  
arrhythmias, including atrial fibrillation/flutter, atrioventricular nodal re-entry tachycardia  
(AVNRT) and junctional rhythm were searched for. 
 
Results: Five (38%) mutation carriers had fascicular or bundle branch block, ten had atrial  
arrhythmias; no ventricular arrhythmias were found. Notching of the R- and S waves – including  
initial QRS fragmentation - and prolonged S-wave upstroke were present in all the affected family  
members. Notably, four (31%) affected family members had a stroke before the age of 31 and two  
experienced premature death. 
 
Conclusions: A 12-lead ECG can be used to predict arrhythmias in SCN5A D1275N mutation carriers. 
 
KEYWORDS 
SCN5A D1275N mutation; ECG; arrhythmias; conduction defects  
KEY MESSAGES 
x The 12-lead ECG may reveal cardiac abnormalities even before clinical symptoms occur.  
x Specific ECG findings – initial QRS fragmentation, prolonged S-wave upstroke as  
well as supraventricular arrhythmias - were frequently encountered in all SCN5A D1257N 
mutation carriers. 
x ECG follow-up is recommended for all SCN5A D1275N mutation carriers. 
 
Introduction 
Regulation of the expression and proper function of voltage-gated ion channels at the plasma  
membrane of excitable cells is essential in maintaining cellular excitability and electrical impulse  
propagation. In the heart, voltage-gated sodium (Na+) channels determine the amplitude and slope  
of the action potential upstroke, which are especially important in the control of impulse conduction  
velocity, and in the maintenance of appropriate waves of excitation through the working  myocardium. 
Dysfunction of these channels can lead to life-threatening cardiac arrhythmias (1,2). 
Some mutations associated with cardiac disease have been identified in the gene encoding cardiac sodium 
channel Į-subunit SCN5A, which is responsible for the generation and propagation of action potentials in the 
atrium, ventricle and specialized conduction system (3).  
Genetic defects associated with cardiac electrical disorders are usually found in genes encoding for  
cardiac ion channels. Cardiac Na+ channel dysfunction caused by mutations in the SCN5A gene is  
associated with a number of relative uncommon arrhythmic diseases, including long QT syndrome  
type 3 (LQT3), Brugada syndrome, and short QT interval with Brugada-like electrocardiogram  
(ECG) (2,4), progressive cardiac conduction disease (PCCD), sick sinus syndrome (SSS), and atrial 
standstill, which all potentially can lead to fatal arrhythmias at relatively young age. Various SCN5A 
mutations are known to present with mixed cardiac phenotypes including arrhythmias and dilated 
cardiomyopathy (5). SCN5A mutations are also involved in overlap syndromes of cardiac sodium 
channelopathy. Remme and co-workers provided an overview of the current knowledge on SCN5A mutations 
associated with sodium channel overlap syndromes (6,7). They also discussed the possible role of modifiers 
in determining disease expressivity in an individual patient (6,8,9,10,11,12). 
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Cardiac conduction, as assessed by the PR interval and QRS duration, is an important electrophysiological 
trait and a determinant of arrhythmic risk (13). Atrial standstill is a rare cardiac disorder characterized by the 
absence of electrical and mechanical atrial activity. Atrial standstill can be persistent or transient, and either 
diffuse or partial in the atrial wall involving either one or both atria (14,15). Atrial standstill is characterized 
by bradycardia, diminution or absence of the P wave, junctional (usually narrow complex) escape rhythm 
and failure of atrial excitation, either spontaneously or by pacemaker stimulation. Atrial standstill is 
associated with an increased risk of sudden death due to occurrence of very low escape rhythm and an 
increased risk of thromboembolic stroke due to the high incidence of atrial fibrillation/flutter (3).   
Familiar atrial standstill has been associated with the SCN5A D1275N mutation combined with rare 
polymorphisms in an atrial-specific connexin40 (Cx40) gene (16,17,18,19). In a large Finnish family cardiac 
conduction defects and atrial arrhythmias were also associated with the same SCN5A D1275N mutation, 
although not linked to the polymorphism in the Cx40 gene (20). 
Although no sudden cardiac death was recorded in the family, at least four affected members  
suffered from cardio-embolic stroke by the age of 31 and two of them died of stroke (20). In this  
report we present the ECG findings, including atrial arrhythmias in individuals carrying the SCN5A 
 D1275N mutation. 
Materials and methods 
Subjects 
A Finnish family with 45 members was evaluated at the Heart Center, Tampere University Hospital.  
All participants gave their informed consent for study participation and the local Ethics Committee  
gave their approval for the study (R01128). A blood sample for DNA extraction was obtained from  
43 family members. In this study we report the ECG findings of eleven SCN5A D1275N mutation  
carriers and two deceased obligate carriers. The oldest family member had nine children and only  
the ECGs of the SCN5A D1275N mutation carriers, including the two obligate carriers were analysed 
(Figure 1).   
Genetic analysis  
The genotype analysis of the family members has been previously described in detail by Laitinen- 
Forsblom et al (20). Based on candidate gene approach, a point mutation (guanine to adenine at  
position 3823 in exon 21) in the SCN5A gene was observed causing a substitution of aspartic acid  
with aspargine (D1275N). 
ECG analysis 
A 12-lead surface ECG was recorded at rest and the study participants were not allowed to smoke or drink 
coffee at least six hours prior to the ECG recording.  The ECG electrodes were positioned according to 
standardized protocol at a paper speed of 50 mm/s and 1 mV/cm standardization.  
Heart rate, P-wave duration and amplitude, PR interval and deviation from the baseline, QRS duration, S-
wave amplitude and up-stroke, QT, and corrected QT (QTc; Bazett`s formula) intervals were measured 
manually by one of the investigators (SV). 
Normal P-wave duration was defined as 70-140 ms (21). The P wave was described as flat, if the amplitude 
was < 0.05 mV in the limb leads. 
We used 120 to 200 ms as normal values for the PR interval. The interval was measured in the lead with the 
largest and widest P wave and the longest QRS duration. The P and QRS axis was considered normal when it 
was between - 30° and + 90°. We defined PR-segment depression as > 0.08mV, and elevation as >0.05 mV 
(21).  
For QRS-complex fragmentation (fQRS), we used the definition by Das et al: additional R wave (R´  
prime), notching in nadir of the S wave, notching of R wave, or the presence of more than one R  
prime (fragmentation). Typical bundle branch block (BBB) pattern (QRS > 120 ms) - right or left –  
and incomplete RBBB were excluded from the definition of fQRS (22, 23). In left anterior fascicular block 
(LAFB) QRS duration may be normal or slightly prolonged (21). The upper limits of the S-wave amplitude 
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in leads V1-V3 were 1.8, 2.6, and 2.1 mV, respectively (20).  The QT- interval was measured according to 
established methodology (21). 
The diagnosis junctional escape rhythm required at least three successive complexes. Both the  
typical finding with a narrow QRS and possible cases with broad QRS due to pre-existing  
intraventricular conduction defect were included (21).   
Atrial standstill is characterized by bradycardia (HR< 50/bpm), the absence of P waves and a  
junctional narrow or slightly wide QRS complex and regular escape rhythm (16,17,21).  
 
Results 
 
Subjects 
In genetic analysis, we found eleven SCN5A D1275N mutation carriers and two obligate carriers.  
The mutation in the SCN5A gene present in this family result in the substitution of asparagine for  
aspartic acid at aa 1275 (D1275N). One of the obligate carriers was the oldest family member  
(patient I:1; Figure 1) of this pedigree and another one (patient II:2) was the father of two mutation  
carriers (patients III:5, III:6). Both of these obligate mutation carriers had passed away before this  
study was initiated. Four of nine children of the oldest obligate mutation carrier (patient I:1) had the  
SCN5A mutation. Only the mutation carriers of these children are presented in the figure 1. Four mutation 
carriers (patients II:2, II:3, II:4, and III:6) of the family had encountered thromboembolic stroke by the age 
of 31 years, two of them (father II:2 and son III: 6) died at young age; the father at the age of 30 and the son 
even at the age of 21 (Figure 1). 
 
Electrocardiografic characteristics of the family. 
Five of eleven (38%) mutation carriers had a VVIR-type of pacemaker implanted due to a  
bradycardic junctional rhythm (patients III:6 and III:7, Figure 1) or atrial fibrillation with 
symptomatic bradycardia (patients I:1, II:4, and III:5). The oldest family member (patient I:1) had 
atrial fibrillation with slow ventricular response at the age of 38 years and her ECG showed LAFB  
and RBBB before pacemaker implantation. She had anticoagulation therapy because of atrial  
fibrillation, but no history of stroke. Nine (69%) SCN5A D1275N mutation carriers had atrial  
fibrillation or flutter.  
Transient atrial standstill was observed in one patient (III:7) (8%); he also had paroxysmal RBBB  
and LAFB. Two other patients - father and son - (II:2 and III:6) with junctional rhythm had no  
documented atrial tachyarrhythmias before premature death due to stroke. The son (III:6) also had  
RBBB and LAFB.   
In all patients carrying the SCN5A D1275D mutation, we found a distinct initial pattern of QRS  
fragmentation with notching of the R wave (Figure 2). This change was prominent in leads II, III or  
aVF. The fragmentation seemed to be more prominent during junctional rhythm than during sinus  
rhythm (Figure 3). All the SCN5A D1275N patients, who progressed from sinus rhythm to atrial standstill, 
showed an increase in the amplitude of the initial fragmentation of the QRS  
complex. 
All 13 (100%) patients had fragmentation of the nadir of the S wave in at least one of the leads V1- 
V3 and also a prolonged S-wave upstroke. 
The P wave was generally flat in all mutation carriers in conjunction with remarkable PR 
depression in three (23%) individuals (II:2, III:4, III:7).  The P wave could not be analyzed in three  
patients (II:2, III:5 and III:7) due to junctional rhythm.   
The QTc interval was normal in the 12-lead ECG in all mutation carriers.  
(Figure 2 and table I). 
 
Discussion 
 
We describe a large family with a mutation in the SCN5A gene (D1275N) with variable clinical phenotypes, 
including supraventricular arrhythmias, atrial standstill and sudden death due to thromboembolic stroke. The 
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12-lead ECG proved to be abnormal in all affected family members. Atrial arrhythmias and atrial standstill
were probable etiologic factors for thromboembolic stroke, and the deaths occurred at the age of 31 or
younger. Typical changes of the 12-lead ECG predict conduction defects and atrial arrhythmias in the
patients with the mutation SCN5A (D1275N). Many rare and common SCN5A variants are associated with
cardiac conduction defects (24).
Cardiac conduction, as assessed by the PR interval and QRS duration, is an important electrophysiological
trait and a determinant of arrhythmic risk (13). The ECG is characterized by different waves that represent
specific phases of the cardiac activation sequence: the P wave reflects atrial depolarization, the QRS
complex represents ventricular depolarization, and the T wave indicates ventricular repolarization (25).
PR-segment changes 
A wide, notched or low-amplitude Ta can predict an interatrial conduction disturbance with or without atrial 
enlargement. The Ta wave represents atrial repolarization and the interval from the beginning of the P wave 
to the end of Ta is the atrial equivalent of the ventricular QT interval (26). Theoretically, the analysis of atrial 
repolarization may reveal important information regarding arrhythmic propensity, as does QT-interval 
analysis in case of ventricular arrhythmias. PR depression may be considered as a marker of atrial 
repolarization abnormality with similar arrhythmogenic potential as the ST elevations for ventricular 
arrhythmias.  
Conditions that significantly reduce Na+-current (i.e Brugada syndrome mutations) may selectively  
shorten the duration of the epicardial action potential. This condition creates a temporal imbalance  
between endocardial and epicardial repolarization, and such electrical heterogeneity may underlie  
the ST-segment elevation and pro-arrhythmic manifestations of the Brugada syndrome (27). Three of our 
SCN5A gene mutation D1275N carriers in sinus rhythm had a remarkable PR depression in many leads just 
before junctional rhythm episodes.  
Therefore, we propose that abnormal PR depression in many inferolateral leads may predict atrial conduction 
defects associated with P-wave prolongation. Therefore, PR depression may be a precursor of atrial 
arrhythmias including conduction disorders, atrial fibrillation and atrial standstill. Also, Makita et al (17) 
showed progressive atrial dysfunction leading to the atrial standstill in SCN5A mutation L212P. 
P wave and PR interval 
SCN5A mutations with loss-of-function properties have been identified in patients with cardiac  
conduction defects, SSS (17) and atrial standstill (16,18). Herfst and co-workers have shown that  
P-wave broadening and a tendency to PR-prolongation are manifested in the ECG of individuals with the
SCN5A/5280delG mutation, presumably due to a reduction in Na+ current (1). PR prolongation was also
associated with increased risk of atrial fibrillation (28), need for pacemaker implantation and excess
mortality (29).  We also found these changes in some of our SCN5A family members even though the
mutation was different.
One of our patients, who underwent an electrophysiology study, proved to have fibrosis of the right atrial
lateral wall. Loss of INa function could induce atrial fibrosis, which may cause atrial fibrillation in
individuals with associated structural abnormalities including increased diastolic ventricular pressure in the
setting of dilated cardiomyopathy with subsequent enlargement of the atria (10). Watanabe et al. studied the
same SCN5A mutation as in our family and they observed slowed and disordered cardiac conduction and
decreased contractile function in mice bearing an SCN5A mutation; mice with two D1275N alleles displayed
worse phenotypes than those with one variant allele. In vitro electrophysiological studies identified reduced
peak cardiac Na+ current as a key defect and this is consistent with the observed reduced conduction velocity
(30). Two of our patients needed upgrading from a VVI-type to a physiologic pacemaker. However, after
atrial lead implantation they were more symptomatic of atrial arrhythmias, suggesting that atrial fibrosis
could disturb pacemaker capture as was suggested by Chiang and co-workers (31).
QRS fragmentation  
Many investigators considered fragmented QRS (fQRS) as an independent predictor of cardiac  
events (32,33,34,35,36).  When looking for an electrical link between the genotype and the phenotype in our 
patients, we noted a distinct ECG pattern with fragmentation of the R wave especially in leads II, III and 
aVF. This fragmentation is a low-amplitude signal at the beginning of the QRS complex with similarities  
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to the epsilon wave in arrhytmogenic right ventricular cardiomyopathy (37), although in a different  
location. In the normal heart, an activated cell of the conduction system moves to positive potential  
because of the rapid inward surge of Na+-ions. Na+ provides the electrical energy for impulse conduction 
(38). Anomalous Na+ current handling in SCN5A D1275N gene mutation may affect the initial part of the 
QRS complex, resulting in the observed R-wave fragmentation. We have no definite explanation for the fact 
that this fragmented signal appeared to be larger during junctional rhythm. Interestingly, all our SCN5A 
D1275N patients, who progressed from sinus rhythm to atrial standstill, showed an increase in the amplitude 
of the initial fragmentation of the QRS complex. It could be speculated that progressive increase of this 
“spike” in the initial part of the QRS may signal disorders in atrial conduction and there by predict cardiac 
thromboembolic diseases.  
All our gene mutation carriers also had fragmentation of the S wave and a prolonged upstroke in the right 
precordial leads in the 12-lead ECG. FQRS has been defined as a marker of arrhythmogenic right ventricular 
cardiomyopathy and the Brugada syndrome, both of which have been linked to Na+ channel dysfunction 
(21). Prolonged S-wave upstroke in leads V1 through V3 is a common ECG feature of arrhythmogenic right 
ventricular cardiomyopathy (37). Morita et al showed an over-representation of patients with the SCN5A 
mutation in patients with fQRS (33% vs. 5% in non-affected individuals) (36) and our results are in line with 
these previous observations. 
 
QRS duration 
In the Cohorts for Heart and Aging Research in Genome Epidemiology (CHARGE) consortium QRS 
genome-wide association study meta-analysis, QRS duration was associated with future development of 
atrial fibrillation (38). Probst and coworkers described progressively increased QRS duration in patients with 
SCN5A-linked hereditary Lev-Lenegre disease affecting the His bundle and its branches (39). Our SCN5A 
D1275N family members had prolonged QRS duration; many of them had different atrial arrhythmias and 
some of them had BBB. It is possible that SCN5A D1275N mutation also causes degenerative 
intraventricular conduction defects. Types of intraventricular conduction defects (such as LBBB, LAHB and 
RBBB) were present in the family with SCN5A mutation in the classical description of idiopathic Lev-
Lenegre disease (39).  
Progressively increased conduction defects predict atrial paralysis and atrial arrhythmias, which are possible 
reasons for cardio-embolic stroke without anticoagulation (39,40). Prost et al demonstrated that carriers of a 
SCN5A mutation need a clinical and ECG follow-up because of the risk associated with severe conduction 
defects (41). Mutations in the cardiac Na+ channel encoded by the gene SCN5A can result in many different 
phenotypes.  The wide array of clinical phenotypes explains the variable outcomes of the same mutation even 
within one family.  
 
Limitations 
Our study did not include long-term follow-up. Therefore, we have no solid data on the consistency of the 
ECG findings.  
We were not able to perform reliable analysis of the P waves during stress test in the study population. 
Therefore, exercise test data was not included.  
The findings presented represent one family with a specific gene mutation. These findings may not 
necessarily apply to other families with mutations in the same gene. More studies are needed to explore the 
complete ECG pattern of SCN5A gene mutations.  
 
 
Conclusions 
In a Finnish family with the SCN5A D1275N mutation, ECG changes were very frequent in the  
mutation carriers. In addition to P-wave and PR changes, typical abnormalities were fragmented R  
waves in the inferior leads II, III and aVF as well as of the S wave in the leads V1-V3 accompanied  
by slow S-wave upstroke and prolonged QRS duration. Atrial electrical changes probably  
predispose to arrhythmias, including junctional rhythm, atrial standstill and atrial fibrillation with  
increased cardio-embolic stroke risk at young age. Our findings confirm that complex and variable  
findings are present in the standard 12-lead ECG in individuals with a single SCN5A mutations.  
Therefore, ECG follow-up of asymptomatic individuals is recommended. 
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Table I.  Distribution of 12-leads ECG parameters of the SCN5A D1275N patients. 
ECG parameters  n = 13 (%) Individual    
Junctional rhythm 4 (31%)       (II:1, II:2, III:6, III:7) 
Atrial fibrillation or flutter 9 (69%)   (I:1, II:1, II:3, II:4, III:1, III:3, III:4, III:5, III:7) 
Atrial tachycardia 1 (8%)      (III:5) 
Flat P wave in lead II 4 (31%)    (II:1, II:2, III:2, III:7) 
P wave > 140 ms 2 (15%)    (II:1, III:2) 
PR interval > 200 ms 4 (31 %)          (II:1, III:1, III:2, III:5) 
Fragmentation of          
initial QRS   13 (100%) 
S-wave upstroke  55 ms 13 (100%)   
in leads V2-3
Notching in nadir of the S wave 13 (100%) 
in leads V1, V2, V3
QRS  120 ms 10 (77%)        (all except II:3, III:1, III:3)   
RBBB 4 (31%)     (I:1, III:6, III:7, IV:1) 
LAFB 4 (31%)     (I:1, II:3, III:6, III:7) 
Pacemaker 5 (38%)     (I:1, II:4, III:5, III:6,  III:7) 
Figure legends 
Figure 1. Pedigree indicating the ECG findings. Four of nine children of the oldest obligate mutation carrier 
(patient I:1) had the SCN5A mutation, only these individuals significant to genetic analysis and their children 
are included. AF = atrial fibrillation or flutter, AT = atrial tachycardia, AV I = grade I atrioventricular block, 
AVNRT = atrioventricular nodal re-entry tachycardia, c = chronic, DCM = dilated cardiomyopathy, LAFB = 
left anterior fascicular block, p = paroxysmal, PAMA = implanted pacemaker, pr Pd = prolonged P duration, 
RBBB = right bundle branch block, SSS = sick sinus syndrome, TIA = transient ischemic attack, y = years  
Figure 2. A typical 12-lead ECG in an asymptomatic patient with the SCN5A D1275N mutation. 
Wide arrow: low amplitude signal at the beginning QRS complex. 
Narrow arrow: notch in S wave 
         : deep S wave in chest leads 
         : Prolonged S-wave upstroke  55 ms 
         :  flat P wave  
         : PR depression 
Figure 3.  Typical large initial fragmentation of the QRS complex with junctional escape rhythm in an 
SCN5A gene D1275N mutation carrier. The arrow shows modification in the progressive growing initial 
fragmentation of QRS complex in inferior leads. 
Table I. Distribution of 12-leads ECG parameters of the SCN5A D1275N patients.  
10 
Figure 1 
Figure 2 
Figure 3
PUBLICATION 
II 
Heterozygous junctophilin-2 (JPH2) p.(Thr161Lys) is a monogenic cause 
for HCM with heart failure. 
Sari U. M. Vanninen, Krista Leivo, Eija H. Seppälä, Katriina Aalto-Setälä, Olli 
Pitkänen, Piia Suursalmi, Antti-Pekka Annala, Ismo Anttila, Tero-Pekka Alastalo, 
Samuel Myllykangas, Tiina M. Heliö*, Juha W. Koskenvuo*  
PLoS One, 2018, 13(9):e0203422. doi: 10.1371/journal.pone.0203422. PMID: 30235249 
Publication reprinted with the permission of the copyright holders. 

RESEARCH ARTICLE
Heterozygous junctophilin-2 (JPH2) p.
(Thr161Lys) is amonogenic cause for HCM
with heart failure
Sari U. M. VanninenID1, Krista Leivo2, Eija H. Seppa¨la¨3, Katriina Aalto-Seta¨la¨1,4,
Olli Pitka¨nen5, Piia Suursalmi6, Antti-Pekka AnnalaID7, Ismo Anttila7, Tero-
Pekka Alastalo3,5, Samuel Myllykangas3,8, Tiina M. Helio¨2ᄊ, JuhaW. Koskenvuo3,9ᄊ
1 Heart Center, Tampere University Hospital, Tampere, Finland, 2 Heart and Lung Center, Helsinki
University Hospital, University of Helsinki, Helsinki, Finland, 3 Blueprint Genetics, Helsinki, Finland, 4 Faculty
of Medicine and Life Sciences, University of Tampere, Tampere, Finland, 5 Divisions of Pediatric Cardiology,
Children’s Hospital/Helsinki University Hospital, Helsinki, Finland, 6 Department of Pediatrics, Tampere
University Hospital, Tampere, Finland, 7 Department of Internal Medicine, Seina¨joki Central Hospital,
Seina¨joki, Finland, 8 Institute of Biomedicine, University of Helsinki, Helsinki, Finland, 9 Department of
Clinical Physiology and Nuclear Medicine, HUSMedical Imaging Center, Helsinki University Hospital and
University of Helsinki, Helsinki, Finland
ᄊ These authors contributed equally to this work.
* sari.vanninen@fimnet.fi
Abstract
During the last two decades, mutations in sarcomere genes have found to comprise the
most common cause for hypertrophic cardiomyopathy (HCM), but still significant number of
patients with dominant HCM in the family are left without molecular genetic diagnosis. Next
generation sequencing (NGS) does not only enable evaluation of established HCM genes
but also candidate genes for cardiomyopathy are frequently tested which may lead to a situ-
ation where conclusive interpretation of the variant requires extensive family studies. We
aimed to characterize the phenotype related to a variant in the junctophilin-2 (JPH2) gene,
which is less known non-sarcomeric candidate gene. In addition, we did extensive review of
the literature and databases about JPH2 variation in association with cardiac disease. We
characterize nine Finnish index patients with HCM and heterozygous for JPH2 c.482C!A, p.
(Thr161Lys) variant were included and segregation studies were performed. We identified
20 individuals affected with HCM with or without systolic heart failure and conduction abnor-
malities in the nine Finnish families with JPH2 p.(Thr161Lys) variant. We found 26 heterozy-
gotes with the variant and penetrance was 71% by age 60 and 100% by age 80. Co-
segregation of the variant with HCM phenotype was observed in six families. Main clinical
features were left ventricular hypertrophy, arrhythmia vulnerability and conduction abnor-
malities including third degree AV-block. In some patients end-stage severe left ventricular
heart failure with normal or mildly enlarged diastolic dimensions was detected. In conclu-
sion, we propose that the heterozygous JPH2 p.(Thr161Lys) variant is a new Finnish muta-
tion causing atypical HCM.
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Introduction
Hypertrophic cardiomyopathy (HCM) is considered the most common form of inherited car-
diomyopathies estimated to affect one in 500 in general population [1]. Diagnosis of HCM is
made by two-dimensional echocardiography showing hypertrophied, non-dilated left ventricle
(LV) in the absence of other cardiac or systemic causes of hypertrophy such as aortic valve ste-
nosis or hypertension [2]. HCMmay manifest at any age but typically in the adulthood. The
clinical course of the disease varies significantly from person to person. Some patients remain
asymptomatic through their life whereas others suffer from arrhythmias or embolic stroke,
develop severe heart failure or experience sudden cardiac death (SCD) even at early age [3–5].
Hereditary HCM is a dominant disorder, commonly associated with mutations in sarco-
mere genes. Phenocopies of HCM include Anderson-Fabry disease (galactosidase alpha, GLA),
Danon disease (lysosomal-associated membrane protein 2, LAMP2), PRKAG2 related glycogen
storage disease (protein kinase AMP-activated non-catalytic subunit gamma 2, PRKAG2), car-
diac amyloidosis, neuromuscular diseases and malformation syndromes (Noonan spectrum
syndromes).[6] Genetic diagnostics has proven as an effective strategy to differentiate between
potential underlying causes and to rule out phenocopies. Accurate molecular genetic diagnosis
helps to detect the genetic cause of those phenocopies that might require special therapy (e.g.
enzyme replacement therapy) [7–9].
The most established genes associating with HCM are myosin binding protein C
(MYBPC3), myosin heavy chain 7 (MYH7), troponin I3, cardiac type (TNNI3), troponin T2,
cardiac type (TNNT2), tropomyosin 1 (TPM1), myosin light chain 2 (MYL2), myosin light
chain 3 (MYL3) and actin, alpha, cardiac muscle 1 (ACTC1) [10]. The role of candidate genes
such as troponin C1, slow skeletal and cardiac type (TNNC1) [11] and actinin alpha 2
(ACTN2) [12] has remained obscure. Diagnostic yield of molecular genetic testing in daily
practice is 25–40% in HCM [10]. This demonstrates the challenge of differentiating genetic
disease from acquired conditions or other systemic diseases and indicates that there are novel
disease genes and more complex genetic variations left to be discovered. Although it has been
difficult to demonstrate phenotypic correlations between different genes and different muta-
tions, there is a significantly worse outcome in patients tested positive vs. negative for muta-
tions in sarcomere genes [13]. A large proportion of the mutations are unique for a family and
have not been reported before. In certain populations, however, founder mutations comprise a
large part of detected mutations. To date HCM founder mutations have been identified in
MYBPC3,MYH7 and TPM1 genes, and reported in the Netherlands [14], Spain [15], South
Africa [16], Finland [17], Italy [18], Japan [19], South Asia [20] and in the Amish population
[21].
Junctophilin-2 gene (JPH2) is the major structural protein in cardiomyocytes for coupling
of transverse (T) tubule-associated L-type Ca2+ channels and type-2 ryanodine receptors on
the sarcoplasmic reticulum within junctional membrane complexes (JMC) [22, 23]. Signaling
between these two Ca2+ channels is required for normal cardiac contractility. Disruption of
the JMC is a common finding in failing hearts. Downregulation of JPH2 gene has been associ-
ated with heart failure and mutations in this gene have been suggested to associate with HCM.
JPH2 was initially published as candidate gene for HCM in 2007 when Matsushita et al. found
p.(Gly505Ser) in four probands among 148 Japanese HCM patients [24] but this variant was
later found to be a common polymorphism present in up 4–6% in Asian/African populations.
Role of the JPH2 in cardiomyopathies has been obscure as only one rare variant segregating
with any type of cardiomyopathy has been published [25].
In this study, we characterize the cardiac phenotype related to JPH2 c.482C>A, p.
(Thr161Lys) variant in nine Finnish index patients and their family members. We also review
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evidence gathered from the literature and variant databases that supports or is against the
pathogenicity of the mutations in JPH2 to highlight challenges we have when rare gene vari-
ants from candidate genes are detected.
Subjects andmethods
The methods for this trial is available as supporting information; see S1 Protocol http://dx.doi.
org/10.17504/protocols.io.[PROTOCOL]
Index patients with the JPH2 variant c.482C>A, p.(Thr161Lys) and their relatives from
four Finnish hospitals were included. A written informed consent was obtained from all par-
ticipants. This study has been approved by the Ethical Review Committee of the Department
of Medicine, University of Helsinki (Dnro 307/13/03/01/11) and by the Ethical Review Com-
mittee of the Department of Medicine, University of Tampere (R08070) and conforms to the
ethical principles outlined in the Declaration of Helsinki.
HCM was clinically diagnosed according to ESC Guidelines [2]. Hypertrophic cardiomyop-
athy (HCM) is defined by the presence of increased LV wall thickness that is not solely
explained by abnormal loading conditions. In adults, the diagnosis of HCM requires LV wall
thickness15 mm as measured by any imaging technique. Correspondingly, the clinical diag-
nosis of HCM in first-degree relatives of patients with LVH15 mm is based on the presence
of otherwise unexplained increased LV wall thickness13 mm. In children, the diagnosis of
HCM requires LV wall thickness more than two standard deviations greater than the predicted
mean.
Family history was obtained and pedigrees were drawn. The adult participants were
assessed clinically at Heart and Lung Center, Helsinki University Hospital, at the Heart Hospi-
tal, Tampere University Hospital or at the Seina¨joki Central Hospital by physical examination,
resting 12-lead ECG, appropriate laboratory tests and transthoracic echocardiography (TTE).
Cardiac MRI was performed in some cases especially in patients with borderline diagnostic
findings at echocardiography. All participants are of Finnish ethnicity.
Molecular genetic studies
Genetic testing was carried out from genomic DNA using the OS-Seq™ (oligonucleotide-selec-
tive sequencing) next-generation sequencing method [26, 27]. The genetic evaluation of the
index patients was performed using the Blueprint Genetics Core Cardiomyopathy or Pan Car-
diomyopathy Panels covering 69 and 103 genes, respectively, associated with cardiomyopa-
thies and their genetic phenocopies (Supplementary file 1). The presence of the variant in
probands’ relatives was studied by bi-directional Sanger sequencing.
Results
Genetic studies
A heterozygous JPH2 c.482C>A, p.(Thr161Lys) (NM_020433.4) variant was observed in nine
unrelated Finnish probands with cardiomyopathy. Altogether the p.(Thr161Lys) was detected
in 20 affected individuals. The variant co-segregated with HCM in six families (Families 2–4,
6–8, Fig 1) and in three families the mutation was found only in the probands (Family 9), in
probands and young family member without HCM (Family 1) or in probands and in another
family member without HCM (Family 5). Systolic heart failure or conduction abnormalities
were observed in every family. These features were present in 12/20 (60%) of the affected
patients including ten heterozygous affected individuals and two obligate carriers. The p.
(Thr161Lys) was absent in three family members without LV hypertrophy who were over 20
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years of age (3.I.2, 5.I.2, 8.II.2). It was also absent in asymptomatic 60-year old female (Family
6.I.2) who was not evaluated clinically and two individuals with LVH likely explained by severe
hypertension (Family 4:I.3 and Family 8:I.2). Pedigrees of the families 2–8 are presented in Fig
1. This heterozygous missense variant has not been observed in the Exome Aggregation Con-
sortium (ExAC) data set, comprised in total of over 60,000 unrelated individuals or in the
Genome Aggregation Database (gnomAD; total of 126,216 exomes and 15,137 genomes). In
silico bioinformatic tools Polyphen, SIFT and Mutation Taster predict it to be deleterious.
Threonine is conserved amino acid at this position among mammals.
The main clinical characteristics of the probands and family members are shown in
Table 1. These include left ventricular hypertrophy (LVH), and in some cases end-stage severe
left ventricular (LV) failure with normal or mildly dilated LV. Average at diagnosis was 26.9
±20.6 years in the nine probands and their maximum LV wall thickness was 20.4±5.2 mm at
age of 34.1. Atrial or ventricular arrhythmias considered abnormal were observed in 13/20
(65%) of the heterozygotes. Pacemaker (PM) or ICD was implanted in 6/20 (30%) and reduced
Fig 1. Pedigrees of seven families affected with the JPH2 c.482C>A, p.(Thr161Lys), (rs587782951, NM_020433.4) variant. Pedigrees of three families affected with
the JPH2 c.482C>A, p.(Thr161Lys), (rs587782951, NM_020433.4) variant. Circles represent women, squares men and triangles gender blinded. Black-filled symbols
represent individuals who fulfill ESC 2008 diagnostic criteria for HCMwith [2]. We also considered as affected with HCM one family member (Family 8:I.3) who had
imminent cardiomyopathy with borderline LVH (12 mm), 3-degree AV block, RBBB and severe systolic heart failure. Genotypes: +/- heterozygous for the JPH2 p.
(Thr161Lys), -/- wild type allele,  MYBPC3 p.(Gln1061). Age of the family members at last follow-up, maximum LV wall thickness and some other key signs of clinical
disease are listed below the symbols. Arrows indicate index patients. Abbreviations listed in Table 1.
https://doi.org/10.1371/journal.pone.0203422.g001
Heterozygous junctophilin-2 (JPH2) p.(Thr161Lys) is a monogenic cause for HCMwith heart failure
PLOSONE | https://doi.org/10.1371/journal.pone.0203422 September 20, 2018 4 / 14
Table 1. Clinical characteristics of the probands and their family members.
Family Age
(M/
F)
Genotype Conduction
defect
Arrhythmias PM,
ICD
LV-
WT
LVEDD
(mm)/ EF (%)
proBNP
(ng/l)
Age at
dg
Phenotype Other
Family 1
I.1 52M +/- no AF ICD 20 46/56% 400 47 HCM
Family 2
I.1 44M +/- no no no 16 46/72% 76 44 HCM
II.1 12M +/- no VT no 23 48/77% 315 12 HCM
II.2 16M +/- pRBBB no no 6 51/63% NA - normal
Family 3
I.1 48M +/- RBBB no no 15 49/72% 44 41 HCM
II.1 24M +/- LBBB VT ICD 29 44/75% 145 13 HOCM Pk-grad 81mmHg
Family 4
I.2 45M n.a. AVB3, LAHB,
RBBB
AF, VT PM 28 55/20% 8425 17 HOCM,
SHF
Pk-grad 50mmHg
Died 45 y
I.3 57F -/- no no no 14 43/60% 33 - LVH/
Hypertens
BP 160/110 mmHg
II.1 25M +/- no SVT no 22 45/67% 104 9 HCM
II.2 17M +/- LAHB no no 20 49/55% NA 1 HCM
III.3 8M +/- no no no 11 35/>50% NA 1 HCM
Family 5
I.1 54M +/- no SVT no 10 50/70% NA - normal SVT ablation
I.2 53F -/- no no no 11 44/83% 164 - normal
II.1 25F +/- RBBB, LAHB VES, VT,
SVT
no 22 43/60% 5700 12 HCM, SHF Multiple VSDs, PDA operated aged 2
years. During pregnancy LVEF 45%
Family 6
I.1 62M +/-, LAHB AF no 15 40/52% 998 61 HCM
I.2 60F -/- NA NA NA NA NA NA - NA
II.1 F (+/-,) NA NA NA NA NA NA - HCM
III.1 8F +/-, NA no no 11 33/>60% 3928 7 HCM
Family 7
I.2 76F +/- LAHB AF no 27 49/56% NA ? HCM
I.3 72F +/- no AF no 17 45/60% NA ? HCM
I.4 80F (+/-) no AF no NA NA NA ? ? Died age 80 y
II.1 52M +/- AVB1 VES, SVT no 23 49/63% NA 43 HCM
II.2 49M +/- AVB1 no no 21 60/50% NA ? HCM
II.3 48M +/- no no no 11 NA NA - normal
III.1 20F +/- no SVT no 12 44/66% NA 19 normal
Family 8
I.1 43F (+/-) AVB3, LBBB AF, VT PM 18 70/30% 6637 25 HCM, SHF Died aged 43. HF. WT at autopsy 15
mm.
I.2 60F -/- no no no 13 40/71% 160 - LVH/
Hypertens
I.3 76F +/- AVB3, LAHB,
RBBB
no PM 12 46/40% 5267 67 HCM Mixed cardiomyopathy
II.1 47M +/- AVB1, LBBB AF, VT ICD 15 51/37% 4426 36 HCM, SHF
II.2 49F -/- no no no 10 49/66% 31 - normal
III.1 15M +/- no no no 7 46/66% NA - normal
Family 9
(Continued)
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LVEF (<47%) or elevated proBNP concentration (>300 ng/l) was observed in 9/20 (45%) of
the patients. Penetrance of HCM was 48%, 71% and 100% by age of 40, 60 and 80, respectively.
Family 1. Proband of this family was diagnosed HCM at age 47. His genotype positive
(not drawn on pedigree) son was phenotype negative with maximal wall thickness of 10 mm at
age 22, which is in line with age-dependent penetrance of cardiomyopathies.
Family 2. Proband (II.1) of family 2 developed HCM at age of 12 and has significant bur-
den of arrhythmias. Subsequently, his genotype positive father was found to have also HCM
and arrhythmias. Proband’s brother was genotype positive yet phenotype negative at age of 16.
Family 3. Proband (II.1) developed HCM at age of 13 and LV wall thickness increased up
to 29 mm by age 24. He had also LVOT obstruction with 81mmHg systolic gradient. The
patient was prescribed beta blockers and disopyramide, and LVOT gradient decreased to
20mmHg. His symptoms, chest pain and shortness of breath presenting during light walking,
were suppressed by the medication. His genotype positive father has also HCM but no arrhyth-
mias. The proband has ventricular arrhythmias. Both affected individuals in this family have
preserved systolic function.
Family 4. Proband (II.1) is a male with clinical diagnosis of HCM at age 9. He has had
recurrent episodes of sustained atrial tachyarrhythmias. On echocardiography, maximal LV
wall thickness was 22mm. Proband’s 17-year-old genotype positive brother (II.2.) had maximal
LV thickness of 20mm. He and proband’s son were diagnosed at very early age. Proband’s
father (I.2) was diagnosed with HCM aged 17 years as his ECG showed inferolateral T-inver-
sions like the ECGs of his both sons and echocardiography revealed septal thickness of 17mm.
Later he developed variable 2–3 degree AV block and received pacemaker. He had also LVOT
obstruction with 50mmHg systolic gradient. The patient was prescribed beta blockers and dis-
opyramide and LVOT gradient decreased to 21 mmHg. At age 26, his LVEF was 70%. During
the follow-up, maximal septal thickness increased to 28mm and posterior wall to 20mm. The
patient had paroxysmal atrial flutter and later chronic atrial fibrillation (AF). By the age of 40
years, the patient developed NYHA 3 dyspnea and his LVEDD was 58mm, LVEF 40% and sep-
tal thickness 18mm. He had right heart failure and ascites, proBNP was 8425ng/l. Aged 45
years LVEDD was 55mm and LVEF 20–25%. The patient was listed for heart transplantation
but died aged 45 years due to heart failure and sepsis. He deceased before the NGS technology
became to clinical use and his genotype remains unknown. His disease fits well with the phe-
notype described here in genotype positive individuals. Genotype of proband’s mother is also
unknown, thus we were not able to confirm that the JPH2 variant was inherited from the
affected parent. Index patient’s father’s mother had also HCM and died aged 42 years while
Table 1. (Continued)
Family Age
(M/
F)
Genotype Conduction
defect
Arrhythmias PM,
ICD
LV-
WT
LVEDD
(mm)/ EF (%)
proBNP
(ng/l)
Age at
dg
Phenotype Other
I.1 63F +/- no AF PM 19 45/60% 4082 63 HCM
Index patients are marked in bold. Symbols and abbreviations: Age (M/F)–age and gender (M, male; F, female); Genotype–+/- is heterozygous and (+/-) obligatory
heterozygous for p.(Thr161Lys) in JPH2 and -/- is wild type,  heterozygous forMYBPC3Gln1061; R/LBBB–presence of right/left bundle branch block; LAHB–left
anterior hemiblock; AVB1-3 –atrioventricular block types 1–3; Arrhythmias–AF for atrial fibrillation/flutter, SVT for supraventricular tachycardia (>10 episodes short
episodes per day or SVT requiring cardioversion), VT for ventricular tachycardia 3 beats with frequency>100/min, VES for ventricular extrasystoles>1000 per day,
SVES for supraventricular extrasystoles>5000 per day; PM, ICD, CRT-P/D–pacemaker, implantable cardioverter-defibrillator, cardiac resynchronization therapy
device; LV-WT-maximal left ventricular wall thickness measured by echocardiography or cardiac MRI; LVEDD & EF–left ventricular end-diastolic diameter (mm) and
ejection fraction (%); Age at dg-age at diagnosis of cardiomyopathy; Phenotype–phenotype at diagnosis, HCM–hypertrophic cardiomyopathy, LVH–left ventricular
hypertrophy; SHF–systolic hear failure; Other–other significant clinical features
https://doi.org/10.1371/journal.pone.0203422.t001
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sleeping and her father (proband’s father’s maternal grandfather) died aged 45 years due to an
assumed cardiogenic reason (not drawn in pedigree). As a whole probands and two adult fam-
ily members heterozygous for the variant fulfilled the criteria for HCM, whereas one individual
(I.3), who is negative for the variant has LVH likely explained by severe hypertension (blood
pressure 160/110mmHg) and obesity (BMI 32 kg/m2).
Family 5. Proband (II.1) had multiple VSDs, mild mitral stenosis and patent ductus arte-
riosus necessitating surgery aged 2 years. HCM was diagnosed when she was 12. ECG showed
RBBB likely due to previous cardiac surgery, abnormal amount of ventricular and atrial pre-
mature complexes and she also suffers from SVTs and VTs. She had high levels of pro-BNP
(5700 ng/L) although having normal systolic function at echocardiography. Her genotype pos-
itive father has no morphological HCM phenotype but he underwent ablation for SVT with
good response.
Family 6. Proband (III.1) is a girl who developed HCM by the age of 7 years. She has also
a well-established pathogenic nonsense mutation inMYBPC3 (c.3181C>T, p.(Gln1061)). Her
pro-BNP levels are high (3928 ng/L). She has inherited both of the variants from his mildly
affected grandfather through her mother who has HCM and is obligate carrier of both
variants.
Family 7. In this family, the index patient (II.1), his brother (II.2), mother (I.2) and moth-
er’s sister (I.3) were heterozygous for the JPH2 p.(Thr161Lys) variant. They all fulfilled the
imaging criteria of HCM with maximal LV wall thicknesses of 17-27mm. None of these
patients had heart failure. Mother’s other sister (I.4) who was an obligatory carrier died at age
80 due to mesenterial thrombosis. Her son is heterozygous for the JPH2 variant. Twenty-year-
old daughter (III.1) of the index has borderline phenotype (septal thickness 12 mm) and her
ECG showed abnormal Q-waves at I, II, aVF, V5-6 leads and episodes of ectopic atrial rhythm.
Family 8. The index patient (II.1) is heterozygous for the JPH2 p.(Thr161Lys) variant. He
was a previously sportive male who presented with decreased exercise tolerance at the age of
36 years. ECG showed LVH and on echocardiography LV was 51/36mm, EF 55% and septum
14mm at maximum. Five years later septummeasured 15mm fulfilling the HCM criteria. At
age of 45, ECG showed sinus rhythm and trifascicular block (LBBB + type 1 AV block). TnT
concentration was constantly increased up to 48 ng/l (normal range< 15ng/l) and proBNP
concentration has increased up to 4426 ng/l. He has had paroxysmal atrial fibrillation (AF)/
flutter and monomorphic ventricular tachycardia (VT). Coronary angiography was normal.
Cardiac MRI demonstrated extensive late gadolinium enhancement (LGE) especially at septal
and anterior regions. FDG-PET did not detect signs of inflammation. Endomyocardial biop-
sies from left and right ventricles remained non-diagnostic and showed mainly fibrosis.
Electrophysiologic study demonstrated VT. On echocardiography, LV was 51mm, septum
14mm, PW 12mm and EF 37%. Hemodynamics were restrictive. The patient has received an
ICD. His mother (I.1) was an obligatory carrier of the variant. She presented with loss of
weight, fainting and palpitations aged 28 years and ECG showed LBBB. In cardiac catheteriza-
tion, LVEDP was elevated and left ventricular cineangiography (LV-cine) showed stiff septum,
compatible with HCM. Eight years later she was examined due to tachycardias and collapse
episodes. Maximum LV wall thickness was 18 mm. In LV-cine, EF was 32%, stroke volume
38ml. The patient received pacemaker due to episodes of syncope and tachyarrhythmia. At age
40 she had atrial fibrillation and 3-degree AV block and at age 42 her LVEDD was 70 mm and
EF 30%. She was treated with digoxin, furosemide, amiodarone, atenolol, captopril and warfa-
rin. Cardiac CT showed dilated left atrium and ventricle but normal pericardium. Before
death at the age of 43, she had heart failure (HF) and repeated VT’s. Autopsy showed fibrotic
changes especially at endocardium of posterior and septal walls. There was very thin and
fibrotic area with a size of 3x4 cm in the anterior LV wall. Maximum wall thickness in autopsy
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was 15mm. Clinical diagnoses comprised cardiomyopathy, endocardial and myocardial fibro-
sis. No material for genotype analysis was available. Mother’s sister (I.3) is also heterozygous
for the p.(Thr161Lys) variant and was considered affected as she has imminent cardiomyopa-
thy with borderline LVH (12 mm), AF, 3-degree AV block, RBBB and severe systolic heart fail-
ure not explained by other causes. She has received a PM. Proband’s non-carrier aunt (I.2) had
mild LVH likely due to hypertension. Proband’s non-carrier brother (II.2) had normal find-
ings in cardiac evaluations as well as proband’s genotype positive son (III-1) who was 15 years
old at last follow-up.
Discussion
We have identified the JPH2 p.(Thr161Lys) variant in nine Finnish index patients with HCM
and have shown co-segregation of the variant with cardiomyopathy in six of these families. In
the other three, only the index person presented HCM phenotype due to the size of the family
or the young age of the variant carriers. This is the first JPH2 variant shown to be causative for
HCM.
For almost twenty years data has accumulated on the role JPH2 in cardiac physiology. How-
ever, little is known about the significance JPH2 as a causative gene for cardiomyopathy. JPH2
is a cardiac specific member of the junctophilins and it has emerged as a potentially important
regulator of excitation-contraction coupling in cardiomyocytes. Several studies have
highlighted the importance of JPH2 for normal cardiac physiology [23, 28]. Mice with acute
conditional cardiac specific knockdown of JPH2 have a high incidence of mortality with a
rapid development of systolic heart failure [29]. These mice demonstrated grossly enlarged
hearts with dilated ventricles and reduced systolic function on echocardiogram. In another
mouse model study, heterozygous JPH2 p.(Glu169Lys) mice had a higher incidence of pacing-
induced AF secondary to abnormal spontaneous Ca[2+] waves and increased spark frequency
[30].
Cardiac phenotype related to this variant differs somewhat from typical HCM. Two Finnish
founder mutations for HCM have previously been published one in myosin binding protein C
(MBPC3) gene and the other in alpha tropomyocin (TPM1) gene [17, 31]. The JPH2 p.
(Thr161Lys) variant presented here differs from the other two in clinical presentations. The
JPH2 variant associates with earlier disease onset (27 years vs. 52 and 49 years) than the
MYBPC3 p.(Gln1061) or TPM1 p.(Asp175Asn), respectively, although no patients under age
of 16 were included in the previous study [17]. Systolic heart failure was observed in 5 (25%)
and LV dysfunction was present in half of the affected patients with JPH2 variant when defined
by EF<47% or elevated proBNP. Of the probands withMYBPC3 p.(Gln1061), none has had
congestive heart failure. However, dyspnea was present in 31%. Also none of the index patients
with the TPM1 p.(Asp175Asn) mutation had significant systolic dysfunction (EF<46%) and
only one (5%) had a history of systolic heart failure. Severe conduction defects defined by
3-degree AV-block or R/LBBB was observed in nine (45%) and AF in nine (45%) of the
affected individuals or obligate carriers with JPH2 variant, but no SCDs were detected in our
families. Of the individuals withMYBPC3 p.(Gln1061) variant, 26% presented syncope/pre-
syncope, 23% had either chronic or paroxysmal atrial fibrillation, 9% have had sustained VT
or ventricular fibrillation and 26% had family history of SCD. Three out of 34 (9%) HCM
patients carrying the TPM1 p.(Asp175Asn) presented with a documented SCD at young or
middle age [31]. Additionally, life-threatening arrhythmias were induced with programmed
ventricular stimulation (PVS) in one third of patients carrying this mutation. Of the probands
with TPM1 orMYBPC3 founder mutation, ICD was implanted in 2 (10%) and 7 (20%) patients
respectively and no significant conduction problems necessitating pacemaker implantation
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where described in the index publications. These observations highlight the significant differ-
ences in clinical presentation of the patients with the previously characterized founder muta-
tions compared to proposed JPH2mutation described in this study. However, the degree of
LV hypertrophy may be similar in patients with these founder mutations (22±5 mm, 18±6 mm
and 20±5 mm with variant inMYPBC3, TPM1 or JPH2, respectively), although the JPH2 vari-
ants carriers were younger at a time of evaluation compared to carriers of other founder muta-
tions. It should be still keep in mind that significant variation in clinical presentation within
and between the families with the same mutation exists in all types of HCM.
There are altogether 19 JPH2 variants associating with dilated or hypertrophic cardiomyop-
athy listed in the HGMD (Qiagen) and ClinVar databases (July 8, 2017) presented in Table 2.
Seventeen of them are missense variants. Before this study, no convincing evidence of segrega-
tion within large pedigrees except for the p.(Glu85Lys) [25] and no de novo JPH2mutations
have been reported in patients with HCM. In 2007, Landstrom et al. found two rare missense
Table 2. All JPH2 variants described in literature and rare JPH2 variants submitted to ClinVar Database with phenotype information.
JPH2 Variant
(NM_020433.4)
Pheno gnomAD PP MT Index
(n)
Family
(n)
Co-seg Class Other Reference
c.253G>A, Glu85Lys DCM 0/0 D D 1 9 Yes LP Penetrance 78% (Sabater-Molina et al. 2016)
c.301A>C, Ser101Arg HCM 0/0 PD B 1 0 No VUS (Landstrom et al. 2007)
c.421T>C, Tyr141His HCM 0/0 D D 1 0 No VUS (Landstrom et al. 2007)
c.494C>T, Ser165Phe HCM 0/0 D D 1 0 No VUS (Landstrom et al. 2007)
c.502A>C, Ser168Arg HCM 0/0 D D 1 0 Np VUS ClinVar 222654
c.505G>A, Glu169Lys HCM 0/0 D D 1 1 ? VUS (Beavers et al. 2013)
c.559G>A, Gly187Ser HCM 1/0 PD B 1 0 No VUS ClinVar 222655
c.565G>A, Ala189Thr SUD 94/0 B B 1 0 No LB (Narula et al. 2015)
c.692G>A, Arg231Gln Sdr 39/0 D B 1 0 No LB (Farwell et al. 2015)
c.723C>G, Ser241Arg DCM 0/0 D D 1 0 No VUS ClinVar 155801
c.1013A>G,
Glu338Gly
SCD 0/0 D D 1 0 No VUS Enlarged RV (Neubauer et al. 2016)
c.1213G>T, Ala405Ser HCM 3/0 D D 1 0 No VUS Ala405Thr 18 het gnomAD, De
novo?
(Beavers et al. 2013)
c.1227C>G,
Asn409Lys
DCM 0/0 PD D 1 0 No VUS ClinVar 222656
c.1282C>T, Gln428 DCM 13/0 - - 1 0 No VUS ClinVar 222657
c.1513G>A,
Gly505Ser
HCM 589/7 B B 4 0 No Benign (Matsushita et al. 2007, Manrai et al.
2016)
c.1540G>A,
Gly514Ser
LVNC 1/0 D D 1 0 No VUS ClinVar 222658
c.1564C>T,
Arg522Trp
DCM 0/0 D D 1 0 No VUS ClinVar 222659
c.1750C>A,
Gln584Lys
LVNC 1/0 B B 1 0 No VUS ClinVar 180592
c.2011-1G>T HCM 0/0 - - 1 0 No VUS (Xu et al. 2015)
Abbreviations: Pheno, phenotype; gnomAD, number of heterozygotes/homozygotes in the gnomad reference population consisting 120,000 individuals; PP, PolyPhen;
MT, MutationTaster; D, probably damaging in PolyPhen and disease causing in MutationTaster; PD, possibly damaging; B, benign in PolyPhen and polymorphism in
MutationTaster; Index, number of index patients, Family, number of affected family members with the same variant as index patient; Co-seg, co-segregation; Class,
classification of the variant by the authors relying on ACMG recommendation; LP, likely pathogenic; VUS, variant of uncertain significance; LB, likely benign; SUD,
Sudden unexplained death; Sdr, complex syndrome
, Non-pass (low quality) variant in gnomAD; LVNC, left ventricular non-compaction cardiomyopathy. Other abbreviations as in Table 1.
https://doi.org/10.1371/journal.pone.0203422.t002
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and one frameshift variant in JPH2 in three probands with HCM but their families were not
studied or genotyped [28]. In 2016, Sabater-Molina showed segregation of the JPH2 p.
(Glu85Lys) with dilated cardiomyopathy with or without left ventricular non-compaction car-
diomyopathy (LVNC) features in a large family [25]. Furthermore, Quick et al have recently
published JPH2 p.(Ala405Ser) variant in a single patient with basal septal hypertrophy and dia-
stolic dysfunction [32]. Most of the previously published variants are absent or rare in ExAC
or gnomAD reference populations and thus they have potential to be disease causing. Truncat-
ing JPH2 variants are relatively rare in ExAC reference population (carrier frequency 1 per
6,030 individuals) but due to small size of the gene, the pLI value is 0.01 which does not suggest
that loss of function alterations would be poorly tolerated. The clinical data on HCM related to
the previously published JPH2missense variants is limited, mostly clinical HCM appears to be
diagnosed after teenage but at least the patient with p.(Glu169Lys) exhibited HCM already at
the age of 5 months [30], similarly as two patients in this study.
We identified one family (Family 6) where all three affected individuals carry the well-
established pathogenicMYBPC3 variant, p.(Gln1061), in addition to JPH2 p.(Thr161Lys) var-
iant. Their phenotypic presentation did not differ significantly from the other families which
are surprising as patients with homozygosity/compound heterozygosity or digenic pathogenic
variants in sarcomere genes generally present at very early age [33–36]. In literature at least
nine patients have been described who had homozygous or confirmed compound heterozy-
gous disease causing variant inMYBPC3 and at least the other variant is not truncating. In
these patients the mean age at onset was 4.1 years. Three of these cases presented at neonatal
phase, of which all died before age of two months [34, 35]. All patients with homozygous or
compound heterozygous truncating pathogenic mutations inMYBPC3 reported so far
(n = 21) were diagnosed with severe cardiomyopathy and/or died within the first few months
of life [35]. At the moment, it is unclear whether compound mutation present in sarcomere
and non-sarcomere gene simultaneously have additive detrimental effect on disease onset and/
or progression.
In conclusion, the JPH2 p.(Thr161Lys) is classified as pathogenic based on ACMG classifi-
cation scheme [37], as the variant resides in a conserved position, is predicted to be deleterious
by in silico prediction tools, is absent in control populations and co-segregates with dominant
HCM in six families. These observations strengthen the role of non-sarcomeric JPH2 as a caus-
ative gene for HCM with or without systolic heart failure and conduction abnormalities. Fur-
ther research is warranted to evaluate JPH2 variants and other genes related to Ca2+ -handling
in the cardiomyocyte to further shed light on the genetic background of HCM. Variant inter-
pretation and correlation to phenotype is still challenging as earlier studies form major pitfalls
by false classifications related to small reference populations, co-incidental segregations and
evaluation of only a small subset of the potentially meaningful genes behind a patient’s pheno-
type. Large-scale genetic research will eventually bring more consistency to the evaluation of
families with inherited cardiac diseases. Unfortunately, most of the submissions of the JPH2
variants in ClinVar reviewed in this work did not include phenotype data and thus provide
limited information for the clinical society. Variant sharing with relevant information of the
phenotype in mutation databases is critically important to develop the field further on.
Supporting information
S1 Protocol. Genetic panels used for the family probands. Probands of each family were
evaluated by either Blueprint Genetics Core Cardiomyopathy Panel (Family 1, 2, 3, 6, 7) or
Pan Cardiomyopathy Panel (Family 4, 5, 8, 9). These next generation sequencing (NGS) panels
are targeted into all protein coding exons and exon-intron boundaries of all target genes (listed
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below). These panels are validated to detect single nucleotide substitutions and small inser-
tions, deletions and indels up to 46 bp. The panels have ISO 15189 and CAP accreditation.
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Abstract
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a highly malignant inher-
ited arrhythmogenic disorder. Type 1 CPVT (CPVT1) is caused by cardiac ryanodine recep-
tor (RyR2) gene mutations resulting in abnormal calcium release from sarcoplasmic
reticulum. Dantrolene, an inhibitor of sarcoplasmic Ca2+ release, has been shown to rescue
this abnormal Ca2+ release in vitro. We assessed the antiarrhythmic efficacy of dantrolene
in six patients carrying various RyR2mutations causing CPVT. The patients underwent ex-
ercise stress test before and after dantrolene infusion. Dantrolene reduced the number of
premature ventricular complexes (PVCs) on average by 74% (range 33-97) in four patients
with N-terminal or central mutations in the cytosolic region of the RyR2 protein, while dantro-
lene had no effect in two patients with mutations in or near the transmembrane domain. In-
duced pluripotent stem cells (iPSCs) were generated from all the patients and differentiated
into spontaneously beating cardiomyocytes (CMs). The antiarrhythmic effect of dantrolene
was studied in CMs after adrenaline stimulation by Ca2+ imaging. In iPSC derived CMs with
RyR2mutations in the N-terminal or central region, dantrolene suppressed the Ca2+ cycling
abnormalities in 80% (range 65-97) of cells while with mutations in or near the transmem-
brane domain only in 23 or 32% of cells. In conclusion, we demonstrate that dantrolene
given intravenously shows antiarrhythmic effects in a portion of CPVT1 patients and that
iPSC derived CMmodels replicate these individual drug responses. These findings illus-
trate the potential of iPSC models to individualize drug therapy of inherited diseases.
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Introduction
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is one of the most malignant
inherited arrhythmogenic disorders. It manifests with exercise-induced premature ventricular
complexes (PVCs), polymorphic or bidirectional ventricular tachycardia, or sudden death, usu-
ally associated with vigorous physical exercise or mental stress.[1–3] Current therapeutic op-
tions include beta-antiadrenergic drugs, flecainide, implantable cardioverter-defibrillators
(ICD) [4–6] and left cardiac sympathetic denervation.[7,8] Better antiarrhythmic medication is
still needed to minimize the need for ICD shock therapies. The most common subtype, type 1
of CPVT (CPVT1) is a dominantly inherited disease caused by mutations in the cardiac ryano-
dine receptor (RyR2) gene.[9,10] The gain-of-function mutations of RyR2 cause increased cal-
cium (Ca2+) sensitivity which can lead to spontaneous Ca2+ release from sarcoplasmic
reticulum, generation of afterdepolarizations, and triggered activity.[4,5,11]
The ryanodine receptor isoform RyR1 is the skeletal muscle counterpart in the gene family.
Mutations of RyR1 result in malignant hyperthermia, a rare but life-threatening complication
of general anesthesia occurring upon administration of volatile anesthetics or depolarizing
muscle relaxants. Dantrolene is a specific and currently the only effective treatment for malig-
nant hyperthermia.[12] Interestingly, dantrolene has also shown to exert antiarrhythmic effects
in animal models of CPVT1.[13–15] Dantrolene has been proposed to act through binding to
the N-terminal parts of RyR1 and RyR2 and restoring inter-domain interactions critical for the
closed state of the RyR2 Ca2+ channel.[16]
Several studies using induced pluripotent stem cell (iPSC) technology [17] have indicated
the ability of CPVT1 patient-specific iPSC derived cardiomyocytes (CMs) to replicate the dis-
ease phenotype in cell culture.[18–24] Dantrolene was reported to rescue the disease phenotype
in iPSCs derived CMs from a single RyR2mutation carrier [20] but no in vivo data exists on its
effects on CPVT1 patients.
In the present study, we report the proof of principle of the antiarrhythmic activity of dan-
trolene in a cohort of CPVT1 patients. In addition, we demonstrate that the in vivo drug effects
are closely reproduced in iPSC-derived patient-specific CMs, and provide evidence for muta-
tion-specific effects of dantrolene in CPVT1.
Materials and Methods
The protocol for this trial is available as supporting information; see S1 Protocol and S2
Protocol.
Clinical Study Scheme
The study was approved by the Ethical Review Committee of the Helsinki University Hospital
(HUS 396/13/03/01/12) and was in accordance with the institutional guidelines and the Decla-
ration of Helsinki. A written informed consent was obtained from all patients. Clinical trial
was registered with EudraCT (2012-005292-14). Participants were recruited between 1st March
2013 and 29th May 2014. Follow up time of the patients was three days after the dantrolene in-
fusion. Four patients participated the study at the Helsinki University Hospital and two at the
Tampere University Hospital, Heart Center. The authors confirm that all ongoing and related
trials for this drug are registered.
Patients
The study group consisted of 6 individuals (mean age 50±10 years, range 37–59 years, 5 fe-
males), who were molecularly defined heterozygous carriers of different gain-of-function RyR2
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mutations causing CPVT1. CPVT1 patients carried the following mutations: c.168-301_c.273+
722del1128mutation (later called as exon 3 deletion) or point mutations p.P2328S
(c.6982C>T), p.T2538R (c.7613C>G), p.L4115F (c.12343C>T), p.Q4201R (c.12602A>G) or p.
V4653F (c.13957G>T). Mutation nomenclature was based on RyR2 reference sequence
NM_001035.2. The mutations were located in the four mutation hotspot clusters of the RyR2
gene (Fig 1).[11] Patients and families carrying mutations P2328S [3,10,25], exon 3 deletion
[3,26], Q4201R [10,25] and V4653F [10,25] have been described in detail earlier.
All mutations were associated with exercise-induced ventricular arrhythmias and syncopal
spells. All except L4115F were associated with one or more cases of sudden death at young age
in the family. An ICD had been implanted in five of them; one has received an adequate shock
therapy. Five out of the six patients had a history of syncopal spells upon a frightening situation
or physical exercise, and they all used a beta-adrenergic blocking agent (daily dose of 160 mg of
propranolol, 7, 5 to 10 mg of bisoprolol or 95 mg of metoprolol) during all study phases. No
other medications were in use. The patients were otherwise healthy without hypertension, dia-
betes, or evidence of other heart disease. None of them had bundle branch block.
In cardiac ultrasonography, left ventricular end diastolic dimension and systolic function
were normal in all patients (data not shown). Basic laboratory parameters including hemoglo-
bin, white blood cell count, plasma sodium, potassium, and creatinine concentrations were an-
alyzed prior to administration of the drug and they were all within the normal range in every
study patient (data not shown). Two of the patients with ICD showed atrial pacing at rest prior
to exercise; all others had sinus rhythm. Electrocardiographic parameters are presented in
Table 1.
Clinical Exercise Stress Test
All RyR2 patients underwent the exercise stress test three times. On the first morning a baseline
study was carried out. The test was repeated in the afternoon of the first day after intravenous
infusion of dantrolene sodium (Dantrium, 1.5 mg per kg of body weight). The third exercise
test was performed on the second day to assess the effects after dantrolene sodium washout
and to demonstrate the reproducibility of the basic exercise test.
Exercise tests were performed with a bicycle ergometer. The initial load was 30 W, followed
by increments of the load by 15 W each minute. In the baseline study, the patient was
Fig 1. RyR2 protein, mutations studied in the present study andmutation clusters 1–4.Mutations in this
study (arrows) are located in different parts of the RyR2 protein and mutation clusters. Clusters are
represented as black lines numbered from 1 to 4. Cluster 1 comprises of amino acids (AA) 44–466, cluster 2
AA 2246–2534 and cluster 3 AA 3778–4201 and these three clusters are located in the N-terminal and
central regions of the protein and form the cytoplasmic domain. Cluster 4 comprises of AA 4497–4959 and
forms the transmembrane domain, which is located in the C-terminal region. The figure is modified from [11].
doi:10.1371/journal.pone.0125366.g001
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instructed to target to a submaximal workload in order to be able to repeat the exercise stress
test. In the consecutive phases of the study, the workload target was the same as that achieved
in the first study. A twelve-lead electrocardiogram (ECG) was recorded continuously at paper
speed 25 or 50 mms-1 and amplification of 0.1 mV/mm throughout the exercise test. After ces-
sation of exercise, ECG was recorded continuously for the first 8 minutes. Both the maximum
workload achieved and the heart rate at which ventricular bigeminy first appeared were re-
corded whenever applicable. Numbers of PVCs during exercise and at recovery phase as well as
the maximum number of consecutive PVCs were counted. Plasma creatinine, sodium, potassi-
um and calcium were measured at rest before the first exercise test. The exercise tests and the
iPSC studies were done separately and blinded.
Characterization of iPSC Lines
The iPSC study was approved by the ethical committee of Pirkanmaa Hospital District
(R08070) and written informed consent was obtained from all the participants. Patient-specific
iPSC lines were established as described earlier.[17] Studied iPSC lines were UTA.05605.CPVT
generated from patient with RyR2 exon 3 deletion, UTA.05208.CPVT from patient with muta-
tion P2328S, UTA.07001.CPVT from patient with mutation T2538R, UTA.03701.CPVT from
patient with mutation L4115F, UTA.05503.CPVT from patient with mutation Q4201R,
UTA.05404.CPVT from patient with mutation V4653F and UTA.04602.WT from a healthy
control individual.
All the CPVT-iPSC lines were characterized for their karyotypes, mutations, pluripotency,
immunocytochemistry, embryoid body (EB) and teratoma formation. Endogenous and exoge-
nous gene expressions were examined by RT-PCR using 1 μl cDNA and 500 nmol/L of each
primer in one PCR reaction. β-actin and GAPDH served as the housekeeping genes. Detailed
reaction conditions and PCR primers for iPSC characterization have been described earlier.
[27] Endogenous pluripotency markers at the protein level were studied with immunocyto-
chemistry. The iPSCs were fixed with 4% paraformaldehyde (PFA, Sigma-Aldrich, Saint Louis,
USA). Primary antibodies anti-SOX2, anti-NANOG and anti-tumor-related antigen (TRA)1-
81 (all 1:200, from Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-OCT3/4 (1:400,
R&D Systems) were used. Cells were mounted with Vectashield (Vector Laboratories, USA)
containing DAPI for staining nuclei. To confirm the mutations of the CPVT iPSC lines with se-
quencing the DNA was isolated using DNA Tissue XS-kit (Macherey-Nagel GmbH & Co.,
Düren, Germany). The genomic region containing the expected mutation was amplified using
PCR. Each PCR product was directly sequenced in both directions using BigDye Terminator
v3.1 and ABI 3730xl DNA Analyzer (Applied Biosystems, Carlsbad, CA, USA). In addition to
Table 1. Electrocardiographic parameters.
Before dantrolene (n = 6) After dantrolene (n = 6) p-value
Heart rate (min-1) 61±5 60±5 NS
P (ms) 109±14 110±14 NS
PQ (ms) 154±31 163±34 NS
QRS (ms) 86±8 87±5 NS
QT (ms) 419±22 407±18 NS
QTc (ms) 418±35 409±35 NS
Comparison of electrocardiographic parameters of all patients before and after the dantrolene infusion. NS
indicates no signiﬁcant.
doi:10.1371/journal.pone.0125366.t001
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direct sequencing, exon 3 deletion (1128 nucleotides) was also confirmed using PCR and aga-
rose gel electrophoresis. Karyotypes of the cell lines were determined using either standard G-
banding chromosome analysis (Medix laboratories, Espoo, Finland) or KaryoLite BoBs assay
(Perkin Elmer) based on BACs-on-Beads technology (Molecular and Systems Immunology
and Stem Cell Biology, Turku Centre for Biotechnology, University of Turku, Finland). The ex-
pression of markers characteristic of ectoderm (Nestin or SOX-1), endoderm (AFP or SOX-17),
and mesoderm (VEGF-R2) development were studied from EBs maintained in EB-medium
(KO-DMEM with 20% FBS, Non-Essential Amino Acid (NEAA), L-glutamine and penicillin/
streptomycin) for 5 weeks. EB RT-PCR primers can be seen in S1 Table. The teratoma study
was approved by ELLA- Animal Experiment Board of Regional State Administrative Agency
for Southern Finland (ESAVI/6543/04.10.03/2011). IPSCs were injected into nude mice under
the testis capsule and tumor samples collected 8 weeks after injection, followed by fixation with
4% PFA and staining of the sections with hematoxylin and eosin.
Cardiomyocyte Differentiation and Characterization
iPSCs were co-cultured with murine visceral endoderm-like (END-2) cells (Humbrecht Insti-
tute, Utrecht, The Netherlands) to differentiate them into spontaneously beating CMs. The
beating areas of the cell colonies were mechanically excised and treated with collagenase A
(Roche Diagnostics).[28] Single CMs were immunostained with anti-cardiac-troponin-T
(1:1500, Abcam, Cambridge, MA, USA), anti-α-actinin (1:1500, Sigma) and anti-connexin-43
(1:1000, Sigma).
Ca2+ Imaging
Dissociated spontaneously beating CMs on a coverslip were loaded with 4 μmol/L Fura 2-AM
(Life Technologies, Molecular Probes). CMs were continuously perfused with 37°C HEPES
based perfusate during measurements and the perfusate consisted of (in mmol/L): 137 NaCl,
5 KCl, 0.44 KH2PO4, 20 HEPES, 4.2 NaHCO3, 5 D-glucose, 2 CaCl2, 1.2 MgCl2 and 1 Na-pury-
vate (pH was adjusted to 7.4 with NaOH). Ca2+ measurements were conducted on an inverted
IX70 microscope (Olympus Corporation, Hamburg, Germany) and cells were visualized with
UApo/340 x20 air objective (Olympus). Images were acquired with an ANDOR iXon 885 CCD
camera (Andor Technology, Belfast, Northern Ireland) synchronized with a Polychrome V
light source by a real time DSP control unit and TILLvisION or Live Acquisition software
(TILL Photonics, Munich, Germany). Fura 2-AM in CMs was excited at 340 nm and 380 nm
light and the emission was recorded at 505 nm. For Ca2+ analysis, regions of interest were se-
lected for spontaneously beating cells and background noise was subtracted before further data
processing. The Ca2+ levels are presented as fura ratio units of F340/F380. Ca2+ peaks were ana-
lyzed with Clampfit version 10.2 (Molecular Devices, USA).
The percentage of abnormal Ca2+ transients, such as multiple peaks comprising of two
peaks, irregular phases, oscillations, and varying amplitude manifested as low peaks, were
calculated from each studied cell line. Beating frequency and diastolic Ca2+ levels of CMs were
analyzed during spontaneous baseline beating, and during adrenaline perfusion. These param-
eters were compared between mutated and control cell lines and also between each mutated
cell line. Some results of Ca2+ cycling of CPVT-P2328S and control cell lines have been pub-
lished before [21] and parts of these results have been included here.
For dantrolene studies, the changes in Ca2+ were recorded during spontaneous baseline
beating, spontaneous beating during 1 μM adrenaline perfusion and spontaneous beating
during 1 μM adrenaline together with 10 μM dantrolene (Sigma) perfusion. If a CM displayed
Ca2+ transient abnormalities during adrenaline perfusion, it was exposed to dantrolene. Drug
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effects of dantrolene were categorized into three groups. In “responder” group dantrolene abol-
ished virtually all the Ca2+ handling abnormalities, in “semi-responder” group dantrolene re-
duced them by more than 50%, in “non-responder” group dantrolene reduced them by less
than 50%. Diastolic Ca2+ levels and beating frequency were compared between adrenaline and
dantrolene responses of responder CMs (exon 3 del, P2328S, T2538R, L4115F) and non-re-
sponder CMs (Q4201R, V4653F, controls). For this, adrenaline response values were divided
by dantrolene response values, separately for each cell.
Statistical Analysis
Statistical analysis of in vivo studies was made with SPSS 21.0 statistical software package
(SPSS, Chicago, IL). Data are presented as average + 1 SD. Comparisons between phases were
performed by the non-parametric Wilcoxon test. The significance of in vitro differences be-
tween two groups was evaluated with the unpaired Student’s t-test. The significance of
changes within a group was evaluated with the paired Student’s t-test. Data are expressed as
average ± S.E.M. and n refers to the number of cells. P<0.05 was considered statistically signifi-
cant in both in vivo and in vitro.
Results
Antiarrhythmic Effects of Dantrolene in Cpvt1 Patients
In the baseline study, patients exercised on an average 8±2 minutes reaching a maximum heart
rate of 134±17 min-1. Exercise bicycle testing induced polymorphic PVCs in all patients and
non-sustained ventricular tachycardia (NSVT, episodes of 3 to 4 consecutive PVCs) in three of
them. The average threshold sinus rate for the appearance of PVCs was 105±9 min-1. The total
count of PVCs during the workload was 172±119 (range 43–391).
All six patients tolerated the target dose 1.5 mg/kg of intravenous infusion of dantrolene but
reported considerable muscle weakness as a side-effect. Dantrolene did not affect atrioventricu-
lar conduction or the QT interval (Table 1). Dantrolene decreased the prevalence of PVCs in
four patients, whereas in two patients the number of PVCs remained virtually the same (Fig 2).
Dantrolene seemed to reduce arrhythmias in patients with the mutation in the N-terminal or
central region of the RyR2 protein (Figs 1 and 2). Thus, dantrolene abolished 97% of PVCs in
the patient with exon 3 deletion (cluster 1), 88% of PVCs in the patient with P2328Smutation
(cluster 2), 33% of PVSc in the patient with T2538Rmutation (right after cluster 2) and 77% of
PVCs in the patient with L4115Fmutation (cluster 3). In contrast, dantrolene abolished only 1
to 2% of PVCs in patients carrying mutation closer to (Q4201R, end of cluster 3) or within the
transmembrane region (V4653F, cluster 4).
Fig 3 illustrates an example of the PVCs and NSVT episodes during the baseline study and
after dantrolene. Dantrolene increased significantly the threshold at which the arrhythmias ap-
peared from 105±9 to 120±17 min-1. The duration of the exercise phase and the maximal
heart rate achieved during the exercise were similar to those in the baseline study. On day 2,
after wash-out of dantrolene, the prevalence of PVCs was approaching that in the first
baseline test.
Characterization of iPSC Lines Confirms Pluripotent Stem Cell
Characteristics
iPSC lines from six CPVT1 patients with above-mentioned RyR2mutations were generated.
Results of the P2328S and control iPSC line characterizations have been published before.
[21,27] All studied endogenous pluripotency genes (Nanog, Rex1, Oct 3/4 and Sox2) were
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turned on and the expression of retrovirally encoded reprogramming factors c-Myc, Klf4, Sox2
and Oct 3/4 was silenced (Fig 4A and 4B). CPVT1 iPSC lines expressed endogenous pluripo-
tent markers Nanog, Oct3/4, TRA 1–81 and SOX2 also at the protein level (Fig 4D). Pluripo-
tency was further confirmed by teratoma formation and with in vitro embryoid body (EB)
formation expressing all three germ layers (Figs 4C and 5G). The presence of the RyR2muta-
tions was confirmed from all the CPVT1 iPSC lines with DNA sequence analysis (Fig 4E). All
the iPSC lines had a normal karyotype (Fig 4F). In addition to sequencing, the presence of the
exon 3 deletion was confirmed with PCR (S1 Fig).
iPSC Derived Cms Display Abnormal Ca2+ Cycling
iPSCs were differentiated into spontaneously beating CMs (Fig 5A). When compared to CMs
derived from the healthy individual, CPVT1 CMs demonstrated marked Ca2+ transient abnor-
malities such as multiple peaks comprising of two peaks, irregular phases, oscillations, and
varying amplitude manifested as low peaks (Fig 5B) both in baseline and in response to adrena-
line. Although these abnormalities were common with all six mutations examined, some differ-
ences between RyR2mutations were also observed. Accordingly, Ca2+ transient abnormalities
were somewhat more common in the cluster 4 mutation than in cluster 1, 2 and 3 mutations
(Fig 5C).
Adrenaline increased the beating frequency of each cell line studied (Fig 5D). All RyR2mu-
tated CMs had lower beating frequency both at baseline and during adrenaline perfusion than
control CMs. Adrenaline produced significantly elevated diastolic Ca2+ levels only in P2328S
CMs, while diastolic Ca2+ levels were lower or similar in other mutant CMs compared to con-
trol CMs (Fig 5E). Exon 3 deletion CMs had both lower beating frequency and diastolic Ca2+
level when compared to other mutations (Fig 5 and S2 Table).
Fig 2. Features of the PVCs.Number of PVCs in exercise stress test before and after administration of intravenous dantrolene and 24 hours after
dantrolene wash out.
doi:10.1371/journal.pone.0125366.g002
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iPSC Derived Cpvt1 Cms Reproduced the Clinical Antiarrhythmic
Responses to Dantrolene
Effects of dantrolene were divided into three groups based on their Ca2+ responses. In “re-
sponder” group dantrolene abolished all the Ca2+ handling abnormalities, in “semi-responder”
group dantrolene reduced them by more than 50% and in “non-responder” group dantrolene
reduced them by less than 50%. iPSC derived CMs were found to markedly reproduce the vary-
ing individual clinical responses of dantrolene (Fig 6). In cell lines with the mutation in the N
terminal or central region of the RyR2 protein dantrolene abolished or reduced the majority of
Ca2+ transient abnormalities (Fig 6). These mutations were within or in close proximity of clus-
ters 1, 2 or 3 (Fig 1). A detailed analysis indicated that in CMs with exon 3 deletion, P2328S,
T2538R or L4115F, dantrolene abolished or reduced by more than 50% of Ca2+ abnormalities
in 65–97% of cells (Fig 6).
In striking contrast, the effect of dantrolene was only minimal in CMs carrying a mutation
at the end of cluster 3 (Q4201R) or in the transmembrane region (cluster 4, mutation V4653F)
(Fig 6), in accordance with the in vivo dantrolene infusion data. Dantrolene had no effect on
the Ca2+ transients in control CMs. Dantrolene did not significantly affect the diastolic Ca2+
levels of CMs in which Ca2+ transient abnormalities were abolished (S2 Fig). Dantrolene in-
creased significantly the diastolic Ca2+ levels of control and Q4201R CMs where Ca2+ transients
were unaltered by the drug. There was no correlation between the antiarrhythmic effect of dan-
trolene and its effect on beating frequency (S2 Fig).
Discussion
We have studied the antiarrhythmic potential of dantrolene in the treatment of CPVT1. To
this end, we assessed the efficacy of intravenously administered dantrolene in patients carrying
various RyR2mutations and compared these effects to in vitro studies using iPSC derived CMs
generated from the same patients. Our findings demonstrate that intravenous dantrolene, a
drug used to treat another ryanodine receptor disorder, malignant hyperthermia, abolished or
markedly reduced arrhythmias in a subgroup of CPVT1 patients with specific RyR2mutations.
By combining evidence from in vivo and in vitro studies, we propose that the location of the
RyR2mutation affects the antiarrhythmic effect of dantrolene in CPVT1.
Previously dantrolene has been shown to have beneficial effects on cardiac function in ex-
perimental animal models of CPVT1 [13–15,29,30] and in iPSC derived CMs from a CPVT1
patient with an N-terminal S406Lmutation [20], but no studies in patients have so far been re-
ported. It is also important to take into consideration that even if a drug is found to be benefi-
cial in the patient-derived iPSC-CMs, it cannot be automatically concluded that this will
translate into a clinical benefit. Here we show that dantrolene given intravenously has an anti-
arrhythmic effect also in some but not in all patients with CPVT1. This antiarrhythmic effect
was observed only in patients with RyR2mutations in the N-terminal or central regions of
RyR2 protein (clusters 1–3), whereas virtually no effect was seen in patients carrying mutations
at the end of cluster 3 or in the transmembrane region (cluster 4). Although a dose-dependent
effect cannot be excluded, similar observations on mutation-specific drug responses have been
obtained in some other genetic disorders including long QT syndrome type 3 [31], cystic fibro-
sis [32], as well as in certain neoplastic diseases.[33] Recognition of potential mutation-specific
Fig 3. ECG examples of a 38-year-old patient carrying the RyR2 P2328Smutation. (A) Resting ECG showing sinus rhythm and normal QRS
morphology. (B) Exercise ECG at the highest work load of 105W in the baseline study before dantrolene. PVCs include couplets and polymorphic NSVTs.
(C) Disappearance of ventricular arrhythmias after administration of dantrolene (work load 105W). (D) Exercise test on day two after 20-hours wash-out of
dantrolene showing return of PVCs (work load 105W).
doi:10.1371/journal.pone.0125366.g003
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responses will be important for future drug development: one drug may not work for all pa-
tients even if the phenotype is the same.
Currently, beta-antiadrenergic medication is the first line antiarrhythmic treatment for all
CPVT patients. Flecainide has also shown beneficial effects.[34,35] ICDs are used if severe ar-
rhythmic events occur despite optimal beta-blocking treatment. However, use of ICDs is not
without risk since ICD-shocks may further aggravate catecholamine release and initiate an un-
controlled electric storm. Very recent data suggest that left cardiac sympatectomy may be high-
ly effective in patients refractory to medical therapy.[7,36] Although dantrolene as such would
not be suitable for long-term treatment of CPVT1 due to its side effects, and although only a
subset of patients would benefit from it, our data shows its antiarrhythmic potential. It also
suggest that it could be administered by intravenously to CPVT1 patients in emergencies such
as incessant ventricular tachycardia.
Fig 4. Characterization of CPVT1 iPSCs. (A) Expression of pluripotency markers shown by RT-PCR, β-actin or GAPDH serving as a housekeeping gene.
(B) None of the exogenous genes are expressed in CPVT1 cell lines. (C) EBs express markers from all the three embryonic germ layers. (D)
Immunocytochemical stainings and expression of pluripotency markers. Scale bar 200 μm. (E) Sequencing analysis confirmed the RyR2mutation in each
cell line. (F) All the cell lines had normal karyotype, example picture fromQ4201R cell line. (G) Teratomas made from a CPVT-iPSC line further confirms
pluripotency, example pictures from L4115F cell line.
doi:10.1371/journal.pone.0125366.g004
Fig 5. Characterization of CPVT-iPSCs derived CMs. (A) Immunocytochemical stainings of cardiac markers where red represents troponin T, green
connexin-43 and blue DAPI-staining for nuclei. Scale bars 200 μm. (B) Representative traces of a control CM showing normal regular Ca2+ transients and
CPVT1 CMs showing abnormalities like multiple peaks, low peaks, irregular phases and oscillations in Ca2+ handling. (C) Quantification of percentage of
CPVT1 and control iPSC CMs exhibiting abnormal Ca2+ transients at baseline (bl) and during adrenaline perfusion (adr). (D) Frequency and (E) Diastolic
level of intracellular Ca2+ of all CPVT1 and control CMs. Numbers of cells analyzed in C, D, and E, exon 3 del n = 48, P2328S n = 72, T2538R n = 52, L4115F
n = 110,Q4201R n = 63, V4653F n = 29, Controls (WT) n = 28. As an exception, number of WT cells analyzed in D, and E, in bl n = 54 and adr n = 27 and
number of P2328S cells in bl n = 90 and adr n = 47. Grey bars indicate cells at baseline and black bars during adrenaline perfusion. Error bars, SEM. *P<0.05
CPVT1 versus control, with Student’s t-test. Significance’s of mutation specific differences, see S2 Table.
doi:10.1371/journal.pone.0125366.g005
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Fig 6. iPSC derived CMs reproduced the clinical responses of dantrolene. (A) In vivo and in vitro effects of dantrolene correspond within each RyR2
mutation. In vitro drug effects were categorized into three groups (responders, semi-responders and non-responders) depending on how dantrolene affected
to the amount of Ca2+ abnormalities when compared to adrenaline response. In vivo responder group show the percentage of the abolished PVCs when
compared to the baseline. Numbers of cells analyzed in exon 3 del n = 16, P2328S n = 32, T2538R n = 17, L4115F n = 36,Q4201R n = 22, V4653F n = 13. (B)
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More than 150 mutations in RyR2 gene have been reported so far and they are clustered in
four hotspots.[11] One third of the reported mutations are in clusters 1 and 2 and the rest are
equally distributed between clusters 3 and 4. Only 10% of RyR2mutations have been found
outside these clusters.[11] The location of the RyR2mutation appears to be critical for a favor-
able effect of dantrolene. The binding site for dantrolene is localized in the N-terminus of RyR2
between amino acid 601 and 620.[13,37] The dantrolene-binding sequence is considered to
constitute part of the domain switch region, suggesting that dantrolene is involved in the cor-
rection of defective unzipping and allosteric stabilization of interdomain interactions between
the N- terminal and central regions of RyR2, resulting in inhibition of Ca2+ leak [16,30,38] and
in fact, this has been demonstrated in previous studies.[13,16,37] Also our data demonstrate
that dantrolene abolished arrhythmias in CPVT1 patients with mutations of N terminal or cen-
tral domain, suggesting that a defective inter-domain interaction within the RyR2 could be the
underlying arrhythmogenic mechanism in the exon 3 deletion, P2328S, T2538R and L4115F.
However, dantrolene did not suppress T2538R-related arrhythmias to the same extent as ar-
rhythmias caused by other central region mutations. It has been speculated that differences in
the mode of interdomain interaction in dantrolene binding regions may result in differences in
its antiarrhythmic efficacy.[30] Furthermore, other drug-binding regions in the carboxyl-ter-
minal half of the RyR2 or additional low affinity drug binding sites in the N-terminal area
could exist.[13] No previous studies on the effects of dantrolene on RyR2mutations in or close
to the transmembrane are available; here we show that dantrolene has no or only minimal ef-
fect on arrhythmias if mutations are located in these areas. It is interesting that the patient with
Q4201Rmutation did not respond to dantrolene even though this mutation is located in cyto-
solic portion of RyR2 and in cluster 3 although in its terminal part. This finding indicates that
the location of the mutation in certain mutation cluster does not necessarily determine the an-
tiarrhythmic response, and highlights the utility of the iPSC model for individual functional
analysis.
Our data showing similar patient-to-patient variation in dantrolene effects in the clinical
setting and corresponding iPSC-CMmodels suggest that, at least in theory, it may be possible
to tailor an individual's medication in cell culture without predisposing the individual to the
potentially serious side-effects of a drug. Dantrolene did not affect normally beating CMs. This
is consistent with previous reports showing that dantrolene inhibits only abnormal Ca2+ release
and has no effect on the normal Ca2+ transients, suggesting that the native conformation of
RyR2may restrict binding of the drug and that dantrolene binding to RyR2might be dependent
on a specific conformational state present only in mutated cells.[13,37] Defective calmodulin
binding caused by RyR2 domain unzipping has also been shown to be restored by dantrolene
[29,39] which may as well explain why dantrolene exerts effects on diseased but not healthy
hearts.
Besides differences in drug responses, we also saw both similarities and differences in the
CPVT1 in vitro phenotypes depending on the nature of the mutation. The beating frequency of
CPVT1 CMs was lower than that in control CMs. This is in line what has been reported also
with CPVT1 patients.[5,40] All the CPVT1 CMs showed similar disturbances in intracellular
Ca2+ cycling. Ca2+ transient abnormalities were somewhat more common in the cluster 4 mu-
tation than in cluster 1, 2 and 3 mutations. Exon 3 deletion differed from all the other muta-
tions by having lower diastolic Ca2+ levels and beating frequency both at baseline and during
Representative traces of dantrolene responder in vitro in an L4115Fmutated CM. Adrenaline causes Ca2+ cycling abnormalities and dantrolene abolishes all
the abnormalities. (C) Representative traces of semi-responder in vitro in a P2328Smutated CM. The cell has abnormal Ca2+ cycling at baseline and during
adrenaline perfusion and dantrolene reduces the abnormalities by abolishing the oscillation but leaving some low peak Ca2+ spiking.
doi:10.1371/journal.pone.0125366.g006
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adrenaline perfusion. Exon 3 encodes secondary structure elements that are crucial for folding
of the N-terminal domain. It has been proposed that RyR2 with exon 3 deletion has evolved ad-
ditional means to regulate Ca2+ release, by altering the conformation of the domain [41], which
may result in the observed differences in Ca2+ transients.
There are certain limitations in our study. First, only six CPVT1 patients and their iPSC cell
lines were studied; however, we emphasize that despite the very rare nature of this disease we
were able to examine in detail six different disease-causing mutations. Second, under the condi-
tions of the study design we were permitted to study only acute effects of intravenously admin-
istered dantrolene. Third, although we titrated the dose of dantrolene according to the weights
of the patients, serum levels of the drug were not measured and could have varied from patient
to patient, resulting in concentration-dependent variation in clinical responses. Fourth, we
used only a fixed concentration of dantrolene, selected on the basis of the work by Jung et al.
[20], in our iPSC studies. Fifth, immature phenotype of the iPSC-CMs may produce variation
in arrhythmias. However, in our previous study [21] the electrophysiology of CPVT1
iPSC-CMs appeared fairly mature. We have also shown here and in our previous study [21]
that arrhythmias are substantially more consistent in CPVT1 CMs than in control CMs.
In conclusion, we have shown here the proof of principle that intravenously administered
dantrolene suppresses ventricular arrhythmias in the congenital RyR2 defect and that the loca-
tion of the RyR2mutation may affect the antiarrhythmic effect of this drug. We also demon-
strate that iPSC derived patient-specific CMs correctly predict the clinical response to
dantrolene in CPVT1 patients with varying RyR2mutations. Our data support the notion that
iPSC-derived CMs could serve as a platform for drug development and for design of
personalized medication.
Supporting Information
S1 Fig. Confirmation of exon 3 deletion. Exon 3 deletion of 05605. CPVT cell line was also
confirmed with PCR and agarose gel electrophoresis.
(TIF)
S2 Fig. Ca2+ transient parameters as a response to dantrolene. (A) Diastolic Ca2+ level and
(B) beating frequency in responder and non-responder CMs. Values during adrenaline perfu-
sion were divided by values during dantrolene perfusion, separately for each cell. Green bars in-
dicate responder CMs and purple bars non-responder CMs. Error bars, SEM.  indicates
significant difference between adrenaline versus dantrolene within a group, P<0.05. Numbers
of cells analyzed in exon 3 del n = 13, P2328S n = 29, T2538R n = 11, L4115F n = 28, Q4201R
n = 15, V4653F n = 10, Control (WT) n = 20.
(TIF)
S1 Protocol. English translated trial study protocol.
(DOCX)
S2 Protocol. Trial study protocol in the original language (Finnish).
(DOC)
S1 Table. Primer sequences for EB RT-PCR.
(DOCX)
S2 Table. Differences between RyR2 mutations in their Ca2+ transient properties during
baseline and adrenaline perfusion. CL indicates cluster numbers. Upward pointing arrow in-
dicates significantly (p<0.05) higher and downward pointing arrow significantly lower diastol-
ic Ca2+ level or beating frequency of the first mentioned mutation when compared to the
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second mentioned mutation. NS indicates that there was no statistical significance between
mutations. As parallel pointing arrows between comparison groups indicate, the average of the
beating frequency and diastolic Ca2+ level inside one mutation group corresponded and the av-
erage of these parameters decrease when moving from P2328S towards transmembrane
area mutations.
(DOCX)
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Electrocardiogram recordings
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